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ABSTRACT 
Harlyn Gynette Skinner: Personal Utility: Examining The Effects Of Genomic Risk Knowledge 
On Motivation Toward Diet And Physical Activity Behavior Changes 
 (Under the direction of Alice Ammerman) 
 
The National Institutes of Health and the Centers for Disease Control and Prevention 
have jointly indicated urgency in researching the use of personal genomics in the assessment of 
disease prevention. One research priority is the use of genomic information in behavior change 
research for reducing the risk for common chronic disease (e.g., cardiovascular disease—CVD). 
Research suggests improvements in motivation toward behavior change with counseling based 
on one gene (genetic counseling) and even better outcomes with counseling based on two or 
more genes (genomic or polygenetic counseling). Currently, little is known about the effect of 
genetic or genomic counseling in minority populations.  
This study examines whether genomic-risk knowledge increases motivation towards diet 
and physical activity changes to reduce CVD-risk in African-American participants from a rural, 
low-income county in eastern North Carolina. To meet this goal, we conducted three inter-
related research projects. First, focus groups were conducted with African-Americans and 
Whites to assess community needs and wants regarding a genomics project (n=35). Findings 
indicated community interest in participation and interest in receiving personalized genomic 
results. Second, intervention messages on the return of personalized CVD genomic-risk were 
developed following the principles of The Protection Motivation Theory and Leventhal’s 
iv 
Common Sense Model. Messages were tested within the target population for comprehension 
and acceptance (n=32).  
Using a 2-arm randomized controlled trial design, returning CVD genomic results were 
compared to an attention control group in sixty-two (n=62) African-Americans. The primary 
outcome was the difference in motivation towards diet and physical activity at 1-month follow-
up compared using a general linear regression model. There were no significant between- or 
within-group results (p=0.51). There was significant within-group moderation by genomic-risk 
category for the intervention group. Those with low genomic CVD-risk self-reported increased 
motivation towards diet and physical activity (0.31 ± 0.18, p=0.09), and increased weekly 
consumption of fruit and vegetables (1.34 ± 0.36, p=0.001). Those with average genomic CVD-
risk self-reported less motivation and no change in fruit and vegetable consumption. Findings 
suggest that genomic-risk knowledge may impact the perceived threat of CVD, but more 
research needs to be done to better understand the best use for this approach. 
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CHAPTER 1: INTRODUCTION 
A. OVERVIEW 
The National Institutes of Health (NIH) and the Centers for Disease Control and 
Prevention (CDC) have jointly indicated urgency in researching the use of personal genomics in 
the assessment of disease risk and prevention. Chief among the research priorities is the 
establishment of an evidence base for effective ways of communicating personal genomic 
information as an approach to behavior change particularly in chronic disease risk reduction 
(e.g., cardiovascular disease—CVD).1,2 High rates of CVD and its risk factors are found in (1) 
minorities,3 (2) those of low socioeconomic status, 3,4 and (3) by geographic boundary 
(Southeastern states);3,4 all such vulnerable populations can be found in rural North Carolina 
(NC). CVD mortality and morbidity can be effectively decreased by improvements in diet and 
physical activity, but this does not ameliorate CVD disparity. Disparity can be partially 
explained by genetic variation. 
Research demonstrates positive improvements in motivation toward behavior change 
when individuals receive counseling based on one gene (genetic counseling) and even better 
outcomes when individuals receive counseling based on two or more genes (genomic 
counseling).5-7 CVD is polygenic in nature.8,9 The full constellation of SNPs (single nucleotide 
polymorphisms) involved in the development of CVD, and many other common chronic 
diseases, has yet to be fully elucidated. Very few studies have been conducted investigating the 
effect of genomic counseling in motivating health behavior change in common chronic diseases; 
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even fewer specifically in CVD.10 To our knowledge, none have been conducted exclusively in 
an African-American population. Comparing participants’ genomic profile to existing genomic 
risk markers for CVD identified from fine mapping and admixture studies, and then returning 
that genomic information to the participant, provides the basis for the current proposal. This 
study concentrates on the most vulnerable population—African-Americans living in a low 
socioeconomic area in the Southeastern United States. The primary goal of this study is to 
determine if genomic knowledge will increase motivation towards CVD risk reduction 
health behaviors as compared to the control group in a randomized proof-of-concept study 
with 62 African-American (AA) residents from the vulnerable population of Lenoir County, NC.  
 
B. FORMATIVE AIMS AND RATIONALE 
B.1. FORMATIVE AIM 1 
Determine acceptance of genomic research in the African-American community in 
Lenoir County. 
RATIONALE: There is a historical context of mistreatment by and lack of consent for 
medical research in AA communities. This has led to a culture of mistrust. To determine if a 
genomics study would be acceptable to the community, focus groups were conducted with AAs 
and Whites in Lenoir County. 
 
B.2. FORMATIVE AIM 2 
Adapt CVD genomic risk intervention materials for African-Americans in Lenoir 
County. 
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RATIONALE: To our knowledge, previous genomic risk communication literature largely 
focused on Whites. Given that ancestry is linked to genomic variation and that the most effective 
communication strategies can vary across cultural lines, adaptation of the current methods in the 
literature was necessary. 
 
C. EXPERIMENTAL AIMS AND HYPOTHESES 
C.1. EXPERIMENTAL AIM 1 
Using a randomized controlled design, determine the effect of conveying CVD genomic 
risk via culturally and literacy appropriate materials on motivation toward changing diet and 
physical activity behaviors relative to no genomic risk communication (using an attention-
control delayed intervention approach). 
HYPOTHESIS: Motivation to change diet and physical activity will increase for AAs 
receiving genomic knowledge relative to those receiving no genomic information. Effects will be 
moderated by genomic-risk category. 
 
C.2. EXPERIMENTAL AIM 2 
Determine the effect of receiving genomic risk information versus no risk communication 
on psychosocial factors—constructs of Protection Motivation Theory: threat appraisal, perceived 
vulnerability, perceived severity, perceived fear, perceived efficacy, response cost, response 
efficacy, and fatalism. 
HYPOTHESIS: Threat appraisal, perceived vulnerability, perceived severity, perceived fear, 
perceived efficacy, and response efficacy will increase while response cost will decrease among 
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AAs receiving genomic knowledge relative to those receiving no genomic information. Fatalism 
will not change. Effects will be moderated by genomic-risk category. 
 
C.3. EXPERIMENTAL AIM 3 
Determine the effect of receiving genomic risk information versus no risk communication 
on self-reported change in diet and physical activity behaviors. 
HYPOTHESIS: Reported diet quality will become more healthful but reported physical 
activity will not change for AAs receiving genomic knowledge relative to those receiving no 
genomic information. Effects will be moderated by genomic-risk category. 
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CHAPTER 2: LITERATURE REVIEW 
 
A. CARDIOVASCULAR DISEASE DISPARITIES — REGION & RACE 
Cardiovascular disease (CVD) is the most common cause of morbidity and mortality in 
the United States.11 In 2014, 614,348 people died from CVD11 and at least 200,000 of those 
deaths could have been prevented.12 
The risk of suffering from CVD is 49% higher than the U.S. average for those living in 
the Stroke Belt—an 11-state region of the southeastern United States, which includes North 
Carolina.4,13 Residents in the Stroke Belt have poorer health outcomes and a higher prevalence of 
obesity compared to the rest of the country.4 Situated in the heart of the Stroke Belt is Lenoir 
County, North Carolina. CVD is the leading cause of death in Lenoir County of adults aged 35 
years and older (ranked 1st with 365.1 deaths per 100,000 compared to 192.7 deaths per 100,000 
statewide).3,14,15 Lenoir County residents report their most pressing health concerns as obesity, 
Type 2 Diabetes Mellitus (T2DM), and heart disease.15 Additionally, the age-adjusted obesity 
rate (BMI  > 30) in Lenoir County is 37.0% compared to 29.7% statewide.3,16 These facts 
illustrate disparity in CVD and its risk factors within Lenoir County and define residents as a 
vulnerable population.  
Nationwide, African-Americans (AAs) are at 20% higher risk of CVD mortality 
compared to Whites and are nearly twice as likely to die from preventable CVD.11,12 AAs also 
have higher rates of CVD risk factors compared to Whites—hypertension, T2DM, obesity, and 
smoking; hypercholesterolemia prevalence (as measured by statin use) is lower compared to 
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Whites.3,13 The disparity in CVD and its risk factors widens in the Stroke Belt; in Lenoir County, 
AAs are at a 90% higher risk for CVD mortality than their White counterparts.4,13,14 
 
B. LIFESTYLE CHANGE — PART OF THE SOLUTION BUT DOES NOT ELIMINATE DISPARITY 
B.1. LIFESTYLE 
Environmental risk factors for CVD have been well established: smoking status, 
hypertension, hypercholesterolemia, type 2 diabetes, and obesity.17-19 These risk factors are 
strong predictors of CVD morbidity and mortality. A multitude of studies have demonstrated that 
lifestyle change targeting these risk factors lowers CVD risk.19-23 The Nurses’ Health Study 
suggests that a healthy lifestyle can lead to an 83% reduction in the risk of CVD; participants 
with a healthful lifestyle, noted the following healthy behaviors: not smoking, having a BMI < 
25, consuming < ½ alcoholic beverage per day, engaging in moderate to vigorous physical 
activity for 30 minutes per day, and scoring in the highest 40% for ‘a good diet’.19 (A good diet 
was defined as high consumption of cereal fiber, fish fatty acids, folate, and a high ratio of 
polyunsaturated to saturated fat; and low consumption of foods high in trans-fats and low 
glycemic load.) In particular, studies of Mediterranean diets have demonstrated a beneficial 
effect of such diets on the prevention of CVD and further CVD events.23-26 The Mediterranean 
diet is characterized by olive oil as the main source of dietary oil, generous consumption of fruits 
and vegetables, lots of fish, little red meat (i.e., beef, lamb, pork), and modest consumption of 
alcohol. Meta-analysis confirms that focusing on diet and physical activity is critical in reducing 
CVD risk.21 
Despite the evidence that eating a healthy diet and engaging in physical activity lowers 
CVD risk, there is a widening disparity between North Carolinians and average United States 
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behavior with regard to these lifestyle behaviors. According to the Behavioral Risk Factors 
Surveillance System (BRFSS) Survey, North Carolinians consumed 5 or more fruits or 
vegetables a day and engaged in the recommended levels of physical activity at lower rates 
compared to the average American.3 The disparity gap has also widened between AAs and 
Whites in the past 30 years.27 According to the BRFSS North Carolina Survey, fewer AAs than 
Whites consumed 5 or more fruits and vegetables or engaged in the recommended levels of 
physical activity.28 Overall, despite an effective prescription for lifestyle change to reduce CVD 
risk, AAs are less successful in making diet and physical activity changes that would reduce 
disparity in CVD risk factors and CVD mortality. 
 
B.2. GENETICS 
Studies have established a genetic component to the development of CVD.29-31 Genome-
wide association studies (GWAS) have detected direct associations of genomic variations—
called single nucleotide polymorphisms (SNPs)—with CVD.32 The effect size attributable to a 
single CVD-related SNP is modest at best.33 However, the large number of CVD-related SNPs 
identified in GWAS each explains a small amount of risk meaning that CVD is polygenic in 
nature. CVD genomic risk signatures (GRS)—aggregates of SNPs identified through GWAS 
that contribute to a genetic predisposition towards CVD—can be used to calculate an 
individual’s CVD related genomic risk. These CVD genomic risk signatures are both 
independent predictors of CVD events and predictors of phenotypic risk.34-38 
While there is not racial or regional disparity in the presence of CVD-related SNPs in the 
populous, it is important to mention the limitations of GWAS research. There are many more 
studies with White participants than AA participants. SNPs identified as relevant in sample 
populations of European-ancestry may not be relevant in AAs because of the reliance of GWAS 
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results on ancestral background. However, studies with AA participants have identified a 
multitude of CVD and CVD risk factor related SNPs in those of African-ancestry.39-49 
Additionally, AAs are admixed descendants of European and African ancestors. Admixture and 
fine-mapping studies exist specifically to investigate SNP variations in those of non European-
ancestry.42,44,46-48,50-75 
 
B.3. LIFESTYLE & GENETICS 
Researchers are looking for new ways to motivate health behavior change. Studies 
demonstrate that patients who have previously suffered myocardial infarctions are more 
motivated to make diet and physical activity changes because they perceive themselves more 
vulnerable to further CVD.76 However, public health practitioners want to encourage lifestyle 
change before a myocardial infarction. Protection Motivation Theory postulates that personal 
genomic knowledge may increase perceived vulnerability and motivate lifestyle change before a 
myocardial infarction in a similar manner to what is seen in myocardial infarction patients after 
their first CVD event.77 
 
C. PERSONALIZED RISK COMMUNICATION 
There is a paucity of research on the combined effect of personal genomic risk 
knowledge and lifestyle change on the reduction of CVD risk; none of this research has been 
conducted with AAs in the Stroke Belt. More broadly, there is research on personalized risk 
communication and some research on the effects of genomic risk knowledge. 
In a Cochrane review by Edwards et al (2013), it was demonstrated that personalized risk 
communication has a positive effect over general risk information.78 After receiving tailored 
messages, individuals were 15% more likely to undergo health protective screening (Pooled 
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Odds Ratio: 1.15 [1.02,1.29]).78 These health behavior changes are confirmed by meta-analyses 
which indicates that personalized risk communication messages are shown to be more effective 
over generic comparison messages in affecting health behavior change.79 
In addition to health behavior changes, there are cognition changes in those who receive 
personalized risk communications (Table 2.1). Individuals who receive tailored messages are 
more than four-times as likely to make informed decisions about undergoing screening tests 
(Pooled Odds Ratio: 4.48 [3.62,5.53]).78 Personalized risk communication also affects an 
individual’s understanding of risk perception making the participant’s understanding of their risk 
46% more accurate (Pooled Odds Ratio: 1.46[1.13,1.88]).78,80 Knowledge has been shown to 
increase 2- to 7-fold as the result of tailoring.78 Across studies, anxiety was non-significantly 
decreased implying that personalized risk communications might lessen anxiety about health 
behavior change (Standard Mean Difference: -0.13 [-0.29,0.03]).78 In summary, personalized risk 
communication increases knowledge about risk and engenders more accurate risk perception 
leading to increased informed decision making about health behavior change. 
  
Table 2.1: Odds Ratios from Previous Research on Personalized Risk Information 
 Type of Risk Communication 
Numerical Categorical List of Risk Factors 
Uptake of Screening 0.95 [0.78,1.15]81-86 1.29 [1.11,1.51]87-92 ---- 
Informed Decision 2.08 [1.14,3.81]81 --- 4.98 [3.97,6.24]93,94 
Perceived Risk 1.22 [0.91,1.64]82,95 2.50 [1.48,4.20]96  
Knowledge 2.11 [1.52,2.91]81-83  7.13 [5.79,8.79]93,94 
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C.1. PERSONALIZED RISK COMMUNICATIONS AND HEALTH LITERACY 
As noted in Table 2.1, there are several different modalities through which risk can be 
presented—numerical, categorical, or a list of risk factors. The least effective modality is 
numerical. This may due to poor health literacy.  
According to Berkman et. al. (2011), ‘health literacy’ is defined as the ability to: 1) “read 
and understand text to locate and interpret information in documents (print literacy)”; 2) “use 
quantitative information for tasks (numeracy)”; and 3) “speak and listen effectively (oral 
literacy).”97 The 2003 National Assessment of Adult Literacy found that 14% of adults 
(approximately 30 million people) have below basic health literacy.98 Low health literacy has 
long been associated with low health knowledge, poor disease self-management, and poor health 
outcomes.99-103 Specifically, those with low health literacy have poorer skills in taking 
medications,104-106 interpreting medication and nutrition labels,107-109 and have higher all-cause 
mortality rates in the elderly.110-112 Similarly, low numeracy has been associated with poor self-
management of chronic disease, including higher utilization of emergency department 
services.113-116 
Low numeracy is also a concern in personalized risk communications. According to the 
2003 National Assessment of Adult Literacy, 22% of adults have below basic quantitative 
skills.98 Even highly educated adults have been shown to have inadequate understanding of 
probabilities and risks.117-121 These miscomprehensions of numerical information are suggested 
to result in poor risk estimation (regardless of format), improper calculation of disease 
probability, and inconsistent treatment decisions when outcomes are expressed in terms of 
absolute versus relative risk.118,120,122,123 Poor numeracy and subsequent disease risk perceptions 
have been shown to affect health behaviors.120,124-126 In cancer research, low numeracy has been 
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associated with the overestimation of risk leading to either increased cancer screening or 
fatalistic avoidance of cancer screening.120,127-131 All of these numeracy concerns could 
contribute to the non-significant change in health behavior seen when providing numerical risk 
estimates.  
Tailored communication efficacy is thought to be more relevant to the individual and 
therefore more comprehensible.132 Evidence shows that literacy and numeracy must be taken into 
consideration when conveying risk information. Additionally, research suggests that giving both 
verbal and written information increases comprehension.133 Making informed choices about 
health behaviors and increasing adherence to those behaviors is seen as the goal for personalized 
risk communication.78 
 
D. PERSONALIZED GENOMIC RISK COMMUNICATION 
Personalized risk communication has been applied to the field of genomics both in 
commercial industry and in public health.  
 
D.1. DIRECT-TO-CONSUMER 
Direct-to-consumer genetic testing (DTC-GT) companies provide personalized genomic 
risk information for common diseases to the public for-profit. In 2008, DTC-GT was become a 
$70.2 million global market and the number of companies offering DTC-GT services has risen 
dramatically.134-136 While there is clear public interest in genomic testing, research suggests that 
testing of this kind can be confusing to patients and has yet to be proven definitively useful to 
population health. Studies demonstrate that genomic knowledge in the populous is low and 
consumers often still have questions about their DTC-GT results.137-142 Given these knowledge 
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deficits, questions have been raised as to whether DTC-GT marketing encourages inappropriate 
applications of genetic tests, as well as questions about the ramifications of communicating 
genomic results in the absence of a knowledgeable professional to help interpret results.2,143 
Additionally, research suggests that DTC-GT may have limited public health impact. To this 
writer’s knowledge, very few studies have been performed that systematically test health 
behavior change in response to DTC-GT. The few studies that have been performed show little 
evidence that the provision of DTC-GT results alone result in sustained behavior change.144-146 
 
D.2. DIET AND PHYSICAL ACTIVITY 
In the field of public health, some studies have been performed on personalized genomic 
risk information’s effect on health behaviors. Past studies have mostly been in the fields of 
smoking cessation and cancer (not discussed here). However, there are limited numbers of 
studies on personalized genomic risk information’s impact on an individual’s diet and physical 
activity behaviors.  
In a Cochrane review by Marteau et al (2010), genomic based risk communications were 
found to more than double uptake of a healthful diet (Pooled Odds Ratio: 2.24 [1.17,4.27]) and to 
have no effect on physical activity (Pooled Odds Ratio: 1.03 [0.59,1.80]).5 These results are 
based on findings from two studies: Marteau et al (2004) and Chao et al (2008).  
Marteau et al (2004) performed a randomized controlled trial (RCT) on the impact of 
genomic risk communication for familial hypercholesterolemia on perceived control and health 
behavior change—diet, physical activity, adherence to statin medications, and smoking.147 
Intervention participants received routine clinical diagnosis and behavioral advice plus, findings 
for point mutations in the LDLR and APOB genes. Control participants received routine clinical 
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diagnosis and behavioral advice. Dietary measurement was self-reported fat intake measured at 
baseline and the 6-month follow-up. Physical activity measurement was self-reported frequency 
of vigorous physical activity measured at baseline and the 6-month follow-up. Results showed a 
trend towards genomic risk recipients being more than twice as likely to have a lower fat diet 
(Odds Ratio: 2.10 [0.99, 4.43]) and no change in physical activity at the 6-month measurement 
(Odds Ratio: 0.99 [0.55,1.790]).5  
Chao et al (2008) performed a RCT on the impact of genetic risk communication for 
Alzheimer’s disease on health behavior change—diet, physical activity, medication and vitamin 
use.148 Intervention participants received Alzheimer’s education, APOE genotype, and their 
lifetime risk based on their APOE genotype. Control participants received Alzheimer’s education 
and a numerical risk estimate based on family history and gender. Dietary measurement was self-
reported diet changes aimed at reducing Alzheimer’s risk measured at baseline and 1-year 
follow-up. Physical activity measurement was self-reported physical activity changes aimed at 
reducing Alzheimer’s risk measured at baseline and 1-year follow-up. Results demonstrated a 
trend towards genetic risk recipients being more than twice as likely to alter their diet to reduce 
Alzheimer’s risk (Odds Ratio: 2.69 [0.75,9.70]) and no change in physical activity to reduce 
Alzheimer’s risk at 1-year (Odds Ratio: 1.40 [0.27,7.19]).5 
Also of note is the Arkadianos et al study (2007).7 In a non-randomized design, this study 
investigated the impact of genomic risk communication for diet (nutrigenetics) on weight 
management. Participants in a weight management clinic were offered genotyping for 24 SNPs, 
and a personalized diet and exercise plan based on that information. The comparison group 
received standard diet and exercise plans from the weight management clinic. There was no 
difference between intervention and comparison groups at most time points—45 days, 100 days, 
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and 300 days. However at > 300 days post return of results, weight management clinic patients 
who received nutrigenetic diet and exercise plans lost significantly more weight compared to 
weight management clinic patients with standard diet plans (Odds Ratio 5.74 [1.74,22.52]). Put 
another way, nutrigenetics subjects lost 5.6% of their original body weight compared to a 2.2% 
weight gain in comparison subjects.7 
Results from these three studies, combined, imply that receiving personalized genomic 
risk communications may result in dietary change, however genomic risk assessment effects 1) 
may require a long-term intervention (~ 1 year), and 2) may be most beneficial in conjunction 
with lifestyle skill training. Results imply that physical activity behaviors are not affected by 
genomic risk assessment. It is important to note several key limitations of these studies: 1) It is 
unclear how risk was conveyed (i.e., verbally, written, using numerical estimates, using 
categorical estimates, taking into account literacy, etc.); 2) Most of these studies were low 
intensity lifestyle programs that did not teach lifestyle change skills; 3) Participants tended to be 
White, highly educated women, thereby limiting generalizability. 
 
D.3. TYPE 2 DIABETES MELLITUS AND CVD 
There is an emerging body of literature on personalized genomic risk assessments applied 
to Type 2 Diabetes Mellitus (T2DM) and cardiovascular disease (CVD) interventions. To our 
knowledge, there are only four of these types of studies, two of which have yet to report results 
(Table 2.2).  
Godino et al (2012) investigated the effect communicating personalized T2DM genomic 
risk results on objectively measured physical activity measured using the Actiheart® monitor 
(N=569).149 Intervention group one received a genomic risk estimate and standard T2DM 
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prevention lifestyle advice. Intervention group two received a phenotypic risk estimate and 
standard T2DM prevention lifestyle advice. The control group received no risk information, only 
standard T2DM prevention lifestyle advice. Participants were followed for eight weeks. There 
were no significant between-group findings.150 
Grant et al investigated the effect of personalized genomic risk on motivation towards 
diabetes prevention (N=108).151 In their intervention, they included a 12-week lifestyle 
intervention program modeled after the Diabetes Prevention Program.152 At the end of the 
intervention, program attendance and motivation were measured as the main outcomes. There 
were no differences between intervention and control groups for either outcome at 12-weeks. A 
major strength of this research compared to the studies mentioned above is the use of a proven-
effective lifestyle program. There were no differences between groups with this short-term study.  
The Arkadianos study, described above, suggests that a longer-term study coupled with 
the intensive lifestyle program might be more effective. Additionally, Arkadianos et al found that 
when giving genomic results in conjunction with an intensive lifestyle program, intervention 
participants with fasting blood glucose levels >100mg/dl were almost twice as likely to have 
fasting blood glucose levels <100 mg/dl at >300 days when compared to the control group (Odds 
Ratio: 1.98 [1.01,3.87]).7 
Other related studies, including Cho et al (2012), and Knowles et al (2012) have yet to 
publish study results.  
The five studies mentioned above promise to yield interesting results. However, these 
studies have several key limitations: 1) most assessed short-term programs; 2) most are low-
intensity lifestyle programs, if any counseling at all; 3) most do not take into account health 
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literacy or numeracy issues in their genomic counseling; and 4) the study populations are largely 
highly educated White populations.  
There are also research projects underway on how to use genomic risk information to 
improve health behaviors in common diseases at National Human Genome Research Institute 
(NHGRI) Centers for Excellence in the Ethical, Legal, and Social Implications Research Centers 
across the country. The application of personal genomic risk assessments to common diseases is 
an upcoming research field, which has been deemed an urgent priority by the NIH and the 
CDC.1,2 This proposal seeks to answer that call by contributing to the evidence base of effective 
ways of communicating personal genomic information as an approach to behavior change in 
CVD disease risk reduction. 
 
TABLE 2.2: TYPE 2 DIABETES MELLITUS AND CARDIOVASCULAR DISEASE RETURN OF GENOMIC RESULTS STUDIES 
T2DM 
Study 
(N) 
Design Follow-
up 
Intervention Control Primary 
Outcome 
Secondary 
Outcome 
Primary 
Results 
Secondary 
Results 
Grant 
2013151
,153 
N=108 
2-arm 
RCT 
 
In-
person 
12-
weeks 
Genetic risk 
+ 12-week 
diabetes 
prevention 
program 
12-week 
diabetes 
prevention 
program 
Program 
attendance 
 
Motivation 
Weight 
change 
 
Weekly 
exercise 
and diet 
logs 
 
Diabetes 
risk 
perception 
 
Stages of 
change for: 
low fat 
diet, 
exercise, 
and weight 
loss 
No 
differen
ces 
between 
groups 
Increased 
stage of 
change for 
exercise 
Godino 
2012149
,150 
N=569 
3-arm 
RCT 
 
Mail 
After 
receipt 
of letter 
 
Genetic risk 
estimate + 
standard 
lifestyle 
advice sheet 
Standard 
lifestyle 
advice sheet 
Objectively 
measured 
physical 
activity 
Self-
reported: 
 
Diet 
 
No 
differen
ces 
between 
groups 
More 
accurate 
estimates of 
perceived 
risk in 
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8-weeks  
Phenotypic 
risk estimate 
+ standard 
lifestyle 
advice sheet 
Weight 
 
Intentions 
to be 
physically 
active 
 
Intentions 
to engage 
in a 
healthy 
diet 
 
Anxiety 
 
Diabetes-
related 
worry 
 
Self-rated 
health 
 
Perceived 
risk 
intervention 
groups 
compared 
to control 
group 
Cho 
2012154 
N≅506 3-arm RCT  
In-
person 
3 
months 
 
1 year 
 
 
Genetic risk 
+ one 
counseling 
session with 
healthcare 
staff at 
participant’s 
physician’s 
office 
 
One 
counseling 
session with 
healthcare 
staff at 
participant’s 
physician’s 
office 
One 
counseling 
session with 
healthcare 
staff at 
participant’s 
physician’s 
office 
Insulin 
resistance 
(HOMA-
IR) 
 
BMI 
Diet 
pattern 
 
Physical 
activity 
 
Waist 
circumfere
nce 
 
Perceived 
risk 
 
Not 
reported 
yet 
Not 
reported yet 
CVD 
Study Design Follow
-up 
Intervention Control Primary 
Outcome 
Secondary 
Outcome 
Primary 
Results 
Secondary 
Results 
Knowles 
201210 
N≅100 2-arm RCT  
In-
person 
3 
months 
 
6 
months 
Genetic risk 
+ 3 clinic 
visits 
3 clinic 
visits 
LDL 
cholesterol 
Blood 
pressure 
 
Weight 
 
Diet 
 
Hemoglobin 
A1c 
Not 
reported 
yet 
Not 
reported 
yet 
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Exercise 
patterns 
 
Smoking 
 
Stages of 
change 
 
Risk 
perception 
 
Medication 
compliance 
 
Attitudes 
towards 
medications 
 
Anxiety 
 
E. PSYCHOSOCIAL IMPACT 
The psychological impact of returning genomic results has been measured across many 
studies. The most frequently studied concept is perceived risk and intention to change health 
behavior. Findings for these measures are inconsistent.  
A Cochrane review reports that perceived risk becomes more accurate as a result of 
genomic information (Pooled Odds Ratio: 1.46[1.13,1.88]).78 However meta-analysis suggests 
there is no change in perceived risk over time.146 Perceived risk has also been found to affect 
other psychosocial measures—anticipated worry and test-induced distress. However, this effect 
is not linearly related with genomic risk nor is it related to interest in undergoing genomic testing 
or perceived benefits from genomic testing.155 Perceived risk has yet to be fully elucidated in 
genomic studies. Therefore, further research is needed to better understand perceived risk’s 
relationship with genomic risk results. 
Likewise, intention has yielded contradictory results across previous studies. A Cochrane 
review reports no change in intention towards a more healthful diet or increased physical activity 
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in response to genomic risk information (Standardized mean difference: 0.18 [-0.02,0.38]).5 
However, when analyzing intention to change health behaviors by genomic risk categories, some 
studies have found that participants who are told they are at low genomic risk then have lower 
intentions towards healthy behaviors.89,156 For this reason, experts have cautioned against the 
promotion of “genetic invulnerability” in participants with “lower” genetic risk. Some experts 
suggest that stressing gene-environment interaction and personal control in message framing will 
counteract the effect of lowered healthy behavior intentions.157 
Other psychosocial constructs have been measured, but the research thus far is either 
inconsistent or suggests there is no effect. These measures include anxiety,5,78 outcome 
expectations,5 perceived control,158 motivation.151 While genomic risk information may motivate 
health behavior change, the psychological underpinnings motivating such a change have yet to 
be fully elucidated. 
 
F. GAPS IN KNOWLEDGE 
Review of the literature has highlighted four critical gaps in knowledge. First, the impact 
of personal genomic knowledge on psychological changes, health behavior change, and disease 
prevention has yet to be fully elucidated. Second, the motivational effect of personal genomic 
knowledge to lessen health disparities has yet to be addressed. Third, current translational 
genomic studies efforts have not taken into account best practice lifestyle change methods with 
the accompanying individual- and community-level supports. Fourth most current translational 
genomic studies have not created communications that are comprehensible by the general public. 
Therefore, the overarching goal of this proposed research project is to fill those research gaps. 
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G. HEART HEALTHY LENOIR 
 This investigation was conducted as ancillary study to the Heart Healthy Lenoir (HHL) 
study. HHL was a five-year three-project coordinated study spanning the CVD care continuum 
from prevention to treatment to genomics research aimed at reducing CVD risk disparities in a 
rural, low-income county in eastern North Carolina: the HHL Lifestyle Study was a community-
based lifestyle intervention program designed to reduce CVD risk disparity by improving eating 
patterns, promoting physical activity, and supporting weight loss; the HHL Hypertension Study 
was a clinic-based lifestyle intervention program designed to improve blood pressure control of 
patients through their primary care practices by targeting medication and lifestyle management at 
the patient and practice level; and the HHL Genomics Study explored genomic factors associated 
with CVD risk and intervention success. All HHL Genomics participants were also enrolled in 
the Lifestyle or Hypertension studies. 
 
H. SUMMARY 
Enrolling AAs from The HHL Genomics Study, this proposal seeks to determine if 
genomic-risk knowledge will increase motivation towards diet and physical activity as compared 
to no risk communication. 
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CHAPTER 3: A CONCEPTUAL MODEL DEPICTING A 
HYPOTHESIS FOR THE COMMUNICATION OF GENOMIC RISK 
 
A. PROTECTION MOTIVATION THEORY 
Protection Motivation Theory (PMT) suggests that engaging in risk-reducing lifestyle 
changes is governed by an individuals’ perception of risk of the disease.124,159 PMT is based on 
expectancy-value theory which states that adoption of behavior is a function of expectancy 
regarding the consequences of the behavior and the value of those consequences.160 In PMT, 
these cognitive mediational processes take two forms—threat appraisal and coping appraisal. 
Threat appraisal is the process of evaluating a fear appeal—information developing a disease 
state—relevant to the individual’s perception of how threatened the person feels. Threat 
appraisal consists of the following constructs: perceived vulnerability, perceived severity, and 
fear arousal. Coping appraisal is the process of evaluating a fear appeal relevant to the 
individual’s perception of the recommended behavior change to address the fear appeal. Coping 
appraisal consists of the following constructs: response efficacy (Will the behavior change be 
effective?) and self-efficacy (Do I believe I’m capable of performing the behavior?). Threat and 
coping appraisal is predictive of protection motivation which is predictive of concurrent 
behavior.161 However, activating threat appraisal without providing the skills necessary for 
positive coping appraisal may result in maladaptive coping responses—i.e., fatalism. Research 
has shown that individuals at high genetic risk could be fatalistic which results in the lack of 
motivation to make diet and physical activity lifestyle changes.158,162 However, very few studies 
have empirically measured fatalism resulting in insufficient current evidence for fatalism as a 
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mediating mechanism of motivation. This type of maladaptive response has been theorized to 
inhibit protection motivation. 
Research has shown that patients who have just suffered a cardiac event have higher 
motivation towards diet and physical activity changes.77,163 According to PMT, the fear appeal is 
the healthcare provider warning of another cardiac event, the threat appraisal is the patient’s 
perceived risk of another cardiac event, and the coping appraisal is the patient’s perception of 
diet and physical activity change. In cardiac patients, PMT has shown that increased feelings of 
vulnerability results in higher levels of motivation towards diet change.77 This relationship does 
not exist with physical activity.163 However, coping appraisal is strongly associated with both 
diet and physical activity motivation.77,163 Parallel mechanisms to threat and coping appraisals 
have been suggested in the study of personalized genomic risk communications.5,78 Additionally, 
deeper exploration of the mechanisms of motivation towards behavior change due to genomic 
knowledge has been named as a priority in the literature.164,165 For these reasons, PMT is the 
central theorem of this study. 
In summary, genomic risk information may be internalized as more personally relevant 
than general non-personalized risk information. This could lead to a higher threat appraisal based 
on: 1) increased perceived vulnerability due to the use of genomics, 2) increased perceived 
severity of CVD because the genomic results are about CVD, and/or 3) increased fear due to 
increased perceived vulnerability and severity. This could also lead to higher coping appraisal: 1) 
increased perceived response efficacy of diet and/or physical activity changes, and/or 2) 
decreased perceived response-cost of diet and/or physical activity changes. Both threat-appraisal 
and coping-appraisal could lead to protection motivation. Threat-appraisal might also activate 
maladaptive coping-appraisal, which would inhibit protective motivation. Activation of coping-
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appraisal might also inhibit maladaptive coping-appraisal. Overall, protection motivation could 
lead to changes to diet and exercise.
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CHAPTER 4: USING COMMUNITY-BASED PARTICIPATORY 
RESEARCH PRINCIPLES TO DEVELOP MORE UNDERSTANDABLE 
RECRUITMENT AND INFORMED CONSENT DOCUMENTS IN 
GENOMIC RESEARCH1 
 
A. OVERVIEW 
Heart Healthy Lenoir is a transdisciplinary project aimed at creating long-term, 
sustainable approaches to reduce cardiovascular disease risk disparities in Lenoir County, North 
Carolina using a design spanning genomic analysis and clinical intervention. We hypothesized 
that residents of Lenoir County would be unfamiliar and mistrustful of genomic research, and 
therefore reluctant to participate; additionally, these feelings would be higher in African-
Americans. To test our hypothesis, we conducted qualitative research using community-based 
participatory research principles to ensure our genomic research strategies addressed the needs, 
priorities, and concerns of the community. 
African-American (n=19) and White (n=16) adults in Lenoir County participated in four 
focus groups exploring perceptions about genomics and cardiovascular disease. Demographic 
surveys were administered and a semi-structured interview guide was used to facilitate 
discussions. The discussions were digitally recorded, transcribed verbatim, and analyzed in 
ATLAS.ti. From our analysis, key themes emerged: transparent communication, privacy, 
participation incentives and barriers, knowledge, and the impact of knowing. African-Americans 
were more concerned about privacy and community impact compared to Whites, however, 
                                                
1 Skinner HG, Calancie L, Vu MB, et al. Using community-based participatory research 
principles to develop more understandable recruitment and informed consent documents in 
genomic research. PloS one 2015;10:e0125466. 
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African-Americans were still eager to participate in our genomic research project. The results 
from our formative study were used to improve the informed consent and recruitment processes 
by: 1) reducing misconceptions of genomic studies; and 2) helping to foster participant 
understanding and trust with the researchers. Our study demonstrates how community-based 
participatory research principles can be used to gain deeper insight into the community and 
increase participation in genomic research studies. Due in part to these efforts 80.3% of eligible 
African-American participants and 86.9% of eligible White participants enrolled in the Heart 
Healthy Lenoir Genomics study making our overall enrollment 57.8% African-American. Future 
research will investigate return of genomic results in the Lenoir community. 
 
B. INTRODUCTION  
This paper discusses the Heart Healthy Lenoir (HHL) Genomics Study and the use of 
community-based participatory research (CBPR) to engage a rural at-risk community in a 
genomic research study. The HHL Genomics Study is one-third of a larger project designed to 
create long-term, sustainable approaches to reduce cardiovascular disease (CVD) risk disparities 
in Lenoir County, North Carolina. The primary aim of the study is to explore the genomic factors 
associated with CVD risk, clinical outcomes, and responsiveness to CVD risk reduction 
interventions. Participants were recruited from two clinical interventions, the HHL Lifestyle 
Study (ClinicalTrials.gov number: NCT01433484) and the HHL Hypertension Control Study 
(ClinicalTrials.gov number: NCT01425515).166,167 
Lenoir County, North Carolina was chosen for the HHL study for a variety of factors 
including its geographical location in eastern North Carolina, high poverty levels, and the 
community infrastructure. Situated in the heart of the “Stroke Belt”, North Carolina has heart 
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disease, stroke and obesity rates well above the national averages;168,169 Lenoir County rates are 
elevated further still over North Carolina’s averages.170 According to 2014 U.S. Census Bureau 
estimates, 24.9% of Lenoir County residents lived in poverty between 2008 to 2012 which is 
8.1% higher than state averages for the same period.171 The county is also home to many clinical 
and public health efforts, including a community hospital, a federally-funded community health 
center, multiple primary care practices, a local public health department, a revitalized farmers’ 
market, and a community alliance dedicated to improving the county’s health.172 
To our knowledge, prior to our study there have been no genomic studies performed in 
Lenoir County. As such, we used CBPR to engage the community and to learn how best to 
implement our study. Minkler (2010) defines CBPR as “a process that involves community 
members or recipients of interventions in all phases of the research process”.173 The CBPR 
method not only strengthens the relationship between research institutions and their 
communities, but also increases community ownership of health-promoting programs.174 In 
addition, the use of CBPR is an important component of medical research when trying to 
overcome the mistrust of health researchers by vulnerable groups.175,176 According to 2013 U.S. 
Census reports, 40.9% of Lenoir County residents are African-American, compared to 22.0% 
statewide.171 African-Americans are considered a vulnerable group due to a history of 
mistreatment by and lack of consent for medical research conducted on this population (e.g., 
Henrietta Lacks and the Tuskegee Syphilis Study). Therefore, researchers need to be sensitive to 
issues of power and historical context when conducting studies on populations that include 
African-Americans. Corbie-Smith et al. (1999) observed high levels of mistrust regarding 
medical research amongst African-American focus group (FG) participants.176 Many in that 
study mentioned concerns stemming from the Tuskegee Syphilis Study, as well as having a 
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general feeling that they are exploited within the medical research field. The Tuskegee Syphilis 
Study has a continuing legacy that can impact the relationship between African-Americans and 
medical research.176-179 CBPR provides a way for university researchers to hear and address 
community concerns including any historic misgivings in order to promote program feasibility, 
acceptability, and success within the community. These methods can be used to develop study 
materials for the whole community with particular salience for vulnerable groups within the 
community.180-183 In particular, improvements to recruitment and informed consent documents 
can be guided through the use of CBPR methods.184 
In this paper, we present our findings from a CBPR study where we engaged members of 
a rural community that includes a high proportion of African-Americans. Our objective was to 
learn how to design study materials that would instill trust and encourage participation in 
potential research participants, particularly those that are historically under-represented in 
genomic research using feedback and knowledge derived directly from the community. 
 
C. METHODS 
C.1. PARTICIPANTS 
We conducted four FG discussions attended by a total of 35 individuals from Lenoir 
County that were organized into two African-American and two White FGs. We used purposeful 
sampling to ensure that the predominant racial groups in the county, African-American and 
White, were equally represented in our sample. Our recruitment goal was to have racially 
homogenous groups with a balance of men and women. Eligibility criteria included being an 
adult aged 18 and older, English-speaking, and a current resident of Lenoir County. Participants 
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were recruited by key community members (e.g., the Health Director), or through flyers posted 
in the community. Interested participants were screened by phone to determine eligibility. 
 
C.2. FOCUS GROUP GUIDE DEVELOPMENT 
Since we were unaware of any previous genomic studies conducted in Lenoir County, we 
wanted to understand the thoughts, feelings, and concerns both about genomics and heart health 
from Lenoir residents. Co-investigators with experience in the Lenoir community and 
community member assistants worked together to develop a semi-structured discussion guide to 
explore the acceptability of genomic research in Lenoir County based on input from discussions 
with key community residents. The community member assistants were either referred by our 
Community Advisory Council or recruited through a job advertisement in the community. The 
two community member assistants reflected the racial makeup of each FG, either African-
American or White. The community residents who helped develop the guide included Lenoir 
County Health and Human Services agency employees. Based on community input and existing 
literature, we constructed our guide with the hypothesis that there would be unfamiliarity and 
mistrust of genomic research in Lenoir County, and reluctance to participate in a genomics 
study; furthermore, the mistrust and reluctance would be higher in African-Americans.  
 
C.3. FOCUS GROUP PROTOCOL 
The University of North Carolina Chapel Hill Institutional Review Board reviewed and 
approved the study protocol (IRB # 10-0395). The FGs were conducted in winter 2011 with each 
session lasting approximately 90 minutes. Groups were held in a private location at the 
community hospital. A trained co-investigator with extensive qualitative expertise moderated 
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discussions, assisted by a community member of the research team. At the beginning of each 
group, the moderator read the consent form aloud and gave participants the opportunity to ask 
study-related questions before those interested signed the written informed consent form. Next, 
demographic information was collected via survey (e.g., age, race, and education level). Word 
association was then used to assess baseline familiarity with the term ‘genomics’. The FG leader 
then provided an analogy that investigators and community research team members developed to 
help participants define genomics. Next, participants were asked to verbally rate on a scale from 
1 to 10, with 10 being “completely important,” how important genomics is to their health. The 
discussion then commenced covering the following topics: (1) community concerns about 
genomics; (2) thoughts and perceptions about genomics and heart health; and (3) community 
concerns about participation in genomic research. Participants were each paid $25 upon 
completion of the session.  
 
C.4. ANALYSIS 
FGs were digitally recorded and reviewed for quality and completeness. Files were 
transcribed verbatim then verified by listening to the original recordings. To analyze our data, we 
first created a coding scheme using both deductive and inductive methods.185,186 A codebook was 
developed and applied to organize text and assist with interpretation. Using a deductive a priori 
approach, we developed a codebook based on the discussion topics, the hypothesis, and a 
preliminary reading of the transcripts before beginning an in-depth analysis of the data. We then 
incorporated data-driven inductive coding techniques as described by Strauss and Corbin,187 and 
Crabtree and Miller 188 to explore patterns. We applied the codes from the codebook to each line 
of transcript text to identify meaningful units of text, connected the codes and identified themes, 
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and confirmed the findings through a process of clustering the themes.188 While codes were 
mutually exclusive, lines of text could have been marked with multiple codes if more than one 
theme was represented. 
We used a qualitative data analysis software program, ATLAS.ti 6.2, to facilitate 
analysis. After each transcript was imported into the software and coded, we retrieved text on 
specific codes or combination of codes to enable thematic analysis of particular topics.189 From 
this, we looked at the quotes in the context of the documents and assessed the levels of 
agreement and saliency of themes. Finally, we summarized our findings and chose quotes 
representative of each theme for presentation.   
 
D. RESULTS 
D.1. DEMOGRAPHICS 
A total of 35 participants attended the FGs, with 8-10 attendees per group (Table 4.1). 
Across all FGs, participant ages ranged from 22 to 86 years with the average age being 57 years. 
Over half the participants were self-identified African-Americans (n=19). The majority of 
participants were females (n=23). All participants finished high school with approximately half 
having a college degree or higher. Compared to 2013 U.S. Census Bureau statistics for Lenoir 
County,171 our FGs had more African-Americans (due to purposeful sampling), more females 
(66% in the FGs versus 52.2% in Lenoir County), and a higher education level (100% finishing 
high school and 51% having a Bachelor’s degree or higher in the FGs versus 77.8% and 14.1%, 
respectively, in Lenoir County). The majority of FG participants also had a known family history 
of heart disease (n=23) and had health insurance (n=24).  
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TABLE 4.1. CHARACTERISTICS OF FOCUS GROUP SAMPLE (N=35) 
Characteristic FG1 FG2 FG3 FG4 All FGs 
N=9 N=10 N=8 N=8 N=35 
Race      
 African-American 100% 100% --- --- 54% 
N=9 N=10   N=19 
 White --- --- 100% 100% 46% 
  N=8 N=8 N=16 
Age (SD) 48 y (10) 57 y (5) 65 y (13) 60 y (20) 57 y (14) 
Age Range 22y – 56y 48y – 67y 47y – 85y 38y – 86y 22y – 86y 
Gender      
 Male 56% 10% 38% 38% 34% 
N=5 N=1 N=3 N=3 N=12 
 Female 44% 90% 62% 62% 66% 
N=4 N=9 N=5 N=5 N=23 
Education      
 High School Graduate 100% 100% 100% 100% 100% 
N=9 N=10 N=8 N=8 N=35 
 Bachelor’s Degree or 
higher 
56% 50% 25% 75% 51% 
N=5 N=5 N=2 N=6 N=18 
Family History of Heart Disease       
 Yes 33% 70% 75% 88% 66% 
N=3 N=7 N=6 N=7 N=23 
 No 45% 20% 25% 12% 26% 
N=4 N=2 N=2 N=1 N=9 
 Don’t know 22% 10% --- --- 8% 
N=2 N=1   N=3 
Health Insurance       
 Yes 44% 70% 62% 100% 69% 
N=4 N=7 N=5 N=8 N=24 
 No 44% 30% 38% 0% 29% 
N=4 N=3 N=3 N=0 N=10 
 Non-response 12% --- --- --- 2% 
N=1    N=1 
 
Table 4.1 provides demographic characteristics of all focus groups. Data are presented as mean 
(standard deviation), range, or percent and N. 
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D.2. DEFINING GENOMICS 
Only one to two people per FG were familiar with the term “genomics.” Soliciting words 
and ideas participants associated with “genomics” prior to providing the analogy yielded widely 
varied responses such as “geometry,” “informative,” and “a continuing of possibilities.” The 
genomics analogy was then given to provide a conceptual framework for participants to better 
articulate their perspectives during the remainder of the focus group. 
“Genomics is a term that describes the study of all of a person’s genes (their genome), 
including how genes interact with each other and with the person’s environment. This is 
different from genetics, which is the study of a single gene in isolation. Think of 
genomics as a garden and genetics like a plant in your garden. If the plant is not 
flowering, you could study just the plant itself (genetics) or look at the surroundings to 
see if it is too crowded or there is not enough sun (genomics).” 
 
Following the provision of the analogy, participants verbally reported finding the analogy 
helpful in understanding what we meant by genomics for our discussion. Participants also made 
connections between our genomics analogy and family history of common chronic diseases (e.g., 
CVD, type 2 diabetes, or cancer). Participants’ responses suggest that they understood the 
distinction between single gene diseases and genomics, which was the purpose of our analogy. 
Participants then verbally reported genomics as being highly important to their health ranking it 
an 8.5 out of 10, with 10 being “completely important.” This importance did not vary across 
racial groups. 
 
D.3. FOCUS GROUP THEMES 
Five themes emerged from the discussion about genomics: transparent communication, 
privacy, participation incentives and barriers, knowledge, and the impact of knowing. There were 
no major thematic differences between FGs or racial groups; therefore the results for each theme 
are representative of all participants regardless of race. Places where one racial group spoke on 
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additional information (e.g., Theme 2: Privacy and Theme 4: Knowledge) are noted within the 
theme. Below we present a summary of each theme and how we used that information to tailor 
our materials.  
 
D.3.1. THEME 1: TRANSPARENT COMMUNICATION 
D.3.1.A. RESULTS 
 Participants found genomics to be 
a highly “technical word” and requested 
that researchers use simple, non-technical 
language instead. This theme arose when 
discussing how to describe the project to 
the community as well as how to describe the risks and benefits of participation. Many people 
wanted plain-speak, and specificity regarding research aims and the possibility of receiving 
negative health information. Specifically, they wanted research staff to be up-front about any 
risks involved with the study. Participants felt that technical language could obfuscate the 
presence of risk either through poor communication of what would happen to their genomic data 
or poor communication of what could happen to their health as a result of their “genomics.” 
Contrary to our hypothesis, there were no major thematic differences between racial groups. 
 
D.3.1.B. IMPLICATIONS 
 Based on this finding, we incorporated transparent communication into HHL Genomics 
materials. As such, we were purposeful in using non-technical language in study recruitment and 
informed consent materials. Our goal was to have transparent communication that fostered trust 
“I would like to know what you’re really looking 
for. Talk to me” ~ AA 
 
“Be honest and tell it like it really is, and don’t 
try to sugar coat it.” ~ W 
 
Figure 4.1. Transparent Communication 
Quotations 
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between researchers and the community. Working with our community team members, we honed 
language that was easily understood. For example, instead of describing the HHL Genomics 
study aim as “determining whether genomic signatures can be used to predict responsiveness to 
interventions that underlie CVD disparities,” the aim was described as “wanting to learn more 
about genetic factors related to heart disease and needed treatments.” 
 
D.3.2. THEME 2: PRIVACY 
D.3.2.A. RESULTS 
 Many participants discussed 
privacy concerns about the handling of 
personal information and blood. 
Participants wanted transparent 
communication about who would have 
access to their data and that “qualified” 
professionals would handle blood draws (e.g., research staff, physicians, or nurses). Participants 
also wanted explicit assurances that their personal information would be protected, particularly 
regarding how their blood was handled after the study. If these privacy concerns were addressed, 
the majority of participants stated that they would not have barriers against participation in a 
genomics study. 
 African-Americans spoke of a mistrust of medical research that Whites did not. Many 
African-Americans voiced mistrust of science in general and of medical professionals even 
mentioning conspiracy theories. Their main privacy concern was of being identified from their 
genetic information. Despite this and in contrast to expectations, most African-American 
“I would like to know about the privacy part [as an 
incentive to participate].” ~ W 
 
“At the hospital though, after they test your blood or 
use your blood for whatever purpose, isn’t that 
blood destroyed? ... How do you know that’s what’s 
happening [here]? They show [information leaks] 
on TV on the Sci-Fi channel and everything.” ~ AA 
 
FIGURE 4.2. PRIVACY QUOTATIONS 
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participants voiced great trust in HHL researchers and even eagerness to participate in our 
genomic study. 
 
D.3.2.B. IMPLICATIONS 
 The finding about privacy led to the stressing of de-identification of samples and 
participant rights under the Genetic Information Non-discrimination Act (GINA) in the informed 
consent form. Also, recruitment and informed consent materials explicitly discuss the handling 
of blood samples. While the study did decide to keep samples for future research, it was 
emphasized that these samples are de-identified and that participants have the right to withdraw 
their blood from the study at any point in time. 
 
D.3.3. THEME 3: PARTICIPATION INCENTIVES AND BARRIERS 
D.3.3.A. RESULTS 
 Receipt of money was 
named as an incentive for the time 
and financial costs of study 
participation (e.g., travel to the 
study site). Conversely, the 
concern that participation would 
require payment for genomic analyses and blood draws was stated as a barrier to participation. 
“Even though we’re not identifying ourselves and you say after this you know nobody would 
know anybody. How do we know down the road somebody won’t find out who we are?  And 
that’s the only inhibitions that I have.” ~ AA 
 
Figure 4.3. Privacy Quotation—African-American Mistrust 
 
“[A participation incentive would be that] the services are 
gratis and medicine can be that way.  And they cover 
travel.” ~ W 
 
“Prevention. It’s like…be real positive about prevention, 
heart disease and prevention of heart disease.” ~ AA 
  
Figure 4.4. Participation Incentives and Barriers 
Quotations 
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Once the FG moderator explained that study participation would be free, participants stressed the 
importance of explicitly stating that in study materials so that financial concerns would not be a 
barrier to participation. Participants also repeatedly spoke of receiving CVD results from our 
genomic study. Not only was this an important incentive unto itself, but participants also spoke 
of using this information to change their lifestyle. Participants wanted incentives that would 
support lifestyle changes, such as improving diet or increasing physical activity. For example, 
health center memberships, gym shoes, and support in preparing healthy meals were mentioned. 
There were no major differences between racial groups for this theme. 
“[Researchers would benefit from] just recognizing that people are different before you go 
through with the study. I would figure out if people do want an incentive with money or people 
just want to do it just to figure out the information about their genes.” ~ AA 
 
Figure 4.5. Participation Incentives and Barriers Quotation 
 
D.3.3.B. IMPLICATIONS 
From this finding, we learned the importance of stating all monetary gifts and expenses 
(or lack thereof) upfront and explicitly in our recruitment materials. In addition to the monetary 
incentive payment schedule, our materials also included explicit statements that participation in 
our program, which included blood draws and genomic analysis, would not cost participants 
anything, though transportation to the study site was at the participants’ expense. For example, 
after explaining the study protocols, the informed consent document stated, “The program is free, 
but travel costs to and from the measurement visits are not covered.” Additionally, we learned 
that participants saw value in their genomic CVD results and wanted that information returned to 
them. Lifestyle supports were strengthened in the two HHL clinical studies as a result of these 
FGs. HHL Lifestyle participants were provided with healthy recipes and HHL Hypertension 
Control participants were provided with home blood pressure monitors. 
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D.3.4. THEME 4: KNOWLEDGE 
D.3.4.A. RESULTS  
 Participants stated interest in 
genomics for societal, health, and 
individual benefits. Contributing to the 
larger genomics knowledge pool was 
named as important by both White and 
African-American participants. 
Additionally, African-Americans spoke specifically of adding to the knowledge pool about 
African-Americans. All participants stated interest in the perceived health benefits of genomic 
knowledge. Particularly, they believed that genomics could yield knowledge about disease states 
like CVD and Type 2 Diabetes and could then be used to improve their own health and the health 
of future generations of their family. Again, African-Americans shared this sentiment but were 
also interested in the perceived health benefits of genomic research for the African-American 
community at large. Lastly, participants were interested in genomics for the perceived individual 
benefits. In general, participants viewed personal genomic information as an added catalyst to 
make lifestyle changes, and the vast majority of participants wanted individualized genomic 
feedback from the study. The desire for returning genomic results was evident irrespective of 
race. (Additional quotes can be found in Appendix 4.1. Additional Quotations About 
Knowledge.) 
“If I was to do it [the study] I would want some feedback on my results and also the overall 
findings on what I could do to change if I had to do any changes.” ~ AA 
 
Figure 4.7. Knowledge Quotation 
 
“I would love to be part of the solution.” ~ W 
 
“We need to know these things [results of 
genomics research] and we need more support in 
these [African-American] communities, they’re 
not as tight knit as they used to be . . . we need a 
lot of this education.” ~ AA 
 
Figure 4.6. Knowledge Quotations 
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D.3.4.B. IMPLICATIONS  
This finding led us to explicitly state in our recruitment and informed consent materials 
that the HHL Genomics study was being performed to help society. We did this to avoid 
‘therapeutic misconception’ in our materials since our FG participants seemed equally if not 
more motivated to participate in genomic research due to perceived health benefits or the 
possibility of receiving genomic results. Appelbaum defines therapeutic misconception as the 
conflation of research goals with therapeutic treatment.190 Furthermore, we also stated in our 
recruitment and informed consent materials that participants would not receive their individual 
results. Materials stated that since “the results of the blood tests for genomics is not a routine test 
and would not be easy to understand by either you or your doctor, we will not send you the 
results of these tests.” 
 
D.3.5. THEME 5: THE IMPACT OF KNOWING 
D.3.5.A. RESULTS 
VALUE OF KNOWING  
 The consensus among the FGs was that the knowledge gained in genomic studies would 
benefit both society and the individual; furthermore, this information would lead to better health 
decisions. Some participants expressed negativity about receiving personal genomic information. 
Concerns regarding genomic knowledge revolved around the fear of a “pre-determined” disease 
state, confusion around what genomic results would mean, and possible depression and stress 
from thinking about their “genomics” all the time.  
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“You have some that want to know the future, you have some that don’t want to know the future. 
And I guess [knowledge] can be harmful in some ways too, knowing too much.” ~ W 
 
Figure 4.8. The Impact of Knowing Quotation—Value of Knowing 
 
PERCEIVED CONTROL  
 The majority of participants reported feeling that they were ultimately in control of their 
health no matter what their “genomics” said. Repeatedly, participants alluded to genomic 
knowledge as something to empower them in making health decisions. Alternatively, others took 
the perspective that they could not change what was in their genes, sometimes citing family 
disease history as justification. However, the vast majority of participants, regardless of race, felt 
that lifestyle choices were controllable (e.g., smoking, diet, and exercise), and that having 
genomic information would empower them to make lifestyle choices. 
 “It’s not really a study but it’s a group that’s helping us to more [or] less take charge of our 
well-being as far as our health, eating right, and doing the right things as far as you know 
keeping our health intact. So I would try to participate in as many studies as I have to, to take 
care of me.” ~ AA 
 
Figure 4.9. The Impact of Knowing Quotation—Perceived Control 
 
 
D.3.5.B. IMPLICATIONS  
Our findings suggest that knowing individualized genomic results is highly valuable and 
empowering to our FG participants, therefore we explicitly addressed this in our recruitment and 
informed consent materials. Materials explicitly stated that individualized results would not be 
returned. HHL made this decision due to researchers not anticipating return of genomic results 
being so coveted in this community and not having genetic counselors in our research plan. 
Given the range of responses about knowing genomic information, counselors and other forms of 
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support were deemed to be ethically necessary if HHL were to return individualized results to the 
community. 
 
E. DISCUSSION 
The goal of HHL is to reduce CVD risk disparities in Lenoir County, NC. In order for our 
interventions to succeed, we needed a strong relationship with the community as well as the 
ability to enroll a representative sample of the population into our study. Our approach was to 
use CBPR principles to tailor the recruitment and informed consent processes to both foster trust 
and transparency in our relationship with the community and meet our recruitment goals. 
Through FGs, we found that participants were not very familiar with the term genomics. 
This is consistent with previous studies, which demonstrate genetic knowledge to be low 
nationwide.137,138 Christianson et al. (2010) replicated this finding in North Carolina and also 
demonstrated a racial difference in understanding where African-Americans more frequently 
reported less genomic knowledge.191 Regardless, this did not seem to diminish our participants’ 
desire to participate in genomic research. Our hypothesis was that Lenoir County residents would 
be unfamiliar and mistrustful of genomic research and would therefore be reluctant to 
participate; we believed this mistrust and reluctance would be higher in African-Americans. All 
participants voiced trust in HHL researchers and a willingness to participate in our genomic 
study. While African-Americans did speak of a legacy of mistrust and their privacy concerns 
stemming from that, they simultaneously voiced trust in HHL researchers and a willingness to 
participate in our genomic study. Other studies have also reported positive attitudes towards 
participation in genomic research.192 However contrary to some published reports,193 our FG 
participants did not report a difference in willingness to participate by race. (Enrollment into 
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HHL Genomics by our 35 FG participants was not tracked.) Irrespective of race, participants 
expressed two distinct sentiments about genomic knowledge: knowledge as empowering and 
knowledge as predetermination. The Protection Motivation Theory could explain these divergent 
viewpoints. The theory postulates that those with increased perceived threat may engage in 
protective health behaviors while those who believe that people have no control over their health 
may lose motivation to engage in protective health behaviors.159 Research shows that an 
individual’s threat beliefs can predict their perceived control in response to genomic 
knowledge.194 Genomics knowledge was a major participation incentive for our FG participants. 
The majority of participants wanted the option to obtain individualized genomic results. 
Returning genomic data has been documented in other several populations.195-198 In accordance 
with CBPR principles, investigators explored ways to address community wants while being 
cognizant of debate in the field as to whether individual results should be returned and how that 
should be done.199,200 Ultimately, we determined that HHL did not have the infrastructure to 
responsibly return results (e.g., genetic counselors), but as a result of the findings presented here, 
we did initiate an ancillary study investigating methods to return the HHL Genomics Study 
results to the Lenoir community. Future genomic research studies may consider the question of 
returning results early in the planning process in order to be responsive to community wants. 
Limitations in this study include positive bias towards research since our participants live 
in an area with many public health interventions and opted to join the FGs, indicating at least 
some level of trust and interest in medical research. Some participants were also already 
participating in the HHL Lifestyle or Hypertension Control studies. Another limitation is that 
after providing our analogy, participants verbally reported finding the analogy helpful but we did 
not perform word associations or use any other method to determine if participants’ descriptions 
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of genomics changed after receiving the analogy. Lastly, this data is representative only of the 
individuals in the FG, which was purposefully sampled to ensure equal representation of the 
predominant racial groups in the county; all possible opinions of the larger populations may not 
have been captured. Experienced moderators ensured that all voices were heard in the group to 
gain the broadest representation of opinions possible. Future studies may benefit by utilizing 
other data collection methods that allow anonymity, such as a survey, which may elicit divergent 
views that people may be uncomfortable voicing within a group. 
Strengths of this study include that, to our knowledge, this is the first study to include a 
lay-analogy in defining genomics for participants, which seemed to help frame the conversation. 
Another strength of this study is the use of CBPR. Community research team members helped 
develop the FG guide and administer the FGs. Also, our study engaged populations traditionally 
under-represented in medical research, specifically African-Americans and those from 
underserved rural areas. Employing CBPR methods of co-learning to build trust between 
researchers and community members allowed researchers to explore the presence of and 
remedies to misconceptions and suspicions about medical research within the Lenoir community.  
Overall, this study provided valuable information on the motives of potential genomic 
research participants in Lenoir County as well as ways to use that information to tailor informed 
consent and recruitment materials. These efforts resulted in not only high participation in our 
study, but also more African-American than White participants, which is contrary to much of the 
previous literature.192,193 The HHL Genomics Study enrolled 253 African-American participants 
and 185 White participants, which captures 82.8% of the eligible participant pool. Of the eligible 
African-American participants, 80.3% enrolled in our study thereby making the HHL Genomics 
participant population 58% African-American. We believe that using CBPR methods to elicit the 
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community voice and accordingly adjust study materials and communications yielded a 
meaningful consent and recruitment process that enabled us to recruit a high percentage of our 
eligible population and particularly the eligible African-American population. We also believe 
that CBPR methods are generalizable to other genomic research endeavors and could be used to 
improve genomic study participation in historically underserved areas as well as in minority 
populations.  
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CHAPTER 5: COMMUNICATING GENOMICS RESULTS FOR A 
MINORITY AUDIENCE: DEVELOPMENT OF A PROTOCOL 
 
A. OVERVIEW 
Since 2003 there has been a call to include more minorities in genomic research. Given 
the historical context of African-American (AA) exploitation for medical research, this can be a 
challenge in the AA community. Applying participatory research principles to genomic research 
suggests that including return of results in genomic studies may be warranted. However, few 
studies exist to guide the return of genomic results (ROR). This study describes the participatory 
development of a ROR protocol for use in a general African-American audience. 
Six message-testing groups were conducted with AA individuals from a rural southern 
community.  Individual interviews were held to return fictional genomic results, and then focus 
groups were conducted for line-by-line participant feedback. Genetic literacy was assessed at 
baseline. 
Thirty-two African-Americans participated. The group was mostly female (n=30); 
average age was 52 years; most had a high school degree or higher (n=29); and most were high 
genetic literacy (n=24). Three key lessons were learned. 1) Participants preferred the use of 
specialized genetic terms. 2) Participants wanted all self-relevant information. 3) Participants 
wanted genomics education. The final result is an ROR protocol that uses precise scientific 
terminology that is supported by various supplemental materials to introduce and reinforce 
genomic concepts.  
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B. INTRODUCTION 
Since the sequencing of the human genome in 2003, the field of genomic research has 
grown tremendously.201,202 Genomic research holds tremendous promise for illuminating the 
biological bases of disease, identifying pharmacological treatment targets, and birthing the field 
of personalized medicine.30,203-205 However, to date, most genomic research studies focus on 
participants with European ancestry. This leaves other populations, such as African-Americans 
(AAs), underrepresented in genomics studies and subject to ineffective or less effective 
genomics-based health advances.206 This unequal inclusion of AAs in genomic research may 
contribute to race-based health inequalities. The call for more minorities in genomic research 
studies has been a long-standing one,207 but it is imperative to fulfill such goals given the 
applications of genomics research to the public health and assessing genomic-based risk of 
disease, especially in a growing direct-to-consumer market for genetic health products.207,208 
However, in AA communities, the history of misuse and exploitation of the AA 
community by medical researchers, healthcare providers and/or academic researchers has led to a 
culture of mistrust and suspicion towards medical research initiatives.176-178,209-213 Community-
Based Participatory Research (CBPR), a paradigm of research in which clinicians or academic 
researchers partner with research participants to investigate scientific research questions,173 has 
been used in the past to establish relationships and trust and encourage study participation in 
minority communities.214,215 Unfortunately, CBPR techniques are not often applied to genomic 
research studies, though some of our previous work demonstrates that the application of CBPR 
principles to genomic studies may increase AA participation rates.216 
Genomic studies are increasingly investigating the impact of returning personalized 
genomic health information to participants.5,10,148,150,151,217 Particularly, the return of results 
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(ROR) is being researched as a tool to help communicate and therefore affect risk for common 
chronic diseases such as cardiovascular disease (CVD). Research studies investigating how to 
return results to participants in a manner that promotes understanding are few in number, leaving 
a gap in the literature. Additionally, participants in existing ROR studies come from the same 
pool as genomic studies—white, urban, highly educated, high health-literate individuals. 
Therefore, an additional gap in the literature exists regarding how to create ROR information that 
works appropriately with minority communities. The purpose of the current study is to help fill 
those gaps by developing a ROR protocol suitable for use in an AA rural population with literacy 
and numeracy heterogeneity. 
 
C. METHODS 
C.1. BACKGROUND 
This protocol was developed for use in a larger study investigating the personal utility of 
personalized genomic results in motivating participants toward health-protective behaviors 
related to CVD (ClinicalTrials.gov number: NCT02208180). The larger study is a proof-of-
concept randomized controlled trial whose primary outcome is motivation towards diet and 
exercise. The focus of the work presented here is the design and testing of the ROR protocol. 
Our ROR approach was guided by previously published protocols.151,154,157 We were 
interested in developing a protocol that conveyed risk verbally rather than numerically. 
Numerical representation of absolute risk is the most common method for reporting perceived 
risk.218 However, numerical risk estimates can be difficult to understand, even for high literacy 
individuals.219 Given the expected literacy and numeracy heterogeneity of our population, we 
searched for published protocols that considered numeracy and/or literacy issues when reporting 
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genetic information for common chronic diseases. Through a literature review conducted in 
2013, several potential studies were identified.10,149,151,153,154 The Grant and Cho protocols were 
thought to be the best protocol to fit our study population as the approach used in their ROR 
protocols best addressed heterogeneity in numeracy and literacy levels153,154. The Grant protocol 
was used as the core of our protocol with elements of the Cho protocol incorporated.  
In brief, the Grant ROR protocol draws from Leventhal’s Common Sense Model in 
motivational psychology.220 The goals of the session are to increase motivation with a focus on 
risk perception and self-efficacy. Visual aids are used to help bridge genomic literacy and 
numeracy gaps.157 The Cho risk summary was used at the conclusion of our protocol.154 The 
summary was presented in the fashion of a stoplight: Red for summary of genomic information, 
yellow for summary of lifestyle information and statistics about CVD mortality, and green for 
lifestyle recommendations to reduce CVD risk. The lifestyle recommendations given were the 
same as in the Heart Healthy Lenoir (HHL) Project—the parent project for this study.221 
(Appendix 5.1) 
The ROR genomics protocol was designed as a “teachable moment to encourage 
behavior change” in those already at high environmental risk.157 Feelings of fatalism in those at 
high genetic risk and feelings or invulnerability in those at low genetic risk have been shown to 
reduce motivation to change.222 Evidence suggests that balanced messages between risk and 
personal control, such as in this protocol, can pre-empt these extreme mindsets.151,194,223 The 
emphasis on personal control at the end of the protocol was designed to simultaneously motivate 
and avoid harm in participants. 
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C.2. ADAPTATION OF ORIGINAL PROTOCOL 
We made the following adaptations to the Grant Study protocol: changing the gene-
environment educational statistics from representing Type 2 Diabetes to CVD, including an 
additional educational page explaining SNPs at the beginning of the protocol, and a detailed 
verbal script of the ROR protocol was created.  Also, instead of presenting a combined 
phenotype and genotype risk as in the original Grant protocol, these representations were 
separated because of the limited evidence on how to accurately represent a combined risk. The 
Framingham Risk Score (FRS) was used to represent phenotypic risk for CVD. 
In contrast to the Grant study, the protocol in our study was to be administered by 
researchers, not certified as genetic counselors. Therefore, free access to a genetic counselor was 
available as an additional resource for participants. Participants were able to make an 
appointment for a future session with the counselor if they wanted additional counseling after the 
research session. 
Once the initial ROR protocol was designed and scripted, it was then tested in a sample 
from the target population to assess comprehensibility, particularly genomic literacy and cultural 
appropriateness.  
 
C.3. PARTICIPANTS 
In order to test the feasibility and acceptability of the modified Grant/Cho ROR protocol 
in a rural, African American population, we conducted six message-testing groups over the 
course of three weeks. Participants were recruited from HHL—a CVD risk reduction study in 
Lenoir County, North Carolina (details described elsewhere 221,224). Eligibility criteria included 
being African-American, being enrolled in both the Lifestyle Weight Loss groups and the 
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Genomics sub-studies of HHL,221 completing the 24-month HHL follow-up visit, and providing 
express written consent to be contacted for further HHL study opportunities. Mailings and phone 
calls were used for recruitment. Participants were each paid $30 upon completion of the 
message-testing session. The Institutional Review Board at the University of North Carolina at 
Chapel Hill approved this study (IRB# 14-1500). 
 
C.4. MESSAGE-TESTING PROTOCOL 
The message testing protocol consisted of a structured cognitive interview followed by a 
focus group.107,108,225-228 All sessions, interviews and focus groups were digitally recorded. In 
brief, the moderator read the consent form aloud and gave participants an opportunity to ask 
questions before signing the written informed consent. The agenda, individual interviews 
followed by reconvening for a focus group, was explained to the group. It was made clear that all 
“results” returned in the sessions were fictional and did not pertain to any actual participant. 
Trained research assistants conducted the individual interviews in a private room with each 
participant. The cognitive interview session was approximately 20 minutes long. At the 
beginning of the interview, the REAL-G (The Rapid Estimate Of Adult Literacy In Genetics) 
was used to assess genomic literacy;229 an 8-item scale with possible scores ranging from 0 – 8 
with 8 indicated the highest genetic literacy. The research assistant then administered the ROR 
protocol using fictional genomic results. A brief check for comprehension was then assessed, 
asking participants to provide feedback on the clarity of the ROR protocol and any thoughts on 
edits to the materials.  
Participants then reconvened as a group to comment on the protocol. This focus group 
lasted approximately 1 hour and was held in a private location. The primary investigator served 
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as the facilitator and a research assistant served as note-taker. Participants were given a copy of 
the ROR script to help aid the discussion. The moderator then led the group in a page-by-page 
review of the ROR protocol, soliciting participant feedback on script wording, clarity of the 
script and the images, additional genomic education materials desired, and any other text 
changes participants felt would increase comprehension. Genomic and phenotypic risk categories 
were randomly varied among the participants to get feedback on differing risk categories (Table 
5.1).  
After two focus groups, participant feedback was incorporated to produce an updated 
protocol, which was presented alongside the original protocol in the following 2 focus groups 
until a final protocol was achieved after 6 groups.  
 
C.5. ANALYSIS  
Notes and digital recordings were reviewed to ensure accuracy and consensus of protocol 
modifications. After completion of all focus groups, digital recordings were transcribed 
verbatim. A second reviewer verified the transcripts by listening to the original recordings. A list 
of protocol modifications requested by the sample population was developed based on discussion 
topics.  
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TABLE 5.1. FOCUS GROUP DESCRIPTIONS 
Week Groups Phenotypic Risk 
Presented 
Genomic Risk 
Presented 
Resulting Protocol Tailoring 
1 1 & 2 Average High 
Average 
Low 
• Begin protocol with 23andMe “What 
is a SNP?” video. Link also provided 
on last page of protocol. 
• Visual aid for genetic education 
added. 
• Physical cues added to script to call 
attention to visual aids. 
• Chart explaining components of FRS 
and change in components over the 
course of HHL added. 
• For each SNP added: odds risk score, 
general information about metabolic 
pathway. 
• Keyword sheets added. 23andMe 
sheet added to take-home packet. 
Sheet with SNP definition added 
during protocol presentation. 
• NHGRI “Guide to your Genome” 
added to take-home packet. 
• Language adjustment: genetic words 
added, numerical words removed. 
• Color adjustment in summary chart. 
Red to orange. 
2 3 & 4 High High 
Average 
Low 
• Cookbook added to take-home 
packet. 
• Body mass index added to keyword 
sheet during protocol. 
• More genomic education added 
regarding the SNPs in this study. 
• Language adjustment: explanations 
added, numerical words adjusted. 
3 5 & 6 Low High 
Average 
Low 
• None. 
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D. RESULTS 
D.1. DEMOGRAPHICS 
A total of 32 participants attended the message testing groups, with 3-8 attendees per 
group. All participants self-identified as African-American. Participant ages ranged from 27 to 
68 years, mean age was 52 years (Standard Deviation [SD] 10). Most participants were females. 
The majority of participants finished high school with approximately a quarter having a college 
degree or higher (n=7). This population was of average high genetic literacy (Mean [M] 5.0, SD 
2.7; Median 6.0). High literacy participants (n=24) mainly drove this score (M 6.3, SD 1.4; 
Median 6.0). (Table 5.2). 
 
TABLE 5.2. FOCUS GROUP DEMOGRAPHICS 
Characteristic Group 1  
N = 3 
Group 2 
N = 3 
Group 3 
N = 8 
Group 4 
N = 7 
Group 5  
N = 7 
Group 6 
N = 4 
All 
Groups 
N = 32 
Age M(SD) 56y (3) 50y (17) 50y (13) 54y (6) 55 (7) 46 (14) 52y (10) 
Age Range 53y – 58y 31y – 62y 33y – 68y 43y – 61y 46y – 65y 27y – 59y 27y – 68y 
Gender        
Male --- --- N = 1 --- N = 1 --- N = 2 
Female N = 3 N = 3 N = 7 N = 7 N = 6 N = 4 N = 30 
Education        
Less than High School  --- N = 1 --- N = 1 --- N = 1 N = 3 
High School Degree or 
higher N = 3 N = 2 N = 7 N = 6 N = 7 N = 3 N = 29 
REAL-G Score M(SD) 7.3 (0.6) 4.3(3.8) 4.3 (2.7) 4.7 (3.1) 5.9 (1.9) 4.0 (3.6) 5.0 (2.7) 
High Literacy M(SD) 7.3 (0.6) 6.5 (0.7) 5.5 (1.5) 6.4 (1.5) 6.3 (1.5) 7.0 (1.4) 6.3 (1.4) N = 3 N = 2 N = 6 N = 5 N = 6 N = 2 N = 24 
Low Literacy M(SD) --- 0 0.5 (0.7) 0.5 (0.7) 3 1 (0) 0.9 (1.0) --- N = 1 N = 2 N = 2 N = 1 N = 2 N= 8 
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D.2. KEY LESSONS LEARNED 
Three key lessons emerged from the discussion about return of genomics results protocol 
around genomics education, personal utility, and language usage. Below we present a summary 
of each lesson learned and how we used that information to tailor our materials.  
 
D.2.1. LESSON 1: GENOMICS EDUCATION 
Participants requested expanded genomics education materials both within the ROR 
script and as a resource to take home.  
 
D.2.1.A. WITHIN THE ROR SCRIPT 
 The initial script contained one page of SNP education at the beginning of the protocol. 
The information was conveyed primarily verbally using a visual aid. This was done to educate 
participants about SNPs, however, participants wanted more information. Therefore, the first 
page was expanded to include an explanation of genes, DNA, and transcription (Figure 5.1). 
Participants also indicated it was helpful to precede the ROR script with “What are 
SNPs?” “What are SNPs?” is a publically available animated educational video created by 
23andMe.230 Participants found this to be a non-intimidating introduction to the topic as well as 
to have memorable images to help conceptualize the concept of SNPs (Figure 5.2). 
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FIGURE 5.1. GENOMICS EDUCATION IN ROR SCRIPT 
 
  
	
	
 
 						 All	genes	have	the	same	4	DNA	Bases:		A		C		T		G						
Gene	Sequence																																Protein																																												Function		A		T		G		C		T		G																																												Protein	“A”																																												Digests	milk				
	
Person	A:	 	 A			C			C			G			C			T			A			T			G			G			C			G			C			T…		
	
Person	B:	 	 A			C			G			G			C			T			G			T			G			G			C			G			C			T…		 		
 
 
 
 
 
 
 
 
 
SNP	or	
Single	Nucleotide	Polymorphism	or	small	DNA	change		
There	are	no	specific	medical	actions	your	doctor	can	recommend	to	take	based	on	these	results.	
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Figure 5.2. "What Are SNPs?” Video 
 
D.2.1.B. TAKE-HOME RESOURCES 
Participants were provided with two educational resources to take home. The first was a 
publically available “Key Word for Genetics” guide created by 23andMe that explains SNPs and 
phenotypes. The second was a pamphlet entitled “A Guide to Your Genome” created by the 
National Health Genomic Research Institute (NHGRI) (Figure 5.3). Most participants reported 
they liked this information, as additional resources to learn more at home; some participants said 
the extra information did not matter to them. All participants agreed these materials were most 
useful as additional resources rather than as part of the return of results protocol. 
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3a. 23andMe Keywords sheet  3b. NHGRI pamphlet 
https://www.23andme.com/gen101/graphics/geneti
cs/  
 https://www.genome.gov/pages/education/allaboutthehu
mangenomeproject/guidetoyourgenome07.pdf  
 
FIGURE 5.3. TAKE HOME GENOMIC EDUCATION RESOURCES 
  
A G G C A C C A C T G A G
A G G C A C C A C T G A G
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A G G C A C C A C T G A G
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A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
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A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
#1) PHENOTYPE
This word refers to the physical and 
behavioral characteristics of an individual. In 
most cases, both genes and environment 
contribute to phenotype. An example of 
a phenotypic trait is the ability to taste a 
bitter flavor in raw broccoli, which can affect 
whether you like it. (We’ll assume that if you 
can taste the bitterness, you don't like raw 
broccoli.)
#2) GENOTYPE
This word can be used in several ways. It can 
refer to your DNA sequence at a particular 
place, like the SNP shown here (either C or G). 
It can refer to your personal collection of 
genetic variants. As a verb, it refers to the 
process of determining your sequence, as in 
the introductory paragraph.
#3) CELL
Your body contains 50 trillion of these 
microscopic living units. They are found
everywhere, from the surface of your tongue 
to the inside of your bones. Cells perform 
specific jobs in your body. The 
way they perform their jobs affects your 
phenotype.
#4) PROTEIN
Cells perform their jobs with molecular tools 
called proteins. Some proteins are
used as the building blocks of hair. Others are 
used to digest your food. In tongue cells, one 
kind of protein detects bitter chemicals and 
sends a signal to your 
brain. The way a protein works—or
doesn’t—also affects your phenotype.
#5) GENOME
The genome is a master blueprint for making 
all the different parts of you, and 
a complete copy can be found in each of your 
body’s cells. The genome contains about 
20,000 individual blueprints for different 
protein tools, plus a whole lot of other stuff 
whose function is unknown.
#6) GENE
Each kind of protein tool has its own 
blueprint, or gene, located in the cell's 
nucleus. Genes can be turned on or off
in different cells at different times. The gene 
for the protein that detects bitter
things is on in your tongue cells, but 
off in your skin cells.
#7) ENCODE
We say that a gene encodes a protein, 
because it contains specific information your 
cells read in order to build that
protein. If your version of a gene is different 
from a friend’s, it might encode a
different protein. All together, you have 
about 20,000 genes, each encoding a 
different protein.
#8) DNA
The information a gene uses to encode a 
protein is stored in a molecule called DNA. 
There are four “letters” in the DNA alphabet, 
which make up three-letter “words.” Each 
"word" encodes a single bit of a growing 
protein chain. The full-length chain will 
become a working protein. The bits making 
up the protein affect how the protein does its 
job.
#9) SNP
A SNP is a site in the genome where a single 
DNA “letter” often differs from person to 
person. Some (but not all) SNPs appear to be 
associated with variation in different people’s 
phenotypes. In this example, a SNP in the 
gene encoding the protein that responds to 
bitter flavors can have C or G 
variants—leading to a big difference in 
phenotype!
A G G C A C C A C T G A G
ALA PRO LEU
phenotype: broccoli tastes bitter
              genotype: C
phenotype: broccoli tastes ok
            genotype: G
TONGUE CELLS 
SIGNAL THE BRAIN
#3) CELL
TONGUE 
CLOSE-UP #4) PROTEIN
#4) PROTEIN
#5) GENOME
#6) GENE
#7) ENCODE
#8) DNA #9) SNP
#5) GENOME
One of the phenotypes you will learn about when 23andMe genotypes you is whether you can taste a bitter flavor in raw broccoli. Some 
people’s tongue cells make a protein that can detect bitter flavors; others make one that can’t. Each of your cells contains a copy of your 
genome, which is made up of a molecule called DNA. Your genome contains genes, which are blueprints that encode  proteins like the 
one made by your tongue cells. Different people can have different blueprints because of differences in their SNPs. There are two versions 
of the SNP shown here, and each leads to a different version of the gene, which in turn encodes a different version of the protein. One 
version of the protein can detect the bitter flavor of raw broccoli, while the other cannot.
key words for genetics
 
G C A C C A
ALA PRO
A G G C A C
G
C A C T G A G
ALA ALA LEU
C A C
G
C A C
ALA ALA
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D.2.2. LESSON 2: PERSONAL UTILITY 
Phenotypic and genomic risks were represented separately within the ROR protocol. 
Through message testing, we learned participants wanted more information about the data used 
for calculating each type of risk. Participants wanted to know all of the information involved in 
the score derivation (e.g., total cholesterol, HDL, blood pressure, A1c, smoking status, and 
medication status), as well as how these values changed over the course of their two years in 
HHL (Figure 5.4). 
The presentation of the SNP information also evolved over the course of message testing 
(Figure 5.5). Participants requested more information on each SNP; specifically, they wanted to 
know more about the function of each SNP and to what degree each SNP affected their 
phenotype. Additionally, participants requested the exact odds ratios associated with each SNP. 
An instruction sheet on how to read the SNP information was also developed in collaboration 
with participants so they remembered how to interpret this information at home. Participants felt 
all of these modifications would help them understand the protocol both during the presentation 
and when reflecting upon it at home. 
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Figure 5.4. Phenotypic Risk Representation Using Framingham Risk Score 
 
  
	
	
Everybody	has	some	risk	of	
developing	heart	disease.	
		 		
Goal	 Change	in	HHL	 Your	measurements	Total	cholesterol	<	200	 	 	HDL	>	40	 	 	Systolic	blood	pressure	<	120	 	 	No	blood	pressure	medication	 	 	No	diabetes	 	 	No	smoking	 	 	
	
This	is	where	
you	want	to	be.	
Contributions	
to	your	risk	
HIGH	
AVERAGE	
LOW	
NONE	
in	the	next	
10	years	for	
MALE	61	
years	old	
(         )  
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5a. Gene Summary Chart Instruction Sheet  5b. Gene Summary Chart 
   
 
5c. Graphic representation of genomic risk 
 
FIGURE 5.5. GENOTYPIC RISK PRESENTATION 
  
	
	
Gene	Summary	
	
Technical	
name	of	SNP	
Change	
present	 Condition	affected	by	the	SNP	
Heart	
Disease	
Risk	rs543874	 NO	 How	the	body	breaks	down	food	 BMI	 é	0.21%	 	rs6567160	 YES	 How	the	body	breaks	down	food	 BMI	 é	0.07%	 é	
rs2258119	 YES	 How	the	heart	pumps	blood	 Systolic	blood	pressure	(the	top	number)	 é	1.84	mm	Hg	 é rs7903146	 YES	 How	the	body	breaks	down	sugar	 Type	2	diabetes	(T2DM)	 23.3%	é		chance	of	T2DM	 é	rs6511720	 YES	 How	the	body	breaks	down	fat	 LDL-C	(bad	cholesterol)	 8.10	mg/dL		é	LDL	 é	
rs646776	 NO	 How	the	body	breaks	down	fat	 LDL-C	(bad	cholesterol)	 4.46	mg/dL		é	LDL	 	
rs3764261	 YES	 How	the	body	breaks	down	fat	 HDL-C	(good	cholesterol)	 2.79	mg/dL	
ê	HDL	 é	
rs16942887	 NO	 How	the	body	breaks	down	fat	 HDL-C	(good	cholesterol)	 1.27	mg/dL	
ê	HDL	 	
rs2036527	 YES	 How	much	you	smoke	 Cigarettes	smoked	per	day	 0.04	more	cigarettes	 é	
	
	
Your	genetic	heart	disease	risk	is	average	compared	
to	the	average	African-American	population.	
	
	
	
	
	
	
You	cannot	change	your	genes.	
	
	 	
Added	genetic	
information	
HIGH	
AVERAGE	
LOW	
NONE	
13	–	18	SNPs	
6	–	12	SNPs	
	
	
How	to	read	the	Gene	Summary	chart											
Technical	
name	of	SNP	
Change	
present	 Condition	affected	by														the	SNP	
Heart	
Disease	Risk		rs543874	 YES	 How	the	body	breaks	down	food	 BMI	 é	0.21%	 é	
	
	
	
	
	
	
	
	
	 	
Do	I	have	that	SNP??	
Scientific	name	 What	does	that	SNP	do??		It	deals	with…	
What	does	that	SNP	affect??	
(                )  BMI	(Body	Mass	Index)	is	a	measure	of	body	fat.		
How	big	of	an	impact	does	that	SNP	have??	
How	does	an	increase	in	BMI	effect	heart	disease	risk??	
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D.2.3. LESSON 3: LANGUAGE USAGE 
Two main lessons arose about language usage surrounding genomic literacy and 
numeracy.  
The language in the original and adapted protocols was designed for low literacy. In 
developing the exact script with the genetic counselor, we opted for the simplest terms to make 
the protocol comprehensible to the widest possible audience. For example, we used the term 
“small DNA change” instead of “SNP.” Our message testing revealed that participants preferred 
the use of the specialized genomic words, such as SNP. Many participants identified the 
23andMe video as helpful in conceptualizing and remembering the term. However, participants 
still said the simpler definition of SNP would be helpful on a keyword sheet as a reminder. This 
keyword sheet was created in response and placed behind the ROR materials so that is was 
visible during the presentation.  
The Grant protocol was also chosen for the low numeracy considerations inherent in the 
presentation. Participants suggested wording changes when numerical words arose in the 
protocol. For example, on the scales it was suggested that the word “average” be changed to 
“normal”. Ultimately, we decided not to make that change due to the different connotations of 
“average” and “normal.” Conversely, participants requested more numerical information about 
the SNPs. It was decided the presentation of this information should be in percentages as 
participants felt this to be most understandable. 
 
E. DISCUSSION 
With rapidly advancing technologies available for studying the human genome, the field 
of genomic research is expanding quickly and holds great promise for developing more effective 
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and more personalized treatments for common chronic diseases such as CVD.  Despite this 
incredible advancement in genomic technologies and research, African-Americans remain 
underrepresented in genomic studies—a fact which may perpetuate widely observed health 
disparities since pharmacological targets are discovered using primarily European DNA. In order 
to produce appropriate and inclusive treatment options, more African-Americans must be 
included in genomic research studies.  However, given the national history of exploitation of 
African-Americans for medical research, it is most appropriate to conduct genomic research 
among this population in a thoughtful manner, guided by the principles of Community-Based 
Participatory Research (CBPR). A central tenet of CBPR is the return of results to the 
participant, particularly when the community requests results.173,216 
To our knowledge, we present here the first ROR protocol explicitly developed for 
genomic research in African American populations, as well as a process for collaboratively 
developing ROR protocols that can be used for other outcomes and populations.  We found that 
these research participants prefer to discuss genomic concepts using specialized genomic terms 
even if those terms are discipline specific and initially unfamiliar to participants.   
As such, others seeking to develop similar ROR protocols may consider using 
scientifically precise vocabulary for important concepts while using various visual aids 
(handouts, videos) to explain the concepts behind those terms in an accessible way. 
Future genomic research using this or a similar ROR protocol should evaluate the 
cognitive value and acceptability of the protocol in AA populations outside of the American 
South, and additional studies should investigate how knowledge of genomic risk, as 
communicated by this ROR protocol, affects motivation for health-related behavior change 
outcomes. 
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E.1. CONCLUSIONS 
This study is unique in that it concentrates on an AA population. The ROR protocol 
presented here is designed specifically to fill the gap of communication research in AA 
populations using CBPR principles with the goal of using the ROR to study the personal utility 
of personalized CVD genomic results (ClinicalTrials.gov number: NCT02208180). 
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CHAPTER 6: THE RETURN OF RESULTS STUDY: RESULTS FROM A 
RANDOMIZED CONTROLLED TRIAL TO EVALUATE THE CONCEPT 
OF USING PERSONALIZED GENOMIC RESULTS FOR MOTIVATION 
TO CHANGE DIET AND PHYSICAL ACTIVITY BEHAVIORS 
 
A. OVERVIEW 
With the rise of personalized genomics, participants are more frequently asking for or 
expecting their personalized genomic results to be available to them. However an evidence base 
for the communication and effects of personalized genomics has yet to be fully established. This 
study attempts to contribute to that evidence base by evaluating the effect of communicating 
personalized cardiovascular disease genomics risk on motivation towards cardiovascular disease 
(CVD) risk reduction in an African-American (AA) population in rural North Carolina using a 
randomized controlled design. 
A total of 62 participants were randomized to either receive personalized genomic 
information or to an attention control group. Participants were followed for one month at the end 
of which the control group also received their results. Outcomes assessed were self-reported 
motivation, Protection Motivation Theory constructs, fruit and vegetable servings, and physical 
activity. Four groups were planned for, but only three were formed due to the lack of high 
genomic risk participants: average genomic risk intervention group (n=12), low genomic risk 
intervention group (n=19), and control group (n=31). The control group received no genomic 
risk information, regardless of genomic risk status.  
There were no significant differences in between- or within-group motivation towards 
diet and physical activity between baseline and 1-month follow-up (p=0.51). Moderation by 
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genomic risk category for the intervention group revealed some significant findings. The low 
genomic risk intervention group self-reported being more motivated towards diet and physical 
activity (0.3 ± 0.2, p=0.09), and consuming more fruits and vegetables per week (1.3 ± 0.4, 
p=0.001). The average genomic risk intervention group less motivation, and no change in diet. 
Findings suggest that genomic-risk knowledge may impact the perceived threat of CVD. 
Specifically, those of low genomic risk may not be demotivated and those of average risk may be 
demotivated, both of which are contrary to hypotheses in the literature. Future research is needed 
to replicate these findings and further investigate the mechanisms behind this phenomenon. 
 
B. INTRODUCTION 
Personalized genetic information has been commercially accessible since 2007.201,203,231 
The usefulness of this genetic information depends on the clinical utility and validity of the SNPs 
(single nucleotide polymorphisms) involved. Clinical utility concerns the availability and 
efficacy of treatment based on the genetic information. Clinical validity is the accuracy with 
which the genomic information predicts clinical disease.232 Though it is reasonable to 
hypothesize that knowledge of personalized genetic risk factors may be an important motivator 
for health-related behavior change, this remains underexplored.  
The National Institutes of Health and Centers for Disease Control and Prevention have 
jointly called for more evidence regarding the use of personal genomics in disease prevention; 
specifically, there is a need to “assess how genome profiles affect behavior of individuals.” 233 
This can be used in addressing common chronic diseases. This paper attempts to address that 
priority by giving evidence on the use of personal genomics to promote behavior change for 
cardiovascular disease prevention. Enrolling a rural, African-American population in North 
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Carolina, this study evaluates the effect of returning personalized cardiovascular disease genomic 
risk results on motivation towards diet and physical activity. We hypothesized that motivation 
towards diet and physical activity would increase for AAs receiving genomic knowledge relative 
to those receiving no genomic information. Protection Motivation Theory (PMT) constructs were 
theorized to increase; all save for fatalism, which was theorized to remain flat. Fruit and 
vegetable servings were hypothesized to increase with no change in physical activity behaviors. 
All findings were theorized to interact with genomic risk category. Findings were supposed to 
different—or moderated—based on the genomic risk communications received. 
 
C. METHODS 
C.1. PARENT STUDY 
The current study is an ancillary project of the Heart Healthy Lenoir (HHL) study. In 
brief, the primary aim of HHL was to create long-term, sustainable approaches to reducing 
cardiovascular disease (CVD) risk disparities in Lenoir County, North Carolina—a rural, low-
income county in eastern North Carolina. HHL included three coordinated studies: The Lifestyle 
Study, The Hypertension Control Study, and The Genomics Study. The Lifestyle Study 
evaluated a community-based lifestyle intervention aimed at reducing CVD risk and disparities 
in risk through the improvement of eating patterns, promotion of physical activity, and weight 
loss support.221 (ClinicalTrials.gov number: NCT01433484) The Hypertension Control Study 
evaluated a clinical intervention testing a medication and lifestyle management system to 
improve blood pressure control and reduce disparities in blood pressure control among patients 
diagnosed with poorly controlled high blood pressure.224 (ClinicalTrials.gov number: 
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NCT01425515) The Genomics Study explored genomic factors associated with CVD risk and 
treatment success.  
 
C.2. RISK ESTIMATES 
Risk estimates were calculated for all participants. 
 
C.2.1. PHENOTYPIC RISK ESTIMATE 
Phenotypic CVD risk was calculated using the Framingham Risk Score (FRS),234 which 
uses age, systolic blood pressure, total cholesterol, HDL (high-density lipoprotein), gender, 
smoking status, diabetes status, and blood pressure medication status to calculate a 10-year risk 
estimate. To remain consistent with the parent study, the same method of calculation was used in 
this study used the participant’s 24-month measurement values from the parent study.235 If a 
participant reported a cardiac event during HHL, the 2-year FRS estimate was used.236 All 
estimates were framed in comparison to the average risk for the participant’s age and sex group. 
 
C.2.2. GENETIC RISK ESTIMATE 
C.2.2.A. GENOTYPING 
Whole genome genotyping was performed as a part of the HHL Genomics Study. That 
genotyping information was used for the current study. (See Appendix 6.1 for additional 
information about genotyping methods.)  
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C.2.2.B. GENETIC RISK SIGNATURE 
To compile a genomic risk signature (GRS) we consulted with a genetics epidemiologist, 
who guided our procedures. Fine mapping and admixture papers were analyzed for the presence 
of genome-wide association study significant SNPs (p < 5x10-8) in those of African ancestry for 
the following conditions: blood pressure, dyslipidemia, T2DM, BMI, smoking, and CVD. (See 
Appendix 6.2 for the full list.) Allele frequencies for each SNP were taken from the 1000 
Genomes Project using the YRI (Yoruba in Ibadan, Nigeria) population.237 SNP imputation was 
in progress through the beginning of this study; therefore, those SNPs not imputed by the cutoff 
date of the end of February 2016 were not included in this study (Figure 6.1). In total, 9 SNPs 
were identified (Table 6.1). 
An additive risk model was used for the CVD GRS. To compute genomic risk for study 
participants, each SNP genotyped was represented as 0/1/2, indicating the participant’s number 
alleles for a total possible score of 18. Participants were categorized into “high genomic CVD 
risk” (upper quartile; 13-18 SNPs), “average genomic CVD risk” (middle two quartiles; 6-12 
SNPs), and “low genomic CVD risk” (lowest quartile; 0-5 SNPs).  
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FIGURE 6.1. SNP DECISION TREE 3/4/16  
SNPs compiled from admixture and fine 
mapping literature on CVD and its risk 
factors 
(n=23 SNPs) 
Final SNP list 
(n=9 SNPs) 
 SNPs not imputed by baseline 
(n=14) 
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TABLE 6.1. HEART HEALTHY LENOIR CVD GENOMIC RISK SIGNATURE FOR AFRICAN-AMERICANS 
SNP Pheno- type Gene 
Chro- 
mo- 
some  
Effect 
Allele 
Effect 
Allele 
Fre- 
quency 
 Study 
N  
Effect 
size ± 
S.E. 
p-value Refer- ence 
rs16942887 HDL LCAT  16 G 0.70  8,061  
1.27 ± 
0.11 
mg/dL 
1.00x10-10 Teslovich 201056 
rs3764261 HDL CETP  16 C 0.74 
 8,061  
3.39 ± 
0.09 
mg/dL 
3.00x10-18 Teslovich 201056 
 8,318  
2.79 ± 
0.25 
mg/dL 
5.91x10-28 Carlson 201355 
rs543874 BMI SEC16B 1 G 0.25 
 
45,704  
0.060 ± 
0.008 2.00x10
-13 Monda 201353 
 
29,151  −0.0110 2.40x10
-09 Gong 201350 
rs646776 LDL 
CELS
R2/PS
RC1/
SORT
1 
1 T 0.69  7,724  
4.46 ± 
0.63 
mg/dL 
1.48x10-12 Carlson 201355 
rs6511720 LDL LDLR 19 G 0.87 
 8,061  
-6.99 ± 
0.30 
mg/dL 
5.00x10-08 Teslovich 201056 
 9,291  
-8.10 ± 
0.80 
mg/dL 
7.05x10-24 Carlson 201355 
rs6567160 BMI MC4R 18 C 0.23 
 
45,920  
0.059 ± 
0.009 2.96x10
-11 Monda 201353 
rs7903146 T2DM TCF7L2 10 T 0.24  9,844  
0.23 ± 
0.04 3.98x10
-10 Carlson 201355 
rs2258119 SBP C21orf91 21 C 0.23 8,591 
1.84 ± 
0.34 4.69x10
-08 Fox 201144 
rs2036527 
cigarettes 
smoked 
per day 
CHR
NA5 15 A 0.15 32,389 
0.04 ± 
0.01 1.84x10
-08 David 201242 
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C.3. INTERVENTION 
C.3.1. PARTICIPANT SCREENING AND RECRUITMENT 
Participants for the current study were recruited from the HHL Study. In February 2016, 
invitations were sent to HHL participants who met the following criteria: 1) African-American 
(AA), 2) completed the HHL 24-month follow-up visit, 3) agreed to be contacted for future 
studies, 4) were enrolled in the HHL Genomics Study, and 5) were not enrolled in the HHL 
Lifestyle Weight Loss program. Participants from the HHL Lifestyle Weight Loss program were 
excluded from this study because they had more contact with HHL compared to other 
participants, and this group was used as the participant pool for formative research for the current 
study. 
 
C.3.2. RANDOMIZATION 
After providing informed consent, participants completed the baseline questionnaire 
including a health literacy questionnaire. Participants were then randomized to the intervention 
or control group using block randomization by health literacy status (high or low). 
 
C.3.3. INTERVENTIONS 
Participants attended a baseline study visit in the Kinston, North Carolina field office in 
March 2016. After informed consent and the baseline survey, participants were randomized to 
receive either their CVD genomic results (intervention group) or financial management 
counseling (control group). The intervention protocol was designed to be a one-on-one low-risk 
educational session. (See Chapter 5 for more detail.) An attention control group protocol was 
chosen to match the amount and intensity of participant contact. Trained research assistants 
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delivered all interventions during one individual face-to-face counseling session. A post-test 
survey was then administered to assess immediate participant response. Participants were 
brought back to the field office one-month later (April 2016) for a follow-up measurement visit. 
(Figure 6.2) 
 
C.3.3.A. CONTROL GROUP 
An attention control, delayed intervention design was implemented in this study, with the 
control group receiving their genetic information after follow-up measures. During the 
intervention period, the control group did not receive information about diet and exercise, but 
received a modified financial management module. The module was one 15-minute, self-directed 
educational session on how to set and achieve financial goals. Participants were given brief 
educational materials about whatever financial topic they chose—saving, budgeting, creating 
assets, or credit. Then participants were led through how to create a financial goal. Control group 
participants participated in the genomics intervention protocol at the close of the intervention 
period, and after completing final measurements.  
 
C.3.3.B. INTERVENTION GROUP 
The return of results protocol has been described elsewhere (See Chapter 5.) In brief, the 
protocol is a 15-minute empowering, educational session designed to motivate risk reduction 
behaviors by focusing on risk perception and self-efficacy. Materials were crafted to minimize 
feelings of invulnerability in those of low genomic risk.157 Invulnerability concerns center 
around the fear of demotivating participants to make lifestyle changes. A brief genomics 
education unit is completed prior to receiving results. Separate genomic and phenotypic risk 
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estimates were then provided using verbal risk estimates (i.e., “high,” “average,” or “low” risk). 
Visual aids were used to help bridge genomic literacy and numeracy gaps. After receiving 
results, written lifestyle advice from HHL was provided on reducing environmental CVD risks 
such as diet and physical activity. Participants were encouraged to follow the HHL lifestyle 
advice as well as advice from their doctors. A genetic counselor was also available for additional 
follow-up at the participant’s request.  
 
C.3.3.C. LIFESTYLE ADVICE 
This study is unique in that our population had already received the lifestyle change 
instruction in HHL. We capitalized on that by reminding participants of the counseling 
previously received, which can be found elsewhere.221 In brief, the advice focused on dietary and 
physical activity behaviors. The “Med-South Diet” advice focused on fruit and vegetable 
consumption, carbohydrate quality, lean meats, and high quality fats in keeping with a 
Mediterranean dietary pattern. The physical activity advice set goals of walking ≥  7,500 
steps/day or 150 minutes a week broken up into as small as ten-minute segments.  
Advice information is available at 
http://www.hearthealthylenoir.com/sites/default/files/imce/documents/HealthyEatingMaterials.pdf. 
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Figure 6.2. Study Flow Diagram 
Lost to follow-up (n=3) 
§ Illness (n=1) 
§ Couldn’t contact (n=1) 
§ Declined to participate (n=1) 
Lost to follow-up (n=0) 
 
* Participants received intervention after 
measurements were collected. 
ONE MONTH 
FOLLOW-UP 
Allocated to intervention (n=31) Allocated to control (n=31) 
ALLOCATION/ 
INTERVENTION VISIT 
Analyzed  (n= 28) Analyzed  (n=31)  
ANALYSIS 
ENROLLMENT 
Missed study appointment  (n=12) 
 
Assessed for eligibility (n=162) 
Randomized (n=62) 
Excluded  (n=88) 
§ Couldn’t reach (n=27) 
§ Bad contact information (n=22) 
§ Busy during study dates (n=10) 
§ Too far to travel (n=9) 
§ Responded after enrolment dates (n=15) 
§ Declined to participate (n=4) 
§ Deceased (n=1) 
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C.4. OUTCOME MEASURES 
The primary study outcome was motivation towards changing diet and physical activity 
behaviors. It was assessed via self-report using the Prevention and Planning Behaviors measure 
developed by Rini et al; this instrument has never been published, however it has been used by 
another translational genomic research study.238 This scale assesses degrees of influence on 
participants’ motivation to change their health behavior in translational genomic studies, and 
takes into consideration that behaviors could become less healthful rather than more healthful. 
Using a larger genomics study (n=513) with a White, high income, high health and genetic 
literacy population, factor analysis was conducted on this scale. The following subscales were 
created: motivation towards diet and physical activity (n=8; α=0.86), motivation towards stress 
reduction (n=3; α=0.82). 
Secondary outcomes were self-reported as well. They include: motivation sub-scales, 
fruit and vegetable consumption, physical activity, Protection Motivation Theory (PMT) 
constructs, and fatalism. The fatalism scale was comprised of three subscales: predetermination, 
luck, and pessimism. (Table 6.2) (See Appendix 6.3 for data collection instruments.) The post-
test administered immediately after intervention, consisted only of PMT constructs and health 
behaviors. 
The Institutional Review Board at the University of North Carolina at Chapel Hill 
approved this study (IRB# 14-1500). The trial is also registered with ClinicalTrials.gov 
(ClinicalTrials.gov number: NCT02208180). Participants were provided $60 in incentives for 
their participation. 
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C.5. ANALYSIS  
The primary outcome was the 1-month change in motivation for healthy diet and exercise 
behaviors in the intervention group, relative to the control group. We estimated 2-4 participants 
per scale item for this 14-item scale. Using the median estimate, we estimated needing 42 
subjects per arm, or 84 subjects in total.  
A general linear mixed model was used for analysis. We looked at time (baseline and 
follow-up), and intervention group (intervention and control) in a 2x2 model to estimate the 
effect on the outcomes. Moderation analyses were also performed to test interactions with 
genomic risk signature (GRS).239 For this, we used a 2x2x1 model (time x GRS x intervention 
treatment group). Significance for all analyses was set at p < 0.05. A complete-case analysis 
approach was used however some missingness was allowed in variables for which the mean was 
calculated. All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC). The 
Consolidated Standards of Reporting Trials guidelines were followed in the conducting and 
reporting of this study.240 
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TABLE 6.2. MEASURES USED IN RANDOMIZED CONTROLLED TRIAL 
Measure(s) Description  Point Assessed HHL Baseline Post-test 1-month 
Demographics 
Age Used to establish demographics. X    
Gender Used to establish demographics. X    
Race Used to establish demographics. X    
Genomic 
Literacy 
The Rapid Estimate of Adult 
Literacy in Genetics (REAL-
G)229: 8-item measure 
administered by a research 
assistant 
 X   
Health Literacy 
The Short Test of Functional 
Health Literacy in Adults 
(STOFHLA)241: 36-item 
measure 
X 
X 
(If 
unavailable 
from 
HHL.) 
  
Health Related 
Quality Of Life 
Short Form Health Survey (SF-
12)242: 12-item measure  X  X 
Mental Health Mental Health Inventory (MHI-5)243: 5-item measure  X  X 
History Of 
Genetic Testing 
Used to asses if participant or 
any close relatives have ever 
had genetic testing.244: 3-item 
measure 
 X   
Numeracy Subjective Numeracy Scale 
(SNS-3)245: 3-item measure  X   
Education Used to establish 
demographics221    X* 
Marital/Partner 
Status 
Used to establish 
demographics221    X* 
Employment 
Status 
Used to establish demographics.    X* 
Income Used to establish demographics.    X* 
Health Insurance 
Status 
Used to establish demographics.    X* 
Household 
Composition 
Used to establish demographics.    X* 
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Measure(s) Description  Point Assessed HHL Baseline Post-test 1-month 
Risk Estimates 
Diabetes 
Hemoglobin A1c was measured 
from a blood draw at baseline 
and 24 months.  
X    
Cholesterol 
Total cholesterol, HDL, and 
LDL (low-density lipoprotein) 
were measured from a blood 
draw at baseline and 24 months. 
X    
Systolic Blood 
Pressure 
Blood pressure was measured in 
triplicate at baseline and 24 
months. 
X    
Hypertension 
Medication 
Status 
“Do you take medicine for high 
blood pressure or 
hypertension?” Measured at 
baseline and 24 months. 
X    
Smoking Status 
“Do you smoke cigarettes 
now?” Measured at baseline 
and 24 months. 
X   X 
History Of Heart 
Disease 
“Has a doctor ever told you that 
you have had a heart attack?” 
Measured at baseline. 
X    
Genotyping Whole genome genotyping at baseline. X    
Protection Motivation Theory Constructs 
Motivation Prevention and Planning Behaviors238: 12-item measure  X X X 
Threat Appraisal 
Participant identifies the how 
they perceive CVD threat on a 
5-point Likert scale246: 1-item 
 X X X 
Perceived 
Vulnerability 
Participant identifies 10-year 
CVD risk on a percentage 
scale247: 1-item 
 X X X 
Perceived 
Severity 
Participant identifies severity of 
CVD on self-referenced 
questions covering range of 
factors using a 5-point Likert 
scale248: 8-items 
 X X X 
Perceived 
Fear 
Participant identifies feelings of 
fear on a 5-point Likert scale249: 
4-items 
 X X X 
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Measure(s) Description  Point Assessed HHL Baseline Post-test 1-month 
Coping appraisal 
Coping Efficacy subscale of the 
Psychological Adaptation Scale 
used in previous genomic 
research250: 5-items 
  X X 
Perceived 
Response 
Efficacy 
Participant identifies the 
efficacy of diet and physical 
activity on a 5-point Likert 
scale251: 6-items 
 X X X 
Perceived 
Response 
Cost 
Participant identifies the cost of 
diet and physical activity on a 
5-point Likert scale251: 6-items 
 X X X 
Fatalism Fatalism scale with 
predetermination, luck and 
pessimism subscales252: 20-
items 
 X X X 
Health Behaviors 
Fruit and 
Vegetable 
Servings 
A 10-item Block screener253  
 X  X 
Physical Activity  RESIDE (RESIDential 
Environment project) 
Neighborhood Physical Activity 
Questionnaire254:16-item 
measure 
 X  X 
* Demographic information available from the parent study and unlikely to change significantly 
since the parent study was measured at follow-up to reduce subject fatigue during the baseline 
survey. 
 
D. RESULTS 
D.1. PARTICIPANT CHARACTERISTICS 
Between February 2016 and March 2016, invitations were sent to 162 HHL participants 
to participate in the Heart Healthy Lenoir Return of Results (HHL ROR) Study; 74 participants 
(46%) responded positively and were scheduled for a baseline study visit. The most common 
reason for a non-positive response to the study invitation was being unable to reach the 
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participant (17%), followed by incorrect contact information (14%). An additional 12 
participants (7%) did not keep their study appointments after a positive invitation response 
leaving 62 participants to be randomized. Three participants in the intervention group were lost 
to follow-up. (See Figure 6.2.) 
Approximately 15% (n=25) of the target population was either unavailable during the 
study dates or responded after enrollment closed. Analysis was performed to see if the study 
population differed from these possible participants in terms of demographics or HHL study 
enrollment. No significant differences were found. 
There were no significant differences between groups in baseline characteristics in this 
study except where otherwise noted (Table 6.3). There were also no significant differences in 
baseline characteristics between the low and average GRS intervention groups. (See Appendix 
6.4 for additional statistics.) 
Participants in the current study came largely from the HHL Hypertension Study (n=56) 
with 21 participants from the HHL Lifestyle study including 9 participants in both studies. On 
average, about 1 year and 9 months had elapsed between the last HHL visit and the baseline 
HHL ROR Study visit. All participants were self-identified as African-Americans. The majority 
of participants were female (n=44; 71%). The average age was 61 years (Standard Deviation 
[SD] 9). Most participants had graduated 12th grade or higher (n=48; 77%). 
 This sample was mostly high literacy (n=46). The average literacy score was 27.8 (SD 
10.1) on a scale from 0 – 36. Likewise, the sample was of high genetic literacy (Mean [M]±SD 
4.3 ± 2.7 on a scale from 0 – 8). Subjective numeracy scores were ranked average on a scale 
from 1 – 6 (M ± SD 3.2 ± 1.4). 
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 Genomic CVD risk was mostly low (n=40; 65%) across all study participants (n=19; 61% 
in the intervention group). There were no significant differences in the allele numbers of the 
SNPs between the intervention and control groups. Phenotypic risk was almost evenly split 
between low (n=14; 23%) and high (n=13; 21%) across all study participants. (See Tables 6.4 
and 6.5 for population breakdown by FRS and GRS.) Over the course of the 2-year HHL 
intervention, there were no significant differences in the component variables of the Framingham 
Risk Score (i.e., age, systolic blood pressure, total cholesterol, HDL, sex, smoking status, A1c 
values, or blood pressure medication status) when comparing the intervention and control groups 
in this study. However, there was a significant difference between groups in the change in HDL 
(Control vs. Intervention [C vs. I] M ± Standard Error [SE]: -4.2 ± 8.1 vs. 2.0 ±8.6, p = 0.0111) 
 
D.2. PRIMARY OUTCOME 
Post-test measurements were administered to determine the initial reaction of 
participants. Analysis of post-test results did not show any difference between baseline and post-
test. Therefore only baseline (Time 1) and follow-up (Time 3) were used for analysis, except 
where noted otherwise. 
At baseline, participants reported being “a little more” motivated to change their diet and 
physical activity habits. There were no differences between groups (p=0.99). Over time, there 
were no significant between-group differences in motivation toward diet and exercise (C vs I: 
0.06 ± 0.15 vs. -0.08 ± 0.15, p=0.51). The positive value for the control group indicates a non-
significant movement towards increased motivation over the course of the study; the negative 
value for the intervention group indicates the opposite. Moderation analyses showed a significant 
effect of moderation in the intervention group (p=0.01). The low genomic risk signature (GRS) 
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group self-reported being between neutral motivation and “a little more” motivated to change 
their diet and exercise habits at baseline. Over the course of this study, that motivation trended 
towards increasing (0.3 ± 0.2, p=0.09). The average GRS group self-reported being “a little 
more” motivated to change their behaviors at baseline; this regressed towards neutral by follow-
up (-0.5 ± 0.2, p=0.06). (Table 6.6). 
 
TABLE 6.3. PARTICIPANT CHARACTERISTICS 
Characteristic Overall 
(n=62) 
  
Intervention 
Group (n=31) 
Control Group 
(n=31) 
p-
value 
Age M(SD) 60.9 ± 8.6 60.2 ± 9.5 61.5 ± 7.8 0.55 
Male Gender N (%) 18 (29%) 10 (32%) 8 (26%) 0.78 
Education N (%)* 
  
   
0.80 < High School 
11 (19%) 6 (11%) 5 (16%) 
High School 37 (63%) 18 (64%) 19 (61%) 
College and Beyond 11 (19%) 7 (25%) 4 (13%) 
Genomic Risk N (%)    
0.79 
Low 40 (65%) 19 (61%) 21 (68%) 
Average 22 (36%) 12 (39%) 10 (32%) 
High 0 (0%) 0 (0%) 0 (0%) 
Phenotypic Risk N (%)    
0.50 
Low 29 (47%) 14 (45%) 15 (48%) 
Average 11 (18%) 4 (13%) 7 (23%) 
High 22 (36%) 13 (42%) 9 (29%) 
Subjective Numeracy M(SD) 3.2 ±1.4 3.2 ± 1.4 3.1 ± 1.5 0.75 
Health Literacy M(SD) 27.8 ± 10.1 27.9 ± 9.6 27.7 ± 10.7 0.95 
Real-G Score M(SD) 4.3 ± 2.7 3.8 ± 2.5 4.7 ± 2.8 0.18 
Time Since HHL M(SD) 1.8 ± 0.3 1.8 ± 0.3 1.8 ± 0.3 0.59 
*N=59 Overall; N=31 Control; N=28 Intervention  
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TABLE 6.4. PHENOTYPIC RISK BY GENOMIC RISK—OVERALL  
 Phenotypic Risk N (%)  
Genomic Risk N (%) Low Average High Total 
Low 20 (69%)  8 (73%) 17 (77%) 40 (65%) 
Average  9 (31%)  3 (27%)  5 (23%) 22 (36%) 
High  0 (0%)  0 (0%)  0 (0%) 0 (0%) 
Total 29 (47%) 11 (18%) 22 (36%) 62 (100%) 
 
TABLE 6.5. PHENOTYPIC RISK BY GENOMIC RISK—INTERVENTION GROUP  
 Phenotypic Risk N (%)  
Genomic Risk N (%) Low Average High Total 
Low 10 (71%)  3 (75%)  9 (69%) 19 (61%) 
Average  4 (29%)  1 (25%)  4 (31%) 12 (39%) 
High  0 (0%)  0 (0%)  0 (0%) 0 (0%) 
Total 14 (45%)  4 (13%) 13 (42%) 31 (100%) 
 
TABLE 6.6. REGRESSION ANALYSIS FOR MOTIVATION TOWARDS DIET AND EXERCISE 
Label Estimate 
Standard 
Error DF t Value Pr > |t| 
Control Time 1 3.9509 0.2304    
Control Time 3 4.0141 0.2304    
Intervention Time 1 3.9306 0.2365    
Intervention Time 3 3.8556 0.2365    
Control: Time 3 vs. Time 1 0.06318 0.1474 113 0.43 0.6691 
Intervention: Time 3 vs. Time 1 -0.07500 0.1513 113 -0.50 0.6212 
Control vs. Intervention: Time 3 vs. Time 1 0.1382 0.2113 113 0.65 0.5144 
Intervention Low GRS Time 1 3.6736 0.2827    
Intervention Low GRS Time 3 3.9861 0.2827    
Intervention Average GRS Time 1 4.1875 0.3793    
Intervention Average GRS Time 3 3.7250 0.3793    
Intervention Low GRS: Time 3 vs. Time 1 0.3125 0.1809 113 1.73 0.0868 
Intervention Average GRS: Time 3 vs. Time 1 -0.4625 0.2427 113 -1.91 0.0592 
Intervention: Low GRS vs. Average GRS: Time 3 vs. Time 1 0.7750 0.3027 113 2.56 0.0118 
This measurement used a 5-point bi-polar Likert scale. A score of 3 indicates “no change in motivation.” 
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D.3. SECONDARY OUTCOMES 
See Appendix 6.5 for regression analyses tables. 
 
D.3.1. MOTIVATION TOWARDS STRESS REDUCTION 
At baseline, participants reported being “a little more” motivated to adopt stress reduction 
behaviors, with no differences between groups (p=0.64). Between-group analysis revealed a 
trend towards a difference in motivation between the two groups over time. Over the course of 
the study, the control group trended towards slightly increased motivation to reduce stress while 
the intervention group trended towards slightly decreased motivation to reduce stress (C vs I: 0.2 
± 0.2 vs. -0.2 ± 0.2, p=0.11). There was no significant effect of moderation by GRS in the 
intervention group. However, the trend seen in the between group analysis was probably driven 
by the average GRS group which trended towards regressing towards neutral by follow-up (-0.5 
± 0.3, p=0.08). 
 
D.3.2. PROTECTION MOTIVATION THEORY CONSTRUCTS 
D.3.2.A. THREAT APPRAISAL 
At baseline, participants self-reported that CVD was a “very serious” health threat. When 
asked to rate their chances of developing CVD in the next 10 years, the median percentage was 
40% (range 0 – 100%; Mean 43 ± 29%). Thoughts of CVD made participants feel “somewhat” 
fearful. When queried about the perceived severity of CVD using self-referenced statements 
naming possible consequences of CVD, participants self-reported as neutral on a 5-point bipolar 
Likert scale of agreement. (Sample statement: “My feelings about myself would change if I got 
heart disease.”) Over time, there were no significant between- or within-group differences for 
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threat appraisal, perceived vulnerability, perceived severity or perceived fear. There was a trend 
towards a between-group effect for perceived vulnerability; the control group trended towards 
feeling less vulnerable by one-month while the intervention group trended towards feeling more 
vulnerable (p=0.06). Moderation analysis also revealed a significant effect of moderation by 
GRS but only for perceived vulnerability (p=0.05). The average GRS group significantly 
increased their perceived vulnerability to develop CVD within the next 10 years from baseline to 
follow-up (from 16 ± 9% to 35 ± 9%, p=0.05). The low GRS group started at 49% perceived 
vulnerability that decreased to 46%— not a significant change over time (p=0.58). Related, no 
participants sought consultation with the genetic counselor after their study appointment. 
 
D.3.2.B. COPING APPRAISAL 
Coping efficacy questions self-referred to the information received, therefore the analyses 
for this variable were between post-test (Time 2) and follow-up (Time 3). At post-test, 
participants reported that the information they received in the intervention somewhat helped 
them cope better. (For the control group this was the financial management information. For the 
intervention group this was the CVD genomic information.) In terms of healthful diet changes, 
participants agreed with statements about healthful diet changes being feasible and effective in 
preventing CVD. The same pattern was seen with physical activity changes to prevent CVD. 
There were no between group differences in coping efficacy at post-test (p=0.69) or the other 
variables at baseline [diet response cost (p=0.31), physical activity response cost (p=0.91), diet 
response efficacy (p=0.70), and physical activity response efficacy (p=0.68)]. 
By one-month follow-up, there were no significant between- or within-group differences, 
or significant effects of moderation for coping efficacy, or diet or physical activity response cost 
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or response efficacy. There was a trend towards a between group difference of diet response cost 
with the control group regressing slightly towards neutral and the intervention group rating 
healthful diet changes as slightly more feasible (C vs I: -0.1 ± 0.1 vs. 0.1 ± 0.1, p = 0.09). A 
trend was also seen in physical activity response efficacy (p=0.09). The low GRS group non-
significantly regressed towards neutral (-0.05 ± 0.14, p=0.70). The average GRS group trended 
towards a small increase in the perceived efficacy of physical activity in preventing CVD (0.3 ± 
0.2, p=0.07).  
 
D.3.2.C. MALADAPTIVE COPING 
 The study population self-described themselves as disagreeing with fatalistic statements 
in the measurement scale at baseline with no differences between groups (2.35±0.63, p=0.66). 
The same pattern was seen in the fatalism sub-scales: predetermination (2.47±0.67, p=0.46), luck 
(2.04±0.73, p=0.76), and pessimism (2.34±0.73, p=0.73). At follow-up, there were no between-
group effects of fatalism (C vs. I: 0.1 ± 0.07 vs 0.1 ± 0.07, p=0.93). Likewise, moderation 
analysis showed no interaction between GRS, and time for the intervention group (0.08 ± 0.15, 
p=0.58). Analysis of the subscales over time did not reveal any significant findings.  
 
D.3.3. HEALTH BEHAVIORS 
D.3.3.A. DIET: FRUIT AND VEGETABLE SERVINGS 
 At baseline, this population reported consuming 3.5±1.9 servings of fruits and vegetables 
per week, with no difference between groups (p=0.94). Over time, there were no between-group 
effects for fruit and vegetable servings (p=0.37). There was a significant within-group effect for 
the intervention group (0.6±0.3, p=0.04). Closer investigation via moderation analysis revealed a 
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significant effect of moderation (p=0.03). This was driven by the low GRS group that self-
reported an increase in fruit and vegetable consumption from 3±0.5 servings per week at baseline 
to 4.3±0.5 servings per week at 1-month follow-up (p=0.0005). There was a non-significant 
decrease in self-reported fruit and vegetable consumption in the average GRS group (-0.04±0.48, 
p = 0.94). 
 
D.3.3.B. PHYSICAL ACTIVITY 
 Physical activity was categorized by walking time and active time. Walking time 
included walking for transportation and exercise. Active time included walking time plus all 
other types of moderate and vigorous physical activity. At baseline, the median time spent 
walking per week was 50 minutes (range: 0 – 1200 minutes; average 108±207), and the median 
active time per week was 120 minutes (range: 0 – 4740 minutes; average 242±623); there were 
no differences between groups (p=0.85 and 0.32, respectively). By follow-up, no significant 
between-group, within-group, or moderation effects were found for either of these categories.  
 
E. DISCUSSION 
Recent, rapid advances in genomic technologies have made personalized genomic 
information less expensive, more comprehensive, and more widely available than before, but 
how this information affects health-related behaviors is widely unknown. This personalized 
genomic information could be an important tool to affect individual behavior change, either to 
promote the adoption of healthy behaviors, or to dis-incentivize less healthy behaviors. The 
present study contributes to the evidence base regarding the effect of personalized genomic CVD 
risk knowledge on motivation towards healthy behaviors in a rural African-American population 
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that has historically experienced disproportionate rates of CVD morbidity and mortality.3,11-13 
Importantly, the present study collected data on both motivation towards a healthy diet and 
physical activity behaviors, as well as measures of the behaviors themselves. 
In this small pilot study, we did not observe any significant differences in the 1-month 
change in motivation for healthy diet and physical activity behaviors in the intervention group, 
relative to the control group. However, when we stratified analysis by GRS, we found that those 
in the lowest genomic risk category exhibited self-reported decreases in perceived vulnerability, 
increases in motivation towards diet and physical activity changes, and increases in fruit and 
vegetable consumption. Feelings of fatalism did not change. This may indicate that individual 
knowledge of lower-than-average genomic CVD risk may encourage a focus on healthy lifestyle 
behaviors in order to preserve one’s perceived genomic advantage, or that those with knowledge 
of their own lower-than-average risk may simply be encouraged by the lack of genomic 
impediments to cardiovascular health.  
Compared to theory, this finding is notable in two ways. First, this finding is consistent 
with Protection Motivation Theory. Protection Motivation Theory posits that when an individual 
receives information about their health, this information is then evaluated in terms of the severity 
of the disease (threat appraisal) and the efficacy of the prevention actions (coping appraisal). 
This evaluation can either lead to motivation towards health protective behaviors or maladaptive 
coping (e.g., fatalism). In theory, decreased threat appraisal, and/or increased coping appraisal 
will lead to health protective motivation and behaviors. In this study, the low GRS group self-
reported high coping appraisal (which did not change), decreased threat appraisal, increased 
health protective motivation and increased health behaviors, without any maladaptive coping. 
This suggests that the mechanism of action of this type of health communication may act through 
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the individual’s sense of CVD threat activated by the receipt of genomic information. 
Particularly, it might act through perceived vulnerability since perceived threat and perceived 
fear of CVD was high for this group and did not change. More research is needed to fully 
elucidate the theory constructs behind this phenomenon. 
This finding in the low GRS group is also noteworthy since the literature frequently 
posits that individuals receiving low genomic risk information may develop a sense of 
‘invulnerability.’ This means that the participant would feel like since their genome does not 
predispose them to a disease state that they are less likely—or invulnerable—to developing the 
disease state. This could, in turn, demotivate participants from engaging in common 
environmental risk factor protective behaviors (e.g., smoking cessation, or not eating a high fat 
diet). Our findings suggest the opposite phenomenon in our sample. Instead of feeling 
demotivated, the low GRS group was the most motivated group in this study. Additional 
qualitative research is required to investigate why this group felt more motivated. However, we 
theorize that this phenomenon might have, in part, to do with the way in which the information 
was communicated. The communications protocol used was specifically designed to minimize 
feelings of invulnerability in those of low genomic risk. Instead of simply receiving genomic risk 
information, the protocol also discusses that environmental risk factors contribute more to the 
development of CVD than genomics and that individuals have control over these environmental 
risk factors. In addition, the protocol concludes by offering participants support for making 
environmental risk factor changes in the form of take-home reading materials which included a 
cookbook. These communications materials were designed with participation from the study 
target population. The use of techniques focusing on risk perception and self-efficacy may have 
avoided feelings of invulnerability in this sample. 
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 Opposite findings were seen in the average GRS group. Those in the average genomic 
risk category self-reported increases in perceived vulnerability, decreases in motivation towards 
diet and physical activity changes, and no significant change in fruit and vegetable consumption 
without any changes in fatalism. This may indicate that individual knowledge of average 
genomic CVD risk may demotivate focus on healthy lifestyle behaviors.  
Once again, these findings are consistent Protection Motivation Theory. The average 
GRS group self-reported unchanged high coping appraisal, increased threat appraisal, decreased 
health protective motivation, and stable health behaviors, without any maladaptive coping. Based 
on theory, maladaptive coping should have been activated however that is not what was observed 
in this study. Even though there is demotivation, these findings indicate a lack of harm even with 
negative results. The average GRS participants were eating an average of 4.3 servings of fruits 
and vegetables a week at baseline and this did not change. (This is the same level to with the low 
GRS group increased by the end of the intervention.) Perhaps fatalism is not the proper 
maladaptive coping construct and/or perhaps returning genomic results does not have detrimental 
behavioral effects even when it fails to motivate. Further research can more fully explore these 
questions. 
We also posit that the lack of motivation and behavior change may be due to the 
normalization of unhealthy.255-257 In formative research for the communications protocol for this 
study, participants suggested that when receiving results, the word “average” be replaced with 
“normal.” That would mean that phenotypic and genomic results would be contextualized as 
“high,” “normal,” or “low.” We decided not to make this suggested change, but the idea itself is 
suggestive of a linguistic conflation between “average” and “normal”. For CVD, the ideal 
phenotypic state is not “average” but rather “low”. Many in North Carolina and in Lenoir County 
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are at “average” or even “high” phenotypic risk. These risk states may have become normalized 
because they are frequently socially experienced.256,257 These risk states are not normal, but the 
sense of normality may psychologically reduce the threat of the disease state.258-263 Perhaps this 
sense of normality may also demotivates people towards taking additional steps to change diet 
and physical activity habits. We might be seeing that phenomenon in this study. However, 
rigorous qualitative research is needed to further explore the psychology behind these findings. 
Our findings agree with previous research in this area which have found that knowledge 
of personalized genomic information has not impacted health-related behavior.264,265 Study 
limitations include a low overall sample size and a short follow-up period. Follow-up periods for 
ROR studies can vary greatly, from as little as two months150 to one year.7,154 Longer follow-up 
periods of up to one year have shown that knowledge of personalized genomic data may be more 
effective in maintaining behavior change than it is in initiating behavior change.7 Future studies 
should follow participants for longer periods to assess adherence to lifestyle changes. 
An additional limitation was the primary outcome measure. While designed specifically 
for and used in previous ROR genomics studies, it was not a validated measure. Measures were 
also self-report instead of objective measures. Furthermore, the lack of a rigorous examination of 
non-responders limits our ability to understand if the study population differed in some way from 
the larger population in relation to their views on genomics. 
Lastly, our sample included zero participants who qualified as high genomic risk based 
on the 9 included SNPs, which reduced variation in the sample. Sufficient variation may have 
been necessary to detect any relationship between knowledge of personalized genomic risk and 
motivation toward health-related behaviors. Though we hypothesized that knowledge of high 
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genomic risk may strongly motivate changes in health-related behavior, we are unable to fully 
test this hypothesis using the present study population.   
Strengths of this study include recruitment and retention of a minority population in a 
genomics study. Only three participants (<5%) were lost to follow-up, and more participants 
were interested in joining than could be accommodated by the end of the enrollment period. The 
community-based participatory research (CBPR) principles on which this study was founded 
may serve as a model for future genomics studies trying to recruit and retain a large minority 
population.  
An additional strength is that this study included lifestyle intervention in its ROR. A 
limitation of many studies is the return genomic information without lifestyle change skills for 
disease prevention. Alternatively, this study recruited from an existing research study that taught 
lifestyle change skills to reduce CVD risk. While not a full-scale lifestyle intervention in this 
study, participants received reminders about the skills learned during their previous HHL 
research study participation. The average time elapsed between the original HHL research 
studies and the baseline visit for the current study was likely long enough that any observed 
changes in motivation for health-related behaviors was likely due to the present study, and not 
residual effects from the previous studies. Future studies may investigate returning genomic 
results before or in conjunction with lifestyle interventions rather than after those interventions 
have concluded.  
While only a pilot study, we believe that this study has important implications for the 
recruitment and retention of minorities in genomics research, the use of CBPR principles in 
genomics research, and the modality of ROR communications when studying its effects on 
behavior change. Future studies should more closely examine the theoretical underpinnings of 
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ROR mode of action. Studies should also examine whether motivation differs by type of 
behavior—whether knowledge of personalized genetic risk affects adopting vs. ceasing health-
related behaviors, and should include a longer follow up period if possible.  
As genomic consumer products become more available to the public, it is imperative to 
better understand how the public understands knowledge of personalized genomic information, 
and whether and how it motivates changes in health-related behavior.  
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CHAPTER 7: SUMMARY OF FINDINGS AND 
RECOMMENDATIONS FOR FUTURE RESEARCH 
 
 Evidence of the use of personal genomics in risk reduction for common chronic diseases 
is needed. Cardiovascular disease (CVD) is still the number one cause of death in the United 
States. African-Americans, those of low socioeconomic status, and those living in the 
Southeastern United States are most at risk of CVD mortality. Many of those deaths are 
preventable. The findings from this dissertation research contribute to the literature concerning 
health disparity, genomics communication, and the use of personal genomics in health behavior 
research by (1) establishing the acceptability and want of genomic research when working in 
partnership with rural African-American communities, (2) creating an accessible return of 
genomics results communication protocol for use with a general African-American audience, and 
(3) reporting on the findings of a pilot study conducted to test the impact of returning 
personalized cardiovascular genomics results on motivation towards diet and physical activity in 
a rural African-American population. The sections below summarize these contributions and 
discuss potential implications for future research. 
 
A. SUMMARY OF FINDINGS 
The history of medical research in minority communities is a long and complicated one 
out of which much mistrust has grown.176-178,209-213 But, as medical and public health research 
forges forward into the world of genomics, we need to make sure that minority communities are 
not being left out of these innovations. Aim One focus groups established that participation in 
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genomic research was acceptable in Lenoir County, North Carolina and that participants wanted 
their results returned. Aim Two used participatory methods to create an approachable and 
comprehensible genomics return of results (ROR) communication protocol for use in a general 
African-American audience. Aim Three was a pilot study of return of personalized 
cardiovascular genomic results study for African-Americans, using a randomized-controlled 
attention-controlled delayed-intervention design. While there were no significant between-group 
findings, intervention group moderation analyses suggests that ROR may work primarily through 
variation in perceived threat and that those at lowest genomic risk may demonstrate positive 
motivation and behavior changes with both no impact and no harm done to those of average 
genomic risk. 
 
B. RECOMMENDATIONS FOR FUTURE RESEARCH 
Meta-analysis on previous ROR research has found that knowledge of personalized 
genomic information has not impacted health-related behavior.264 Included in this meta-analysis 
by Cochrane Reviews were diet (n=7 studies) and physical activity behaviors (n=6 studies), but 
no research focusing on these behaviors as they relate to CVD prevention. Additionally, not all 
ROR studies were considered. For example, the Grant study returning T2DM results was not 
included in the Cochrane Review. While mounting evidence suggests a lack of efficacy of ROR 
in behavior change, we suggest that this line of inquiry is still worthwhile. 
The communications methods used to return results is an understudied area and is often a 
weakness in ROR studies. Literacy (health and genomic), numeracy, and genomic knowledge 
issues abound in most previous research. The most common method for ROR is a numerical 
representation, which has suggested as difficult to comprehend.219 Additionally, little educational 
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context is given when providing results. The current study addressed those issues in our ROR 
protocol. Without these communications issues being addressed, an accurate assessment of the 
effect of ROR cannot be done, in our opinion. Future research should be sure to address 
communications concerns in partnership with the target communities for the most accurate 
results. 
The current study was limited in several ways that should be addressed by future 
research, namely the small sample size. The follow-up period and intervention timing were also 
limitations of the current study that could be corrected by future research. Adherence to risk-
reducing health-behaviors may be the true value of ROR—a variable that no studies included in 
the Cochrane Reviews or this study address. Most ROR studies only follow participants for 6 to 
12 months but findings from Arkadianos suggest that a follow-up period of at least one year is 
advisable to see the largest effect of ROR.7 Additionally, the lack of life skills support is a 
limitation of most ROR studies. Participants want this genomic information to learn more about 
themselves and use it to make lifestyle changes.204,216 Therefore, lifestyle change skills are 
advisable to have participants make health-behavior changes. The current study provided results 
after the conclusion of lifestyle change instruction. Anecdotally, many participants mentioned 
that they ideally would have liked to receive their results at the beginning of their two years in 
HHL. Future research might explore the impact of these results when given at the beginning of a 
high-intensity lifestyle program with periodic references to their genomic risk category. (High 
intensity as this is most efficacious in promoting health behavior change.)266 This combined an 
extended follow-up period (1 year+) and a measure of adherence to behavior changes might yield 
evidence as to the efficacy of ROR. 
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Another consideration for future research is the cost involved in ROR. Few cost-effective 
studies have been conducted on this mode of health communication. Unlike other types of 
counseling based on the latest efficacious research, this type of communication requires 
biomedical analyses to be done for every single participant. This type of analysis is much 
cheaper now than it was 10 years ago, but still is an additional cost in addition to the man-hours 
to interpret these results. More hours still are needed to input the information into the 
communications protocol and then implement the one-on-one protocol with participants. Cost-
benefit and cost-efficacy analyses should be performed to balance the expense of this counseling 
with participant demand. 
 
C. RECOMMENDATIONS FOR THEORY 
Protection Motivation Theory was the most applicable theory for the return of genomic 
results in health behavior research. However, more should be done on the conceptualization and 
measurement of theory constructs as it relates to genomic results. For example, there is much 
supposition in the literature about fatalism in response to genomic results. Findings from this 
study suggest that this is not a concern. As such, perhaps the conceptual model should be 
revising to not consider fatalism as a consequence of receiving results. Instead we posit that it 
should be a measure of disposition. Accounting for fatalism in this manner could change the 
conceptualization of which participants might and might not be receptive to genomic results as a 
health behavior change tool. For example, control participants in Aim Three were no different 
from intervention participants on overall fatalism, but where significantly more pessimistic than 
the intervention group. This effect was stable over all three time-points. More study should be 
done to examine this effect and its implications in return of results research. 
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An additional concern is the type of research design used to study ROR. Most studies are 
2- or 3-arm RCTs. While this is generally considered the ideal study design, we suggest that a 
Solomon 4-square design might be of more use in this new field. This type of design would 
allow for better control of the effects of measurement tools. Constructs like diet and physical 
activity response cost and response efficacy are difficult to measure without asking directly what 
participants think about those behaviors. Therefore there might be some reactivity in the 
operationalization of the PMT constructs. A Solomon 4-square design would reveal if this 
supposition has merit; the findings could then be used to refine PMT construct measurement to 
be used in later ROR studies. 
With these refinements to the PMT conceptual model as it applies to ROR and 
refinements in the operationalization of PMT constructs, future studies could more effectively 
study the mechanism of action of ROR. 
 
D. CONCLUSIONS 
 The current study is a small but novel exploration of cardiovascular return of genomic 
results in an understudied, high-risk population—African-Americans. This work lays 
foundational evidence for future work in this field, and importantly future work in this field with 
African-Americans. While much more work needs to be done in the field of return of results, we 
have demonstrated the power of participatory research in the field of genomics. With community 
partnership, minority communities can be recruited and actively engaged in genomics research. 
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APPENDIX 4: SUPPLEMENTAL MATERIALS FOR 
ESTABLISHING COMMUNITY NEED 
 
APPENDIX 4.1: ADDITIONAL QUOTATIONS ABOUT KNOWLEDGE 
Societal Benefits • “If people are willing to contribute in a study that would help 
somebody, […] as a human of humanity or humane person, I think 
people should.” (AA) 
• “[For] the individual impact on the study or individual, and the 
information that will be provided.  And then also the benefits the overall 
benefits that it’s going to make on the community and society in general 
the study will impart.” (AA) 
• “There needs to be some more research and study on African American 
community stress and the heart . . . we worry more and it [has] got to 
do with economics a whole lot of the time . . . the alcohol consumption, 
the smoking cigarettes, the over-eating [of] comfort foods.  Those are 
our stress relievers” (AA). 
• “The overall benefits that it’s going to make on the community and 
society in general” (AA) 
• “I wouldn’t need anything [to participate in a genomics study].  Just to 
know that you might be helping.” (W) 
• “It might prolong somebody else’s [life].” (W) 
• “Might save somebody’s life” (W) 
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• “Wouldn’t need any incentive” (W) 
Health Benefits • “Find out if you have personal disposition to heart disease.” (W)  
• “And if you have the knowledge, [you have] accountability for your 
own self, for your own actions.” (AA) 
• “[To] prevent some things from ever happening” (W) 
• “I would like to have more information too because just like he said 
there’s 14 of us [children] . … It’s probably 10 of us is diabetic because 
Mama and Daddy [are] diabetics. … And if I could do something to 
stop that. If I just know some more information to help me so my 
grandbabies won’t get it, I’d like that” (AA) 
• “What would motivate me is that if I could do anything to help 
somebody else.” (AA) 
• “if I knew I was susceptible to a certain disease I wouldn’t claim it but I 
[…] would try to learn more about it.  I wouldn’t be afraid. I would 
learn something about it what I do to prevent that.” (AA) 
Individual 
Benefits 
• “I definitely would like the report back. […] That would be payment 
enough.” (W)  
 • “Like the history.  You know where you are coming from and you [are] 
going to know where you are going.” (AA) 
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 • “I think knowledge is the best incentive.” (AA) 
 • “So the more I know the better off I am.” (AA) 
 • “I would like somebody to follow up with me and tell me what I could 
do to change.” (W) 
 • “[I’d like to] make the changes [to] live longer […] or comfortabler.” 
(W) 
 • “My brother was 36 he died of cancer.  And if I had more information 
to prevent from getting it, I would do it.” (AA) 
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APPENDIX 4.2: FOCUS GROUP CONSENT FORM 
University of North Carolina-Chapel Hill 
Consent to Participate in a Research Study 
Consent Form for Participants (Phase 1)—Genetics 
________________________________________________________________________ 
 
IRB Study # 10-0363 
Consent Form Version Date: 1/20/2011 
   
 
Title of Study:  Improving Lifestyle to Reduce the Risk of Heart Attack and Stroke 
 
Principal Investigator: Thomas C. Keyserling, MD, MPH (UNC-Chapel Hill) 
UNC-Chapel Hill Department:  Center for Health Promotion and Disease Prevention 
UNC-Chapel Hill Phone number:  919-966-2276, Ext 238 
Co-Investigators:  
-- UNC-Chapel Hill:  Alice Ammerman, DrPH, MPH, RD; Katrina Donahue, MD, MPH; 
Kelly Evenson, PhD; Jacquie Halladay, MD, MPH; Alexandra Lightfoot, EdD; Carmen 
Samuel-Hodge, PhD, MPH, RD; Maihan Vu, DrPH, MPH 
--East Carolina University, Greenville, NC:  Doyle Cummings, PharmD; Stephanie B. Jilcott, 
PhD 
Funding Source and/or Sponsor: National Institutes of Health 
Study Contact telephone number:  919-966-6088 
Study Contact email:  Beverly.Garcia@unc.edu 
 
 
 
What are some general things you should know about research studies?  You are being 
asked to take part in a research study.  You are free to join the study or not.  If you don’t want to 
take part in the study at all, or if you don’t want to answer some questions, that’s okay.  There is 
no penalty if you change your mind after you start the study.  If you decide not to join the study, 
it will not affect the care you receive at this health clinic. 
 
Research studies are designed to obtain new facts.  These new facts may help people in the 
future.  You may not receive any direct benefit from being in the research study.  There also may 
be risks to being in research studies. 
 
We want you to understand the details about the study so that you can make an informed choice 
about being in it.  You will be given a copy of this consent form.  Please ask questions if there is 
anything you do not understand. 
 
Being in the Study is Your Choice 
Before you learn about the study, you should know that: 
1. Your choice to be in the study is voluntary. 
2. You may decide not to join the study. 
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3. If you choose to be in the study, you may stop at any time. 
 
What is the purpose this study?   Our main study goal is to try to understand how our genes 
and family history work together with our environment to affect health.  Before we begin the 
study, we want to talk with men and women who live in Lenoir County to better understand their 
thoughts, feelings, and concerns about genetics and heart health.  You are being asked to take 
part in this discussion group.  
 
How many people will take part in Phase 1 of the study?  In this study, we will talk to four 
groups of 10 to 12 men and women who live in Lenoir County.    
 
How long will your part in Phase 1 of the study last?  It should take about two hours to 
answer the questions. 
 
What will happen if you take part in Phase 1 of the study?  A member of our research team 
will lead the group discussion which should last no more than two hours. The group will be 
asked some questions about their thoughts and feelings about genetics and heart health. No 
questions will be directed to you individually, but instead will be posed to the group. You may 
choose to respond or not respond at any point during the discussion.  The group discussion will 
be audiotaped so we can capture comments in a transcript for analysis. Your information will not 
be shared with anyone but the research staff. 
 
What are the possible benefits from being in this study?  Research like this helps others by 
making clear how we can best help men and women like you.  You may not benefit directly from 
this study.   
 
What are the possible risks or discomforts involved from being in this study?  You should 
not have any discomfort from being in this study.  We think you will be at ease answering the 
questions we will ask you. Although we will be careful to protect your privacy, loss of privacy is 
a potential risk of being in this study.  Also, there is always a chance of unknown risks. You 
should report any problems to the research staff.  
 
How will your privacy be protected?  To make sure what you say is confidential, you can use a 
different name during the project so that nobody connected with the study will know your real 
name.  Also, what other people say during the discussions is confidential, so you should not 
share anything you hear or see in the group with people outside the group.   Your name will not 
appear on the transcript from the tape recording.  Instead, we will make up and use an ID 
number.  The key that links your name and ID number and the study data we collect from you 
will be stored in a locked file cabinet and/or password protected computer.  The tape recording 
of the discussion session will be promptly transferred to a password protected computer and will 
be erased from storage in the tape recorder. 
   
Will you receive anything for being in this study?  You will receive a $25 gift card for taking 
part in this study. You will also be given an information sheet about the Heart-Healthy Lenoir 
Project. 
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Will it cost you anything to be in this study?  It is free for you to be in this study, other than 
your costs to travel to the meeting site or child care if needed. 
 
What if you have questions about this study? You have the right to ask and have answered 
any questions you may have about this research.  If you have questions, or concerns, you should 
contact Thomas Keyserling, MD, MPH (919-966-2276, Ext. 238; jato@med.unc.edu). He is the 
leader of this project and will be happy to answer your questions.   
 
What if you have questions about your rights as a research participant?   
All human research is reviewed by a group of people that works to protect your rights and 
welfare.  If you have questions or concerns about your rights as a research subject you may 
contact, anonymously if you wish, the Institutional Review Board at the UNC-Chapel Hill at 
919-966-3113 or by email to IRB_subjects@unc.edu.  
 
--------------------------------------------------------------------------------------------------------- 
 
Title of Study:  Improving Lifestyle to Reduce the Risk of Heart Attack and Stroke 
 
Principal Investigator:  Thomas C. Keyserling, MD, MPH 
 
Participant’s Agreement:  I have read the information above.  I have had all of my questions 
answered.  
 
 
By placing a check here, I agree that the researchers may call me by phone to see if I am 
willing to take part in a follow-up study or interview.  (If you check yes, we will ask for your 
phone number.)  
 
By signing this form, I agree to be in the study.  If I decide I do not want my information to be 
used, I will tell you in writing. 
 
 
Signature of participant   Date 
 
 
Printed name of participant 
 
 
Signature of person obtaining consent  Date 
 
 
Printed name of person obtaining consent 
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APPENDIX 4.3: FOCUS GROUP GUIDE 
Procedures: 
 
1. The project staff (moderator and facilitator) will greet individuals as they enter the room and 
check off their name on the attendance sheet.  
2. Project staff will give each participant a consent form and survey 
3. The moderator will provide an explanation of the purpose of the focus group meeting and 
introduce him/herself as well as the co-moderator. 
 
Thank you for being here.  My name is _____ and today I will be leading our focus group 
discussion.  A focus group is a meeting where questions are asked to a group of people in 
order understand a specific topic.  The purpose of this focus group is for me to listen to 
your thoughts and experiences about genetics and heart health and suggestions for how we 
can make our study better. 
 
You should feel free to make any sort of comments – positive or negative – about what we 
are talking about today.  There are no right or wrong answers 
 
4. The moderator will review each of the key sections of the consent form. 
 
As you came in today, you were each given a consent form. Let’s go over this form now and 
make sure there are no questions.  
 
Important points to note: 
• Purpose of the study and what participants are being asked to do 
• Length of participation 
• Risks, benefits and compensation 
• Protection of privacy 
∗ Be sure to note that discussions will be recorded if all participants are 
willing. Recording can be stopped at any time at any participant’s request.   
• Who to call with questions 
 
Are there any questions? If you are willing to continue, please sign this form and return it to 
one of the project staff.  
 
5. The moderator will review the ground rules. 
We want everyone to have the chance to share their opinions or experiences.  We want this 
to be a very open discussion.  There are just a few ground rules we want to go over that will 
help everything go more smoothly: 
1. Talk one at a time. 
2. Be respectful of others. You don’t have to agree with what’s said.  
3. Keep today’s discussions private. What is said in this room should stay here. 
4. Remember that you can choose a ‘fake’ name for this discussion. 
5. Does anyone have any questions? 
[Administer survey questions] 
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 (START THE RECORDER) 
 
Ice-breaker:  Let’s begin by going around the table and have each person say their first name 
(fake or real) and then tell the group your favorite place in Kinston. 
 
 
Section 1: Perception of Genomics 
 
One of the terms some people may use when they talk about genetics and health is 
“GENOMICS.”   1. How many of you have ever heard of this term?    
 2. (Moderator: Look for how many people raise their hands).  It looks like we have ________ 
people who have raised their hand. 
 3. This may be a term that you may or may not have heard before.  Now, if someone were to say the 
word “GENOMICS” to you, tell me what comes to your mind.   What have you heard about it? 
LIST 
 
 
For the rest of this discussion, I am going to share with you what we mean by Genomics so that 
we are all on the same page:  
Genomics is a term that describes the study ofall of a person’s genes (their genome) including 
how genes interact with each other and with the person’s environment. This is different from 
genetics which is the study of a single gene in isolation. Think of genomics as a garden and 
genetics like a plant in your garden. If the plant is not flowering, you could study just the plant 
itself (genetics) or look at the surrounding to see if it is too crowded or there is not enough sun 
(genomics). 
 
Genomics is……… 
 1. What might be some benefits or positive things about genomics?  
 2. What might be some drawbacks or negative things about genomics?  
 3. On a scale of 1-10, (1=not at all important and 10=completely important), How important is 
genomics to your health?   
 
PROBE:  Do you feel pre-determined or destined to get certain diseases like heart 
disease? 
 
PROBE:  What factors might affect whether or not you get heart disease?   
 4. What changes, if any, would you make in your lifestyle if you knew you had inherited traits that 
increase your chances of getting heart disease? 
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Section 2:  Safety and Security Concerns 
 1. If you were asked to participate in research that involves using your genetic make-up to develop 
better ways to detect, treat, and prevent things like heart disease, would you participate?  
 2. What things would you need to consider or would want to know about the study? 
 3. What are some things that would be helpful for you in making this decision? 
 4. How comfortable are you with the idea of medical researchers having your genetic information? 
 5. What safeguards or protections do you feel are necessary and appropriate for someone to 
participate in this kind of research study?  
 
 
Section 3. Promotion 
 
 1. How should this study be advertised to the community? 
 2. If we put you in charge of getting the word out to others about this study, what would you do to 
make sure everyone knows about this? 
 
PROBE: What would you say? 
 
PROBE: Where would you put materials and messages? 
 
 
Section: Closing  
 
 
Based on our discussion today, what do you feel are two main things I should take back to our 
team?   
 
Is there anything else you feel we did not cover that I need to know? 
 
We would like to thank you for your time.  Your answers have greatly helped us.  If you have 
any questions about what we have done today, don’t hesitate to call the phone number on the 
bottom of the consent form.  We will be happy to talk with you about the study. 
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APPENDIX 4.4: DEMOGRAPHICS SURVEY 
Patient Demographic Form  
 
 
1. Gender 
  Male 
  Female 
 
2. What is your age?  
 
Years  
 
 
3. What ethnic group do you consider yourself? 
   Hispanic or Latino  
   Not Hispanic or Latino 
 
4. What race do you consider yourself? [Mark all that apply.] 
   American Indian or Alaska Native 
   Asian 
   Black or African American 
   Native Hawaiian or Other Pacific Islander 
   White 
   unknown 
   refused 
 
5. What is the highest level of education you have completed? 
¨ I never went to school 
¨ Some primary school (K-8) 
¨ Finished primary school (K-8) 
¨ Some high school (9-12) 
¨ Finished high school (9-12) 
¨ Some college 
¨ College degree 
¨ Graduate degree 
¨ Unknown 
¨ Other ______ 
 
6.  Does anyone in your family have heart disease? 
¨ Yes 
¨ No 
¨ Don’t know 
 
7.   How important is genetics to your overall health? 
¨ Not at all important 
¨ Somewhat important 
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¨ Mostly important 
¨ Completely important 
 
8.  Do you have any kind of health care coverage, including private health insurance, prepaid 
plans such as HMOs, or government plans such as Health Check, Medicaid Program for 
Children, or NC Health Choice? 
¨ Yes 
¨ No 
 
If yes, what is your primary health insurance plan? This is the plan which pays the medical bills 
first or pays most of the medical bills. 
¨ The State Employee Health Plan 
¨ Blue Cross/Blue Shield of North Carolina 
¨ Other private health insurance plan purchased from an employer or directly from insurance 
company 
¨ NC Health Choice 
¨ Medicaid 
¨ Carolina ACCESS 
¨ Health Check 
¨ South Care 
¨ The military, CHAMPUS, TRI CARE or the VA 
¨ The Indian Health Service 
¨ Other 
¨ Don’t know/Not sure 
¨ Refused 
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APPENDIX 4.5: FOCUS GROUPS CODEBOOK 
Code-Filter:All 
 
 
HU: PSO Genetics  FG 
File: [C:\Users\mvu\Documents\Scientific 
Software\ATLASti\TextBank\PSO  Genetics FG.hprS] Edited by: Admin 
Date/Time: 2012-03-2109:21:27 
 
 
Advertisement  
Comfort Level 
Communication 
Factors Affecting Heart Disease 
Final Thoughts  
Genomics Benefits  
Genomics Drawbacks  
Genomics Perceptions  
Importance Of Genomics  
Knowledge 
Knowledge Value 
Lifestyle Changes  
Participation 
Placement 
Perceived Control 
Predetermination  
Privacy 
Promotion  
Safeguards 
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APPENDIX 5: RETURN OF RESULTS PROTOCOL DEVELOPMENT MATERIALS 
APPENDIX 5.1 EXAMPLE ADAPTED RETURN OF RESULTS PROTOCOL 
 
!
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Heart&Healthy&Lenoir&
Return&of&Results&
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! Participant!ID!! !
! 1!
 !!!!!!!!!!!!!!!!
Most%people%have%this%DNA%sequence:! ! A!!!C!!!C!!!G!!!C!!!T!!!A!!!T!!!G!!!G!!!C!!!G!!!C!!!T…!!
%
A%few%people%have%a%SNP%(small%change):% A!!!C!!!G!!!G!!!C!!!T!!!G!!!T!!!G!!!G!!!C!!!G!!!C!!!T…!! !!
 
 
 
 
 
 
 
 
 
 
 
 
Single!Nucleotide!Polymorphism!(SNP)!
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gene$c&risk&
being&
overweight&
li2le&exercise&
poor&diet&
smoking&
Your%heart%disease%risk%is%made%up%of%%
gene3cs%and%lifestyle%choices.%
2%
Par3cipant%ID%% % %%
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Both%genes%and%lifestyle%choices%contribute%to%
your%overall%risk%of%developing%heart%disease.%
3%
Par3cipant%ID%% % %%
This&can&be&reduced&
by&changes&in&
lifestyle.&
We&can&now&
measure&each&
individual’s&risk.&
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Everybody%has%some%risk%of%
developing%heart%disease.%
4%
Par3cipant%ID%% % %%
HIGH%
AVERAGE%
LOW%
NONE%
&&&&&Lifestyle&
Contribu3ons%to%
your%risk%
 116 
 
 
 
! Participant!ID!! !
! 5!
Gene%Summary%
SNP! Condition! Risk%for%Heart%Disease%Compared%to%Other%
AfricanFAmericans%!rs10913469! BMI! <<!high!/!average!/!low!>>!!rs2568958! BMI! <<!high!/!average!/!low!>>!!rs29941! BMI! <<!high!/!average!/!low!>>!!rs12970134! BMI!/!Weight! <<!high!/!average!/!low!>>!!rs6499640! BMI!/!Weight! <<!high!/!average!/!low!>>!!rs7561317! BMI!/!Weight! <<!high!/!average!/!low!>>!!rs7647305! BMI!/!Weight! <<!high!/!average!/!low!>>!!rs8050136! BMI!/!Weight! <<!high!/!average!/!low!>>!!rs925946! BMI!/!Weight! <<!high!/!average!/!low!>>!!rs10830963! Fasting!plasma!glucose! <<!high!/!average!/!low!>>!!rs7903146! Type!2!diabetes! <<!high!/!average!/!low!>>!!rs12740374*! LDLVC! <<!high!/!average!/!low!>>!!rs3729639*! HDLVC! <<!high!/!average!/!low!>>!*!Protective!from!heart!disease!!
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Your%gene3c%heart%disease%risk%is%average%
with%the%AfricanLAmerican%popula3on.%
6%
Par3cipant%ID%% % %%
HIGH%
AVERAGE%
LOW%
NONE%
&&&&&Genes&
Added%gene3c%
informa3on%
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! Participant!ID!! !
! 7 
Summary%
Item% Result%Genetic!Testing!! You!are!at!<<!high!/!average!/!low!>>!genetic!risk!for!heart!disease!
• You!have!xx!out!of!13!possible!small!DNA!changes!tested!in!fifteen!genes!linked!to!higher!risk!for!heart!disease!in!a!number!of!large!studies.!Other!Things!About!You!that!Raise!Your!Risk! • !<<!insert!CVD!risk!increasing!factors>>!Why!This!is!Important! Heart%disease%is%the%#1%cause%of%death%in%
the%U.S.%
• North!Carolina!has!a!higher!death!rate!than!the!US!average.!!
• Lenoir!County!has!a!higher!death!rate!than!the!North!Carolina!average.!
• AfricanVAmericans!have!higher!death!rates!in!Lenoir!County!and!across!the!U.S.!compared!to!Caucasians.!
BUT,%heart%disease%can%be%delayed,%or%
even%prevented.!What!You!Can!Do!to!Lower!Your!Risk!of!Developing!Heart!Disease! Follow!the!prescription!from!Heart!Healthy!Lenoir.!!
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!
!
"
"
"
Thank"you!"
"!For!questions!please!contact:!Harlyn!Skinner!hskinner@ad.unc.edu!252Q643Q5150!!If!you!would!like!to!speak!with!a!genetic!counselor,!please!contact!Harlyn!Skinner!for!an!appointment!with!Julianne!O’Daniel,!M.S.,!C.G.C.!!!!!!!!! The!Return!of!Results!Research!Study!is!sponsored!by!UNCQCH,!ECU,!National!Institutes!of!Health,!and!the!HeartQHealthy!Lenoir!Community!Advisory!Committee.!This!study!was!reviewed!and!approved!by!the!University!of!North!Carolina!Institutional!Review!Board:!IRB!#!14Q1500!
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Heart Healthy Lenoir Healthy Eating Tips can be found at: 
http://www.hearthealthylenoir.com/sites/default/files/imce/documents/HealthyEatingMaterials.p
df  
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APPENDIX 5.2 KEYWORDS SHEET USED WITH RETURN OF RESULTS PROTOCOL 
 
  
Key Words 
SNP (Single Nucleotide Polymorphism): a small DNA change 
BMI (Body Mass Index): a measure of body fat 
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APPENDIX 5.3 TAKE HOME MATERIALS WITH RETURN OF RESULTS PROTOCOL 
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A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
A G G C A C C A C T G A G
#1) PHENOTYPE
This word refers to the physical and 
behavioral characteristics of an individual. In 
most cases, both genes and environment 
contribute to phenotype. An example of 
a phenotypic trait is the ability to taste a 
bitter flavor in raw broccoli, which can affect 
whether you like it. (We’ll assume that if you 
can taste the bitterness, you don't like raw 
broccoli.)
#2) GENOTYPE
This word can be used in several ways. It can 
refer to your DNA sequence at a particular 
place, like the SNP shown here (either C or G). 
It can refer to your personal collection of 
genetic variants. As a verb, it refers to the 
process of determining your sequence, as in 
the introductory paragraph.
#3) CELL
Your body contains 50 trillion of these 
microscopic living units. They are found
everywhere, from the surface of your tongue 
to the inside of your bones. Cells perform 
specific jobs in your body. The 
way they perform their jobs affects your 
phenotype.
#4) PROTEIN
Cells perform their jobs with molecular tools 
called proteins. Some proteins are
used as the building blocks of hair. Others are 
used to digest your food. In tongue cells, one 
kind of protein detects bitter chemicals and 
sends a signal to your 
brain. The way a protein works—or
doesn’t—also affects your phenotype.
#5) GENOME
The genome is a master blueprint for making 
all the different parts of you, and 
a complete copy can be found in each of your 
body’s cells. The genome contains about 
20,000 individual blueprints for different 
protein tools, plus a whole lot of other stuff 
whose function is unknown.
#6) GENE
Each kind of protein tool has its own 
blueprint, or gene, located in the cell's 
nucleus. Genes can be turned on or off
in different cells at different times. The gene 
for the protein that detects bitter
things is on in your tongue cells, but 
off in your skin cells.
#7) ENCODE
We say that a gene encodes a protein, 
because it contains specific information your 
cells read in order to build that
protein. If your version of a gene is different 
from a friend’s, it might encode a
different protein. All together, you have 
about 20,000 genes, each encoding a 
different protein.
#8) DNA
The information a gene uses to encode a 
protein is stored in a molecule called DNA. 
There are four “letters” in the DNA alphabet, 
which make up three-letter “words.” Each 
"word" encodes a single bit of a growing 
protein chain. The full-length chain will 
become a working protein. The bits making 
up the protein affect how the protein does its 
job.
#9) SNP
A SNP is a site in the genome where a single 
DNA “letter” often differs from person to 
person. Some (but not all) SNPs appear to be 
associated with variation in different people’s 
phenotypes. In this example, a SNP in the 
gene encoding the protein that responds to 
bitter flavors can have C or G 
variants—leading to a big difference in 
phenotype!
A G G C A C C A C T G A G
ALA PRO LEU
phenotype: broccoli tastes bitter
              genotype: C
phenotype: broccoli tastes ok
            genotype: G
TONGUE CELLS 
SIGNAL THE BRAIN
#3) CELL
TONGUE 
CLOSE-UP #4) PROTEIN
#4) PROTEIN
#5) GENOME
#6) GENE
#7) ENCODE
#8) DNA #9) SNP
#5) GENOME
One of the phenotypes you will learn about when 23andMe genotypes you is whether you can taste a bitter flavor in raw broccoli. Some 
people’s tongue cells make a protein that can detect bitter flavors; others make one that can’t. Each of your cells contains a copy of your 
genome, which is made up of a molecule called DNA. Your genome contains genes, which are blueprints that encode  proteins like the 
one made by your tongue cells. Different people can have different blueprints because of differences in their SNPs. There are two versions 
of the SNP shown here, and each leads to a different version of the gene, which in turn encodes a different version of the protein. One 
version of the protein can detect the bitter flavor of raw broccoli, while the other cannot.
key words for genetics
 
G C A C C A
ALA PRO
A G G C A C
G
C A C T G A G
ALA ALA LEU
C A C
G
C A C
ALA ALA
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APPENDIX 5.4 PHASE 1 CONSENT FORM 
University of North Carolina-Chapel Hill 
Consent to Participate in a Research Study 
Adult Participants – General  
Consent Form for Participants (Phase 1) version 2 
________________________________________________________________________ 
Consent Form Version Date: 10/21/14 
IRB Study #14-1500 
Title of Study:  Heart Healthy Lenoir Study: Return of Results 
 
Principal Investigator: Harlyn Skinner, MS  
UNC-Chapel Hill Department:  Nutrition 
UNC-Chapel Hill Phone number:  (919) 966-6088 
 
Faculty Advisor: Alice Ammerman, DrPH, RD 
UNC-Chapel Hill Department: Center for Health Promotion & Disease Prevention 
UNC-Chapel Hill Phone number: 919-966-6082 
 
Co-Investigators: Alice Ammerman, DrPH, RD; Tom Keyserling, MD; Jonathan Schisler, PhD; 
Jacquie Halladay, MD, MPH 
 
Funding Source and/or Sponsor: National Institutes of Health 
Study Contact telephone number:  252-643-5150 
Study Contact email: hskinner@ad.unc.edu 
 
 
About Heart Healthy Lenoir Return of Results 
Introduction 
We invite you to take part in this research project.  This form tells you about the project so you 
can decide if you want to take part in it.  If you do, it is fine to change your mind and withdraw 
from the study at any time.  We think you will benefit from taking part in this study, but you may 
not, as the purpose of research studies is to gain new knowledge that may help others in the 
future.  There also may be risks to being in a research project and these are noted on this form. It 
will not be a problem for your doctors or other health care providers if you do not take part in 
this study or if you start the project and then decide to stop taking part before it is done. 
 
What is the purpose of this new part of the study?    
Some participants have expressed interest in receiving their information from the Genomics 
study. So, we would like to give participants an opportunity to learn about some genomic 
variations that contribute to heart disease risk. We have searched the literature for genomic 
variations that have been shown to be associated with heart disease and its risk factor. We have 
identified 13 genomic variations that contribute to heart disease risk in African-Americans. 
Research has shown that giving people genomic risk information can affect their diet and 
exercise choices. We would like to know if genomic information affects people’s choices about 
diet and exercise to reduce heart disease risk. 
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Our main goal is to try to understand the best way to give African-Americans information about 
genomic variations that contribute to heart disease risk.  To do so, we have developed materials 
that provide information on genomic information and heart disease risk.  We want to talk with 
African-Americans who live in Lenoir County to better understand their thoughts, feelings, and 
concerns about these materials.  You are being asked to take part in this discussion group.  
 
Taking part in this new part of the Study is Your Choice 
Before you learn about the study, you should know that: 
4. Your choice to be in the study is voluntary. 
5. You may decide not to join the study. 
6. If you choose to be in the study, you may stop at any time. 
 
We want you to understand the details about the study so that you can make an informed choice 
about being in it.  You will be given a copy of this consent form.  Please ask questions if there is 
anything you do not understand. 
 
How many people will take part in this phase of the study?  In this study, we will talk to up to 
40 African-American men and women who live in Lenoir County.    
 
How long will your part in this phase of the study last?  It should take about two hours to 
answer the questions. We will first speak to each person individually for about 30 minutes, then 
as a group for about one and a half hours. 
 
What will happen if you take part in this phase of the study?  First, you will review and sign 
this consent form.  Then, there will be an individual and a group discussion. Both discussions 
will be audiotaped so we can capture comments to help improve our materials. You will not be 
identified on the tapes and discussion information will not be shared with anyone but the 
research staff. 
 
First, a member of our research team will speak with you individually. You’ll take a brief survey 
then we’ll present our materials and ask your thoughts about them. Then we will gather everyone 
as a group to ask the group their thoughts about the materials. A member of our research team 
will lead the group discussion, which should last no more than one and a half hours. The group 
will be asked some questions about what they find unclear, what they would change, and how to 
make our materials easier to understand. In the group session, no questions will be directed to 
you individually, but instead will be posed to the group. You may choose to respond or not 
respond at any point during the discussion.  
 
What are the possible benefits from being in this phase of the study?  Research like this 
helps others by making clear how we can best help men and women like you.  You may not 
benefit directly from this study.   
 
What are the possible risks or discomforts involved this phase of the study?  You should not 
have any discomfort from being in this study.  We think you will be at ease answering the 
questions we will ask you. Although we will be careful to protect your privacy; loss of privacy is 
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a potential risk of being in this study.  Also, there is always a chance of unknown risks. You 
should report any problems to the research staff.  
 
How will your privacy be protected?  To make sure what you say is confidential, you can use a 
different name during the group session so that others who take part in this group, who do not 
already know you, will not know your real name.  Also, what other people say during the 
discussions is confidential, so you should not share anything you hear or see in the group with 
people outside the group.   Your name will not appear on the transcript from the tape recording.  
Instead, we will make up and use an ID number.  The key that links your name and ID number 
and the study data we collect from you will be stored in a locked file cabinet and/or password 
protected computer.  The tape recording of the discussion session will be promptly transferred to 
a password-protected computer and will be erased from storage in the tape recorder. 
   
Will you receive anything for being in this phase of the study?  You will receive a $30 gift 
card for taking part in this study.  
 
Will it cost you anything to be in this this phase study?  It is free for you to be in this study, 
other than your costs to travel to the meeting site or childcare if needed. 
 
What if you have questions about this study? You have the right to ask and have answered 
any questions you may have about this research.  If you have questions, or concerns, you should 
contact Harlyn Skinner, MS (252-643-5150; hskinner@ad.unc.edu). She is the leader of this 
project and will be happy to answer your questions.   
 
What if you have questions about your rights as a research participant?   
All human research is reviewed by a group of people that works to protect your rights and 
welfare.  If you have questions or concerns about your rights as a research subject you may 
contact, anonymously if you wish, the Institutional Review Board at the UNC-Chapel Hill at 
919-966-3113 or by email to IRB_subjects@unc.edu.  
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--------------------------------------------------------------------------------------------------------- 
Title of Study:  Heart Healthy Lenoir Study: Return of Results 
 
Principal Investigator: Harlyn Skinner, MS 
Faculty Advisor: Alice Ammerman, DrPH, RD 
 
Participant’s Agreement:  I have read the information above.  I have had all of my questions 
answered.  
 
By placing a check here, I agree that the researchers may call me by phone to see if I am 
willing to take part in the follow-up study of the return of genomic information to study 
participants.  (If you check yes, we will ask for your phone number.)  
 
By signing this form, I agree to be in the study.  If I decide I do not want my information to be 
used, I will tell you in writing. 
 
 
Signature of participant   Date 
 
 
Printed name of participant 
 
 
Signature of person obtaining consent  Date 
 
 
Printed name of person obtaining consent 
 
 APPENDIX 5.5 PHASE 1 RECRUITMENT BROCHURE 
 
 
  
Heart &Hea l thy *
Leno i r *
Return'of'Results'
Research'Study'
Focus*Groups*
Participant*Brochure*
 
*
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Heart3Healthy'Lenoir'Return'of'
Results'Research'Project:'This*
project’s*goal*is*to*understand*how*
people*respond*to*genomic*risk*
information.*
*
*
*
*
1.'What'is'this'study'all'about?***
Some*people*wanted*to*know*their*
heart*disease*risk*results*from*Heart*
Healthy*Lenoir.*This*study*aims*to*
learn*what*people*think*about*their*
genomic*risk*information*for*heart*
disease.*But*first,*we*need*help*
refining*our*materials*to*return*risk*
information.*
*
2.'Who'can'participate?**
African&American*participants*from*
Heart*Healthy*Lenoir.*
*
3.'How'many'people'can'join?**
Up*to*40*people.***
**
4.'How'long'does'the'study'last?**
The*study*lasts*for*1*month.*
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
'
*
*
7.'When'do'the'Return'of'Results'Focus'
Groups'start?'
♦ Study*enrollment*begins*July*2014.**
♦ Study*appointments*will*begin*to*be*
scheduled*in*July*2014.*
*
8.'What'will'it'cost'me?'
The*program*is*free,*but*travel*costs*to*
and*from*the*study*office*are*not*covered.*
'
9.'Will'I'be'paid'to'be'in'this'study?'
You*will*be*paid*for*your*time*completing*
the*study*visit.*You*will*receive:*
♦ $30*gift*card*for*completing*the*focus*
group*(120*minutes).**
*
10.'Are'there'any'possible'benefits'to'
joining?'
We*think*you’ll*enjoy*taking*part*in*the*
discussion.*You*will*help*us*understand*
how*people*respond*to*receiving*genomic*
risk*information*about*heart*disease.**
*
11.'Where'can'I'get'more'information?'
Contact*Harlyn*Skinner,*at*
hskinner@ad.unc.edu*or*call**
252&643&5150*
*
www.hearthealthylenoir.com**
*
*
*
*
For information on open 
positions or to submit your 
resume, please visit our Web 
site at: 
www.lucernepublishing.com 
5.'What'happens'if'I'decide'to'
participate?**
If*you*decide*to*participate,*we*will*
ask*you*to:*
*
♦ Sign*a*consent*form,*saying*you*
agree*to*participate*in*the*project*
♦ Attend*1*focus*group*for*2*hours*
to**
& Answer*a*1&2*minute*survey**
& Speak*individually*about*our*
materials*
& Speak*in*a*focus*group*about*
our*materials*
*
6.'How'can'I'enroll'in'the'study?'
♦ A*study*team*member*will*give*
you*a*call*to*see*if*you’re*
interested.*
*
OR*
*
♦ Call*the*study*office*to*say*you’re*
interested.*
*
252&643&5150*
 
 
 
The*Return*of*Results*Research*Study*is*sponsored*by*
UNC&CH,*ECU,*National*Institutes*of*Health,*and*the*
Heart&Healthy*Lenoir*Community*Advisory*
Committee.*
This*study*was*reviewed*and*approved*by*the*
University*of*North*Carolina*Institutional*Review*
Board:*IRB*#*14&1500*
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APPENDIX 5.6 PHASE 1 STRUCTURED “COGNITIVE” 
INTERVIEW AND FOCUS GROUP PROTOCOL 
 
Procedures 
Participants will be greeted by the moderator and/or note taker upon their arrival. They will be 
asked to sign-in and they will be encouraged to help themselves to refreshments while we wait 
for participants to arrive. The session will begin 10 minutes after participants are asked to arrive. 
Should a participant arrive late, the note taker will assist the participant in checking in and 
getting settled. 
 
Note: Each individual interviewer should have a folder ready with this script, the REAL-G, pens, 
and a ROR script for participants. Each folder will be labeled with the participant’s ID number. 
 
Introduction 
Good (morning/afternoon/evening). My name is _______ and I’ll be leading our discussion 
today.  This is (introduce other research staff). First thank you for taking time to join us. The 
purpose of this discussion is to hear your thoughts and opinions about a program we’re planning 
to help African-Americans understand their personalized risk for heart disease. Today, we’d like 
to learn more about the best ways to talk about 13 small DNA changes that contribute to heart 
disease risk. Specifically, we are interested in creating a final product that has language and 
phrasing that everyone can connect to.  
 
This session should last about two hours. First we’ll talk to you individually for thirty minutes. 
We’ll present our materials and get your initial impressions. Then we’ll gather everyone together 
for a group discussion for about an hour and a half. There, we’ll speak more in-depth about the 
materials. At the end of the group discussion you will receive a Wal-Mart gift card for $30 for 
your time.   
 
We’ll be audiotaping both parts of our discussion for report writing purposes. Everything you 
say is important to us and we want to make sure we don’t miss any of your comments. However, 
I want to assure you that all of your comments are confidential and that nothing you say will be 
connected with your name. 
 
Before we begin, I can take your consent forms from you if you have them. You would have 
received it as part of the packet that was mailed to you. If you don’t have it, I have a copy here 
you can sign and extra copies in case anyone wants to take another one home.  
Moderator Instructions: Collect consent forms and place them in the dedicated consent forms 
folder. 
Now we’re going to break into our individual sessions. We’d like you to experience this like you 
were a participant in our proposed study. A research team member will take you to a private area 
and give you made-up individual results about your risk for heart disease from the Heart Healthy 
Lenoir study. We have not looked at any of your personal information. We made things up to 
give you the experience of being in our proposed study. When we come back together as a 
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group, we’ll talk about your experience getting “your” results and your opinions about our 
presentation of the information. 
 
Individual Interview 
Hi. My name is    and I appreciate your time to be here today. Today, I’m going to 
have you take a brief survey, and then I’ll give you some made-up individual results like you 
were a participant in our proposed study. Our meeting today should take about 30 minutes. Feel 
free to ask me questions along the way. I also have a pen for you to write notes for things to 
discuss with the group later. I’ll ask you about your overall impressions at the end. 
 
I’d like to tape our discussion today. Is it OK to start the recorder now?  
 
You’ll hear me say a series of numbers that will allow us to identify you without me saying your 
name. I do that to maintain your confidentiality. And again, none of the results I’m talking about 
after I start the recorder are real; they are completely made-up. 
 
Interviewer Instruction: Start recorder and state participant number, initials of interviewers, date, 
and time.] 
 
Now I’m going to give you a survey that looks at people’s level of comfort with medical jargon. 
This survey is to help us figure out the best type of materials to develop.  The survey only takes 
1-2 minutes to do. 
Interviewer Instruction: Hand participant REAL-G questionnaire 
I want to hear you read as many words as you can from this list. Begin with the first word and 
read aloud. When you come to a word you cannot read, do the best you can or say “pass” and go 
on to the next word. 
 
Note:  If the participant takes more than five seconds on a word say “It’s okay to pass” and 
point to the next word, if necessary, to move the participant along. If the participant begins to 
miss every word; have him/her pronounce only known words. 
 
Thank you. Again, that is to help us figure out the best type of materials to develop.   
 
Now, I’m going to give you individual heart disease risk results from Heart Healthy Lenoir. I 
also have a written copy here for you to keep. 
 
Interviewer Instruction: Read return of results script. Turn the pages of the participant’s copy as 
well as yours. 
 
That is the end of the script! Before we go back to the group, I have just one question. 
 
Take out 1 – 9 scale sheet. Record participant answer on notes page. 
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Q1. On a scale of 1-9, (1=completely unclear and 9=completely clear), how understandable is the 
information in this document?   
 
Thank you very much for your time. We’ll gather together in the main office now for the group 
discussion. 
 
Encourage participants to help themselves to refreshments while we wait for all participants 
finish their interviews. 
  
 134 
Focus Group Introduction 
Welcome back! For this part of our discussion I’d like to go through our materials more in-depth. 
This part will last about an hour and a half. Please feel free to excuse yourself anytime if you 
need to use the restroom (describe location). Once we’re done with our discussion you will 
receive your gift card to Wal-Mart as a thank you for your time.  
 
Before we start the tape, I’d like to go over a few ground rules that will help everything go more 
smoothly. We want this to be an open discussion and for everyone to have the chance to share 
their opinions or experiences. 
6. Talk one at a time. 
7. Be respectful of others. You don’t have to agree with what’s said.  
8. Keep today’s discussions private. What is said in this room should stay here. 
9. Remember that you can choose a ‘fake’ name for this discussion. 
 
Does anyone have any questions before we get started? 
 
Part A: General Impressions 
I’d like everyone to get acquainted a bit. Let’s go around the room and everyone give me a first 
name and one word to describe your experience receiving the genetic information. (Q1) 
 
Q2. Could anyone expand on that? 
 
 Probe(s): What were your thoughts and feelings when you got the information? 
   What things made you feel positive about the experience? 
What things made you feel negative about the experience? 
What do you find repetitive? 
What needed more explaining? 
 
Part B: Breaking Down the Script 
Now I’m going to give you a copy of our script so you can help us with the wording. This is your 
opportunity to tell me everything I need to change. 
 
The first page is an introduction to the idea of looking at genetics for small DNA changes, or 
SNPs.  
 
Interviewer Instruction: Read first page of return of results script.  
 
Q3. What other background information about SNPs do you want before the discussion? 
 
Q4. We’ve tried to use non-technical terms to explain things. What words do you find to be 
jargon or that we need to do a better job explaining? 
 
Q5. I also wanted to ask you about a few specific words: 
 
a. Genetic. How can we make the use of that word more clear? 
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b. SNP. How can we make the use of that phrase clearer? 
c. Variant. We’ve used the phrase “small DNA change” or “changes” instead. Does that 
phrase make the conversation clearer? 
 
 
Let’s move to Page 2.  
 
Interviewer Instruction: Read second page of return of results script.  
 
Q6. What did you understand the message to be from this page? 
Probe(s): My goal was to talk about the factors that contribute to heart disease. How 
could  
  that message be clearer? 
What things did you find repetitive or in need of more explanation? 
What would you change about the picture? 
 
Let’s move to Page 3.  
 
Interviewer Instruction: Read third page of return of results script.  
 
Q7. What did you understand the message to be from this page? 
Probe(s): My goal was to talk about how genetics and lifestyle choices contribute to 
heart  
   disease. How could that message be clearer? 
What things did you find repetitive or in need of more explanation? 
What would you change about the picture? 
 
Let’s move to Page 4. 
 
Interviewer Instruction: Read four page of return of results script.  
 
Q8. What did you understand the message to be from this page? 
Probe(s): My goal was to talk about lifestyle contributions to heart disease risk. 
How could  
that message be clearer? 
What things did you find repetitive or in need of more explanation? 
What would you change about the picture? 
 
Let’s move to Pages 5 & 6. 
 
Interviewer Instruction: Read five and six page of return of results script.  
 
Q9. What did you understand the message to be from these pages? 
Probe(s): My goal was to talk about genetic contributions to heart disease. How 
could that  
   message be clearer? 
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What things did you find repetitive or in need of more explanation? 
What would you change about the picture? 
 
Let’s move to Page 7. 
 
Interviewer Instruction: Read seven page of return of results script.  
 
Q10. What did you understand the message to be from these pages? 
Probe(s): My goal was to talk summarize your risk of heart disease, why it’s 
important, and  
   what you can do. How could that message be clearer? 
What things did you find repetitive or in need of more explanation? 
What would you change about the picture? 
 
Let’s move to next pages. 
 
These pages are designed to remind you of your personal goals and to remind about the tips on 
how to eat better to reduce your heart disease risk. 
 
Q11. How effective is it to end the discussion with these tips? Do you think there is a better way 
to end the conversation? 
 
Let’s move to the last page. 
 
On the last page, I’ve given you my contact information and told you a genetic counselor is 
available. 
 
Q12. What sorts of questions do you still have after having this discussion? 
Probe(s): Would you want to speak to the genetic counselor?  
What sorts of questions would you ask her? 
 
Interviewer instructions: Hand out NHGRI A Guide to Your Genome. Give them a minute to flip 
through it. 
 
We are also considering including a publication from the National Institutes of Health on 
understanding your genome for participants to take home.  
 
Q13. Do you think this would be helpful to take home? How so? 
 
Part C: Recruitment 
For this last section, I’d like to ask how your opinions about how you would like to be recruited 
into this study. We’re planning on inviting African-Americans from Heart Healthy Lenoir to 
enroll in our study to get their genetic information.  
 
Q14. How should we describe the study to you to peak your interest? 
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Probe(s): What questions would you like answered about the risks and benefits of 
this  
  study before you participate? 
Would you like to be contacted by mail or phone? 
 
Q15. Are there any last comments or suggestions anyone would like to make? 
 
Thank you very much for your time. We appreciate you coming out to share your thoughts with 
us. (Name of note taker) will give you each a gift card for $30 for your participation today.   
 
  
 138 
APPENDIX 5.7 RAPID ESTIMATE OF ADULT LITERACY IN GENETICS 
 
 
RAPID ESTIMATE OF ADULT LITERACY IN GENETICS 
(REAL-G) 
Erby, L.H. et al. (2008). The rapid estimate of adult literacy in genetics (REAL-G): a means to assess literacy deficits in the context of genetics. American 
Journal American Journal of Medical Genetics; 146A(2): 174-181. 
 
Focus Group No.    
Participant #     
Date      
Time      
Interviewer ID    
 
 
List 
Genetic    
Sporadic    
Mutation     
Variation      
Chromosome   
Hereditary        
Abnormality      
Susceptibility    
  
# of (+) Responses:  
  
 
 
LEGEND: (+) = Correct  (—) = Word not attempted  ( / ) = Mispronounced word 
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APPENDIX 6: RANDOMIZED CONTROLLED TRIAL 
SUPPLEMENTAL MATERIALS 
 
APPENDIX 6.1: CONTROL GROUP MATERIALS 
A. SCRIPT 
Introduction 
Hi. My name is ___________ and I appreciate you taking the time to be here today. Today, 
we’re going to talk about health and wealth, take a brief survey, and then schedule your next 
appointment. Our meeting should take about 45 minutes. Feel free to ask me questions along the 
way. I also have a pen for you to write notes for yourself if you’d like. 
 
Do you have any questions before we get started? 
 
I’d like to tape our discussion today. Is it OK to start the recorder now?  
 
Interviewer Instruction: Start recorder and state participant number, initials of interviewers, date, 
and time.] (E.g. 001, CF, Nov 15, 10am) 
 
Part A: Are Health and Wealth Related? 
Q1. What does economic empowerment look like for people in Lenoir County?  
 Probes: What does that phrase make you think of? 
   How would you define it? 
 
Here we have some maps of North Carolina. I’ve stared Lenoir County on each map. The first 
map is people living in poverty. The second map is the obesity rate. The third map is preventable 
heart disease deaths. 
 
Q2. Why are people in Lenoir county poor? 
 
Q3. How do you think money and health are related? 
 Probes: Looking at the maps, what comes to mind? 
 
Q4. How is stress and money related in your life? 
 
Q5. What are some ways to increase individual, family, and community wealth? 
 Ideas:  Money management and budgeting 
Getting out of debt and saving 
Buying a home 
Education and training for better jobs 
Starting a business 
Becoming involved in the political system.  
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Part B: Values 
Here is a list of values some people think are important. 
 
Interviewer Instruction: Have participant mark the three most important to them.  
 
Q6. Of these values, which are the three most important to you? 
Q7. What do these values mean to you?  
Q8. How might these values relate to your life and financial goals?  
 
Part C: Saving / Budgeting / Creating Assets / Credit 
Today we’re going to talk about economic empowerment and how that fits with your most 
important values. We can talk about saving, budgeting, creating assets, or credit. What’s of 
interest to you today? 
 
Interviewer Instruction: Remind the participant that these topics all related to money and health 
buy you are asking them to choose the one to emphasize. 
  
 142 
Part C-1: Saving  
 
Interviewer Goal: Begin a discussion about the importance of saving. Identify potential reasons 
for not saving and items that require savings by using the discussion questions below. This 
should lead into a discussion on the importance of saving (i.e.: having money in emergency 
situations) 
 
Q1. What ways were you taught to save?  
Probes: Who taught you to save? Parents, grandparents, etc 
Were you ever taught to save? 
 
Q2. What have you saved money for in the past? 
 
Interviewer Instruction: Show participants simple ways for them to continue saving by 
discussing the “saving tips” worksheet.  
 
Q3. What are some ways you could save money? 
 
Having a saving account can also help you build wealth. For example, if you save $70 a month, 
you will have $840 at the end of the year. 
 
Interviewer Instruction:  
- Use the “Different types of savings accounts” page to talk about the options of saving. 
- Use “Why keep your money in a bank?” to help explain the real benefit of a savings account—
how your money can grow! 
- Give an example of when your money does not grow (i.e. when you put $1000 in your closet 
for a  
  year) 
- Have participants use what they have learned to fill out the “Pay Yourself First Action Plan” 
worksheet. 
 
Q3. What is one piece of advice you would give to your children about the importance of 
savings, and how to save?  
 
Interviewer Instruction: Skip to Part D. 
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Part C-2: Budgeting  
 
Interviewer Goal: Talk about budgeting in relation to a recipe. 
 
Creating a budget is like a recipe. Our income is the sum of the ingredients, your expenses are 
the quantities to use, and a recipe or budget are both how you put it all together. If you add too 
much flour or spend too much on something, the final product or your income will not work out.  
 
There are four steps to preparing a budget. 
 
Step 1: Keep track of your daily spending. 
 
Interviewer Instruction: Discuss “Daily Spending Diary”. 
 
Step 2: Determine what your monthly income and expenses are the month before they are 
due. 
 
Interviewer Instruction: Discuss “Monthly Income and Expense” and “Monthly Payment 
Schedule” worksheets 
 
Step 3: Find ways to decrease spending. 
 
Interviewer Instruction: Discuss “Tips to Help You Decrease Spending" handout. 
 
Q1. What are some different budgeting techniques that have worked for you? 
 
Interviewer Instruction: Fill out “My ideas for decreasing spending” 
 
Step 4: Find ways to increase income. 
  
This last sheet is a few more ideas to help you budget. 
 
Interviewer Instruction: Discuss “Other Budgeting Tools" handout. 
 
Interviewer Instruction: Skip to Part D. 
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Part C-3: Creating Assets 
 
Interviewer Goal: Lead a discussion on the importance of having a savings account and how it 
can guild wealth. 
 
Q1. What does wealth mean to you? 
 Probe(s): Can you give me an example? 
 
Q2. I have a definition here of wealth as when “the value of the things you own is greater 
than the amount of money you owe (assets)”. What are your thoughts on that? 
 
Q3. What are some assets that don’t help generate wealth? 
 
Q4. What are some assets that do contribute to wealth? 
 
Interviewer Instruction: Discuss examples of wealth creating assets (i.e. house, retirement plan, 
savings account) as well as assets that don’t contribute to wealth (i.e. car, stereo, clothes). 
 
Q5. What is a benefit of saving money in a bank? 
 
Having a saving account can help you build wealth. For example, if you save $70 a month, you 
will have $840 at the end of the year. 
 
Interviewer Instruction:  
- Use the “Different types of savings accounts” page to talk about the options of saving. 
- Use “Why keep your money in a bank?” to help explain the real benefit of a savings account—
how your money can grow! 
- Give an example of when your money does not grow (i.e. when you put $1000 in your closet  
  for a year) 
- Have participants use what they have learned to fill out the “Pay Yourself First Action Plan” 
worksheet. 
 
Coming back to the idea of assets, some debt can also help you build wealth. 
 
Q6. What are some examples where debt is good? 
 
Q7. What are some examples where debt is bad? 
 
Interviewer Instruction:  
- Discuss debt and use “Not all debt is bad debt” to demonstrate cases in which debt is 
contributing positively to your future! 
- Talk about increasing your assets through home ownership. Discuss 3 ways in which investing 
in a home can help you financially by referring to “Using Home Equity to Build Wealth.” 
 
Interviewer Instruction: Skip to Part D.  
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Part C-4: Credit 
 
Interviewer Goal: Lead a discussion on credit and debt 
 
Q1. What does having credit mean to you? 
 Probes: Is it good or bad to have credit? 
 
Q2. Would you say you have good or bad credit? Why?  
 
Q3. Sometimes you can have too much debt, which could make your credit bad. Do you think 
you are in too much debt? 
 
Interviewer Instruction: Use the “15 signs of debt trouble” handout to have a discussion on how 
to tell if you could be in too much debt. 
 
It’s important to stay out of debt and have a good credit history. 
 
Interviewer Instruction: Use the “Tips for Building Your Credit History” handout to talk about 
ways to build one‘s credit history 
 
You can find out if your credit is good or bad with a credit report. 
 
Interviewer Instruction: Use the “What is a Credit Report” handout to discuss the importance of 
a credit report, what it is used for, how to get one and how to read one 
 
Interviewer Instruction: Skip to Part D. 
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Part D: Financial Goals 
 
There are two types of goals: Life and Financial. 
1). Life: This type includes things like getting an education, improving job skills, getting out of 
debt, or starting business.  
2.) Financial: This type includes things like saving money, budgeting, creating assets, or 
improving your credit.  
 
We’re going to talk about financial goals today. 
 
Q1. Now that we’ve talked some about finances, what hopes do you have for your finances? 
 
Q2. Why are these important to you? 
 
Q3. In order to live out these hopes, what do you need to do? 
 
You can help work towards those hopes by setting a goal. 
 
Interviewer Instruction:  
- Use “Setting Goals” to discuss setting goals. 
 
SMART goals can help you figure out and reach your goals. 
 
Interviewer Instruction:  
- Use “How to Increase the Success Rate of Your Goals” to introduce SMART Goals. 
- Just mention the detailed SMART goals rules. They can read them on their own time. 
- Review the example SMART goal. 
 
This next page gives you more information on exactly how to set a SMART goal. Let me give 
you an example of one. 
 
Interviewer Instruction: Review the example SMART goal. 
 
Setting a financial goal to work toward using these guidelines will help you become 
economically empowered. I’m going to give you a copy of the Financial Goal Tip sheets and 
planning worksheets so you can create your own SMART goal at home.  
 
The handouts from the other topics we didn’t discuss today are also in this book for you to read 
on your own time. 
 
Q4. Do you have any questions for me?  
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Part E: Ending 
 
Thank you so much for taking the time to let me talk with you today. I’m going to ask you to 
take one last quick survey, and then we’ll get you scheduled for your next visit.  
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APPENDIX 6.2  GENOTYPING METHODS 
Dr. Schisler, primary investigator for the HHL Genomics Study, and his laboratory team 
at the medical school of the University of North Carolina, Chapel Hill performed whole genome 
genotyping as a part of the HHL Genomics Study. The following is a description of study 
procedures for HHL Genomics. 
Three milliliters of whole blood were obtained from fasted participants at HHL Genomics 
study entry. DNA was extracted from circulating leukocytes using a single monophasic reagent 
containing a chaotropic cell disrupter and a noncorrosive phenol free extraction reagent (DNA 
STAT-60, Tel-Test) as described by Alcorta, Preston and Munger.267 DNA aliquots were 
maintained in a dedicated, locked ultra-low freezer at -80°C. Total genomic DNA (500 ng) was 
processed with standard Illumina reagents and protocols, and hybridized to a Human Omni-
Express Exome BeadChip. 
The Human Omni-Express Exome BeadChip measures > 700,000 SNPs derived from 
previous generation arrays, the HapMap project, with representation on chromosomes X and Y, 
mitochondrial SNPs, known regions of copy number variation, recombination hotspot SNPs, and 
> 240,000 exonic variants. This chip captures 73% of CEU variation and 40% of YRI variation 
(MAF > 5% compared against the June 2011 1kGP data release, r2 > 0.8). The Illumina platform 
has a high level of quality control through the use of three pre-hybridization checkpoints as well 
as Quality Control probes on the array. The Human Omni-Express Exome BeadChip was used in 
conjunction with the Illumina® GenomeStudio software, which allowed automated quality 
control that sorts samples by quality control call rate, visualization of quality control metrics 
across samples, SNP cluster visualization and signature SNP list for tracking. Flexible SNP filter 
and export are also included to enable downstream analysis. 
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Before performing the genetic analyses, the data were examined from each group 
individually for population substructure to ensure that variation was negligible. Identification of 
local elements associated with selected variables (either categorical-such as ancestry, or 
continuous-such as BMI, blood pressure, etc.) including outcome of treatment regimens was 
performed with logistical or linear modeling tools, respectively, in the software package R. For a 
given gene, all SNPs within 10 kb of the untranslated region were tested. Each SNP was tested 
by grouping the selected variable level based on the genotype, and assuming an additive 
relationship between number of 'B' alleles and the variable of interest, using the two-sided 
Cochran-Armitage trend test.268-271 This combination may have inflated the theoretical number of 
false positives from the model. In order to minimize bias, the regression analysis was repeated 
after randomizing the gene-SNP pairs. After 100 such randomizations the permuted statistics 
were compared to actual statistics in order to estimate the empirical false discovery rate at each 
theoretical p-value threshold. This permutation procedure was specific for identifying local-
acting SNPs since it assumes no distant-acting SNPs, and thus was a conservative estimate in the 
presence of the potential selection bias. 
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APPENDIX 6.2.1A: FINE-MAPPING AND ADMIXTURE PAPERS REVIEWED 
 
A. BMI 
• Gong J, Schumacher F, Lim U, Hindorff LA, Haessler J, Buyske S, et al. Fine mapping and 
identification of BMI loci in African Americans. The American Journal of Human Genetics 
2013;93(4):661-671. 
• Liu C-T, Monda KL, Taylor KC, Lange L, Demerath EW, Palmas W, et al. Genome-wide 
association of body fat distribution in African ancestry populations suggests new loci. PLoS 
Genet 2013;9(8):e1003681. 
• Locke AE, Kahali B, Berndt SI, Justice AE, Pers TH, Day FR, et al. Genetic studies of body 
mass index yield new insights for obesity biology. Nature 2015;518(7538):197-206. 
• Monda KL, Chen GK, Taylor KC, Palmer C, Edwards TL, Lange LA, et al. A meta-analysis 
identifies new loci associated with body mass index in individuals of African ancestry. 
Nature genetics 2013;45(6):690-696. 
• Peters U, North KE, Sethupathy P, Buyske S, Haessler J, Jiao S, et al. A systematic mapping 
approach of 16q12. 2/FTO and BMI in more than 20,000 African Americans narrows in on 
the underlying functional variation: results from the Population Architecture using Genomics 
and Epidemiology (PAGE) study. PLoS Genet 2013;9(1):e1003171. 
 B. DYSLIPIDEMIA 
• Carlson CS, Matise TC, North KE, Haiman CA, Fesinmeyer MD, Buyske S, et al. 
Generalization and dilution of association results from European GWAS in populations of 
non-European ancestry: the PAGE study. PLoS biology 2013;11(9):e1001661. 
• Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stylianou IM, Koseki M, et al. 
Biological, clinical and population relevance of 95 loci for blood lipids. Nature 
2010;466(7307):707-713. 
 C. T2DM 
• Cheng C-Y, Reich D, Haiman CA, Tandon A, Patterson N, Elizabeth S, et al. African 
ancestry and its correlation to type 2 diabetes in African Americans: a genetic admixture 
analysis in three US population cohorts. PloS one 2012;7(3):e32840. 
• Haiman CA, Fesinmeyer MD, Spencer KL, Bůžková P, Voruganti VS, Wan P, et al. 
Consistent Directions of Effect for Established Type 2 Diabetes Risk Variants Across 
Populations The Population Architecture using Genomics and Epidemiology (PAGE) 
Consortium. Diabetes 2012;61(6):1642-1647. 
• Hasstedt SJ, Highland HM, Elbein SC, Hanis CL, Das SK. Five linkage regions each harbor 
multiple type 2 diabetes genes in the African American subset of the GENNID Study. 
Journal of human genetics 2013;58(6):378-383. 
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• Jeff JM, Armstrong LL, Ritchie MD, Denny JC, Kho AN, Basford MA, et al. Admixture 
Mapping and Subsequent Fine-Mapping Suggests a Biologically Relevant and Novel 
Association on Chromosome 11 for Type 2 Diabetes in African Americans. PloS one 
2014;9(3):e86931. 
• Long J, Edwards T, Signorello LB, Cai Q, Zheng W, Shu X-O, et al. Evaluation of genome-
wide association study-identified type 2 diabetes loci in African Americans. American 
journal of epidemiology 2012;176(11):995-1001. 
• McCormack S, Grant SF. Genetics of obesity and type 2 diabetes in African Americans. 
Journal of obesity 2013;2013. 
• Ng MC, Saxena R, Li J, Palmer ND, Dimitrov L, Xu J, et al. Transferability and Fine 
Mapping of Type 2 Diabetes Loci in African Americans The Candidate Gene Association 
Resource Plus Study. Diabetes 2013;62(3):965-976. 
• Palmer ND, McDonough CW, Hicks PJ, Roh BH, Wing MR, An SS, et al. A genome-wide 
association search for type 2 diabetes genes in African Americans. PloS one 
2012;7(1):e29202. 
• Saxena R, Elbers CC, Guo Y, Peter I, Gaunt TR, Mega JL, et al. Large-scale gene-centric 
meta-analysis across 39 studies identifies type 2 diabetes loci. The American Journal of 
Human Genetics 2012;90(3):410-425. 
• Waters KM, Stram DO, Hassanein MT, Le Marchand L, Wilkens LR, Maskarinec G, et al. 
Consistent association of type 2 diabetes risk variants found in europeans in diverse racial 
and ethnic groups. PLoS genetics 2010;6(8):e1001078. 
 D. BLOOD PRESSURE 
• Fox ER, Young JH, Li Y, Dreisbach AW, Keating BJ, Musani SK, et al. Association of 
genetic variation with systolic and diastolic blood pressure among African Americans: the 
Candidate Gene Association Resource study. Human molecular genetics 2011;20(11):2273-
2284. 
• Franceschini N, Fox E, Zhang Z, Edwards TL, Nalls MA, Sung YJ, et al. Genome-wide 
association analysis of blood-pressure traits in African-ancestry individuals reveals common 
associated genes in African and non-African populations. The American Journal of Human 
Genetics 2013;93(3):545-554. 
• Hall JL, Duprez DA, Barac A, Rich SS. A review of genetics, arterial stiffness, and blood 
pressure in African Americans. Journal of cardiovascular translational research 
2012;5(3):302-308. 
• Nguyen K-DH, Pihur V, Ganesh SK, Rakha A, Cooper RS, Hunt SC, et al. Effects of Rare 
and Common Blood Pressure Gene Variants on Essential Hypertension Results From the 
Family Blood Pressure Program, CLUE, and Atherosclerosis Risk in Communities Studies. 
Circulation research 2013;112(2):318-326. 
• Shetty PB, Hua T, Bamidele T, Morrison AC, Hanis CL, Rao DC, et al. Variants in CXADR 
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and F2RL1 are associated with blood pressure and obesity in African-Americans in regions 
identified through admixture mapping. Journal of hypertension 2012;30(10):1970. 
• Studies ICfBPG-WA. Genetic variants in novel pathways influence blood pressure and 
cardiovascular disease risk. Nature 2011;478(7367):103-109. 
• Zhu X, Cooper RS. Admixture mapping provides evidence of association of the VNN1 gene 
with hypertension. PLoS One 2007;2(11):e1244. 
 E. CVD 
• Lettre G, Palmer CD, Young T, Ejebe KG, Allayee H, Benjamin EJ, et al. Genome-wide 
association study of coronary heart disease and its risk factors in 8,090 African Americans: 
the NHLBI CARe Project. PLoS genetics 2011;7(2):1-11. 
• Tekola-Ayele F, Adeyemo AA, Rotimi CN. Genetic epidemiology of type 2 diabetes and 
cardiovascular diseases in Africa. Progress in cardiovascular diseases 2013;56(3):251-260. 
• Zhang L, Buzkova P, Wassel CL, Roman MJ, North KE, Crawford DC, et al. Lack of 
associations of ten candidate coronary heart disease risk genetic variants and subclinical 
atherosclerosis in four US populations: the Population Architecture using Genomics and 
Epidemiology (PAGE) study. Atherosclerosis 2013;228(2):390-399. 
 F. SMOKING 
• David S, Hamidovic A, Chen G, Bergen A, Wessel J, Kasberger J, et al. Genome-wide meta-
analyses of smoking behaviors in African Americans. Translational psychiatry 2012;2(5):1-8. 
• Hamidovic A, Goodloe RJ, Bergen AW, Benowitz NL, Styn MA, Kasberger JL, et al. Gene-
centric analysis of serum cotinine levels in African and European American populations. 
Neuropsychopharmacology 2011;37(4):968-974. 
• Han S, Yang BZ, Kranzler HR, Oslin D, Anton R, Gelernter J. Association of CHRNA4 
polymorphisms with smoking behavior in two populations. American Journal of Medical 
Genetics Part B: Neuropsychiatric Genetics 2011;156(4):421-429. 
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APPENDIX 6.2.1.B: LIST OF POTENTIAL SNPS 
TABLE 7. GWAS SIGNIFICANT SNPS FROM FINE-MAPPING AND ADMIXTURE STUDIES 
SNP Phenotype Gene Chromosome Region p < 5x10
-8 Reference 
rs543874 BMI SEC16B 1q25 2.00x10-13 Monda 201353 
rs7586879 BMI ADCY3 2 3.60x10-08 Monda 201353 
rs348495 BMI GNPDA2 4p12 1.60x10-10 Monda 201353 
rs17817964 BMI FTO 16q12 1.05x10-10 Monda 201353 
rs6567160 BMI MC4R 18q21 2.96x10-11 Monda 201353 
rs7708584 BMI, WC (unadjusted to BMI) GALNT10 5q33 3.37x10
-11 Monda 201353 
rs629301 LDL SORT1 1 2.00x10-14 Teslovich 201056 
rs3764261 HDL CETP 16 3.00x10-18 Teslovich 201056 
rs16942887 HDL LCAT 16 1.00x10-10 Teslovich 201056 
rs6511720 LDL LDLR 19 5.00x10-08 Teslovich 201056 
rs3764261 HDL CETP 16 5.91x10-28 Carlson 201355 
rs6511720 LDL LDLR 19 7.05x10-24 Carlson 201355 
rs646776 LDL CELSR2/PSRC1/SORT1 1p13.3 1.48x10-12 Carlson 201355 
rs3135506 HDL, TG APOA1; APOA1/C3/A4/A5 cluster 11 2.02x10
-10 Carlson 201355 
rs7903146 T2DM TCF7L2 10 3.98x10-10 Carlson 201355 
rs328 HDL LPL 8 2.55x10-08 Carlson 201355 
rs543874 BMI SEC16B 1q25.2 2.40x10-09 Gong 201350 
rs116612809 BMI, BMI adjusted for TG BRE 2p23.2 3.60x10
-08 Gong 201350 
rs10474346 DBP GPR98/ARRDC3 5 3.56x10-08 Fox 201144 
rs2258119 SBP C21orf91 21 4.69x10-08 Fox 201144 
rs437470 SBP CXADR 21q21 4.00x10-04* Shetty 201269 
rs437470 DBP CXADR 21q21 6.00x10-04* Shetty 201269 
rs2036527 Smoking (cigarettes smoked per day) CHRNA5 15q25.1 1.84x10
-08 David 201242 
* A GWAS significant p in this study is 9.8x10-4 
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TABLE 8. CANDIDATE SNPS FROM FINE-MAPPING AND ADMIXTURE STUDIES 
SNP Phenotype Gene Chromosome Region p < 1x10
-6 Reference 
rs10261878 BMI, WC (unadjusted to BMI) 
MIR148A-
NFE2L3 7p15 4.57X10
-07 Monda 201353 
rs974417 BMI, WC (unadjusted to BMI) KLHL32 6q16 6.88X10
-08 Monda 201353 
rs10938397 BMI GNPDA2 4 1.81X10-08 Monda 201353 
rs7138803 BMI FAIM2 12 4.37X10-06 Monda 201353 
rs1558902 BMI FTO 16 2.69X10-07 Monda 201353 
rs1320330 BMI TMEM18 2 2.05X10-06 Monda 201353 
rs10501087 BMI BDNF 11 2.51X10-07 Monda 201353 
rs1558902 BMI FTO 16 2.69X10-07 Monda 201353 
rs2075064 WC adjusted for BMI LHX2 9 6.50X10-08 Liu 201351 
rs6931262 WHR adjusted for BMI RREB1 6 5.70X10-08 Liu 2013
51 
rs6867983 WC (unadjusted for BMI) MAP3K1 5 2.70X10-07 Liu 2013
51 
rs7601155 WC (unadjusted for BMI) BRE 2 4.90X10-07 Liu 2013
51 
rs10894604 WHR adjusted for BMI OPCML 11 7.70X10-07 Liu 2013
51 
rs17213965 WHR adjusted for BMI MYH11 16 1.30X10-06 Liu 2013
51 
rs2570467 WC (unadjusted for BMI) PCSK1 5 2.10X10-06 Liu 2013
51 
rs11777345 WHR adjusted for BMI CSMD1 8 4.80X10-06 Liu 2013
51 
rs4730779 WC adjusted for BMI ASZ1 7 6.30X10-06 Liu 2013
51 
rs6739392 WHR adjusted for BMI ETAA1 2 6.20X10-06 Liu 2013
51 
rs1345301 WC (unadjusted for BMI) IL1RL2; IL1RL1 2 7.90X10-06 Liu 2013
51 
rs1294410 WHR adjusted for BMI LY86 6 1.80X10-06 Liu 2013
51 
rs737337 HDL LOC55908 19 6.00X10-06 Teslovich 201056 
rs56137030 BMI FTO 16q12.2 8.30X10-06 Peters 201354 
rs6548240 BMI TMEM18 2p25.3 1.10X10-07 Gong 2013
50 
rs6548238 BMI TMEM18 2p25.3 3.80X10-07 Gong 2013
50 
rs2867125 BMI TMEM18 2p25.3 5.60X10-06 Gong 2013
50 
rs10938397 BMI GNPDA2 4p12 1.70X10-07 Gong 2013
50 
rs2744475 BMI TFAP2B 6p12.3 2.80X10-06 Gong 2013
50 
rs1519480 BMI BDNF 11p14.1 7.80X10-07 Gong 2013
50 
rs62048402 BMI FTO 16q12.2 5.10X10-06 Gong 2013
50 
rs1421085 BMI FTO 16q12.2 6.50X10-06 Gong 2013
50 
rs6567160 BMI MC4R 18q21.32 4.70X10-06 Gong 2013
50 
rs114584581 BMI, BMI adjusted for TG BRE 2p23.2 5.90X10-08 Gong 2013
50 
rs74941130 BMI, BMI adjusted for TG BRE 2p23.2 6.90X10-08 Gong 2013
50 
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rs79329695 BMI, BMI adjusted for TG BRE 2p23.2 3.70X10-08 Gong 2013
50 
rs4802349 BMI, HDL adjusted for BMI, BMI adjusted for HDL DHX34 19q13.32 1.20X10
-07 Gong 201350 
rs17428471 SBP EVX1-HOXA 7 1.40X10-04 Franceschini 201366 
rs1401454 SBP SOX6 11 9.70X10-04 Franceschini 201366 
rs1401454 DBP SOX6 11 5.00X10-03 Franceschini 201366 
rs1990151  SBP IPO13 1 7.39X10-07 Fox 2011
44 
rs13413144 SBP FMNL2 2 5.55X10-07 Fox 2011
44 
rs592582 SBP GPD2 2 4.46X10-07 Fox 2011
44 
rs1858309  DBP GPR98 5 8.76X10-08 Fox 2011
44 
rs7709572  DBP GPR98 5 7.41X10-08 Fox 2011
44 
rs7724489  DBP GPR98 5 1.17X10-07 Fox 2011
44 
rs243601 SBP C21orf91 21 2.61X10-07 Fox 2011
44 
rs243603 SBP C21orf91 21 3.91X10-07 Fox 2011
44 
rs243605 SBP C21orf91 21 3.83X10-07 Fox 2011
44 
rs243607 SBP C21orf91 21 1.99X10-07 Fox 2011
44 
rs243609 SBP C21orf91 21 4.41X10-07 Fox 2011
44 
rs2220511 SBP C21orf91 21 4.68X10-07 Fox 2011
44 
rs12408339 SBP RHBG 1 8.64X10-06 Fox 2011
44 
rs214070 SBP NUCB2 11 8.65X10-06 Fox 2011
44 
rs6511018 SBP SLC25A42 19 5.83X10-06 Fox 2011
44 
rs12985799 SBP SLC25A42 19 3.24X10-06 Fox 2011
44 
rs2012318 SBP SLC25A42 19 6.42X10-06 Fox 2011
44 
rs11666627 SBP SLC25A42 19 3.00X10-06 Fox 2011
44 
rs10417974 SBP SLC25A42 19 3.71X10-06 Fox 2011
44 
rs11187065 Smoking (serum cotinine) IDE 10 8.91X10-06 Hamidovic 201274 
rs667282 Smoking (cigarettes smoked per day) CHRNA5 15 1.81X10
-07 David 201242 
rs3101457 Smoking (cigarettes smoked per day) C1orf100 1q44 2.63X10
-07 David 201242 
rs938682 Smoking (cigarettes smoked per day) CHRNA3 15 3.75X10
-07 David 201242 
rs547843 Smoking (cigarettes smoked per day) LOC503519 15q12 6.16X10
-07 David 201242 
rs3813570 Smoking (cigarettes smoked per day) PSMA4 15 9.85X10
-07 David 201242 
rs1678618 Smoking (age of smoking initiation) SPOCK2 10q22.1 8.25X10
-07 David 201242 
rs1245577 Smoking (age of smoking initiation) SPOCK2 10q22.1 8.30X10
-07 David 201242 
rs1612028 Smoking (age of smoking initiation) SPOCK2 10q22.1 9.28X10
-07 David 201242 
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APPENDIX 6.3: OUTCOME MEASURES 
A. BASELINE SURVEYS 
  
Return of Results
Baseline Information
ENR1 v. 1.0
1 / 9
Developed by the Data Capture Services Unit in the UNC-CH Center for Health Promotion & Disease Prevention
www.hpdp.unc.edu/services/datacapture
/ / 2 0 1
month day year
Date enrolled:
Form completed by: participant only
interviewer only
both
Interviewer ID:
Section B:  About You
Section A:
Î
Now I’m going to give you a survey that looks at people’s level of comfort with medical jargon. This survey
is to help us figure out the best type of materials to develop.  The survey only takes 1-2 minutes to do.
RAPID ESTIMATE OF ADULT LITERACY IN GENETICS  (REAL-G)*
*Erby, L.H. et al. (2008). The rapid estimate of adult literacy in genetics (REAL-G): a means to assess literacy deficits in the context of genetics. American Journal American Journal of
Medical Genetics; 146A(2): 174-181.
correct mispronounced
word
word not
attempted
1.  Genetic
2.  Sporadic
3.  Mutation
4.  Variation
5.  Chromosome
6.  Hereditary
7.  Abnormality
8.  Susceptibility
9832385895
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2 / 9
Developed by the Data Capture Services Unit in the UNC-CH Center for Health Promotion & Disease Prevention
www.hpdp.unc.edu/services/datacapture
Section C:   Health
I’m going to start by asking you some questions about your health right now and your current daily
activities. Please try to answer every question as accurately as you can.
1.  In general, would you say your health is:
excellent very good good fair poor
The following two questions are about activities you might do during a typical day.  Does
your health now limit you in these activities?  If so, how much?
2.  moderate activities, such as moving a table, pushing a vacuum cleaner, bowling or
  playing golf:
yes, limited a lot yes, limited a little no, not limited at all
3.  climbing several flights of stairs:
yes, limited a lot yes, limited a little no, not limited at all
During the past 4 weeks, have you had any of the following problems with your work or
other regular activities as a result of your physical health?
4.  accomplished less than you would like:
yes no
5.  were limited in the kind of work or other activities:
yes no
During the past 4 weeks, were you limited in the kind of work you do or other regular
activities as a result of any emotional problems (such as feeling depressed or anxious)?
6.  accomplished less than you would like:
yes no
8804385893
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Developed by the Data Capture Services Unit in the UNC-CH Center for Health Promotion & Disease Prevention
www.hpdp.unc.edu/services/datacapture
7.  didn't do work or other activities as carefully as usual:
yes no
8.  During the past 4 weeks, how much did pain interfere with your normal work (including
  both work outside the home and housework)?
not at all a little bit moderately quite a bit extremely
The next few questions are about how you feel and how things have been during the past
4 weeks. For each question please give the one answer that comes closest to the way you
have been feeling.
all of
the time
most of
the time
a good
bit of
the time
some of
the time
a little of
the time
none of
the time
9.   have you felt calm
  and peaceful?
10.  did you have a lot of energy?
11.  have you felt downhearted
  and blue?
12.  During the past 4 weeks, how
  much of the time has your
  physical health or
  emotional problems
  interfered with your social
  activities (like visiting with
  friends, relatives, etc.)
 How much of the time during the
past 4 weeks . . .
13.  been a very nervous person?
How much of the time during
the last month have you . . .
14.  felt so down in the dumps that
 nothing could cheer you up?
15.  been a happy person?
all of
the time
most of
the time
a good
bit of
the time
some of
the time
a little of
the time
none of
the time
9377385899
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Developed by the Data Capture Services Unit in the UNC-CH Center for Health Promotion & Disease Prevention
www.hpdp.unc.edu/services/datacapture
Section D:   Genetic Testing
Now I’d like to talk about genetics. Genetics is a term that describes the study of a single gene in
isolation. Think of genetics like a plant. If the plant is not flowering, you could study the plant
(genetics) to see if there’s a problem (genetic testing). I’m going to ask you a few questions about
your experience with genetic testing now.
1. Have you ever had a genetic test? (It’s usually a blood test)  [Mark only one.]
no
yes--just one time
yes--more than one time
not sure
Î
1a.  If yes, what kind of genetic test was performed?
2.  Have you ever had genetic counseling from someone who talked to you about possible genetic causes of
     health problems, such as how genes are inherited in families?  [Mark only one.]
no
yes--just one time
yes--more than one time
not sure
Î
2a.  If yes, what was the health concern that led you to
      genetic counseling?
3. Has anyone else in your family had genetic testing or counseling?  [Mark only one.]
no
yes
not sure
8624385893
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Developed by the Data Capture Services Unit in the UNC-CH Center for Health Promotion & Disease Prevention
www.hpdp.unc.edu/services/datacapture
Section E:   Health Behaviors
In this part, I’m going to ask you about a few health-related behaviors like diet. Thinking about your eating
habits over the past month, about how often do you eat each of the following foods? Remember breakfast,
lunch, dinner, snacks and eating out
2-3 times
a WEEK
4-6 times
a WEEK
once a
DAY
less than
1/WEEK
once a
WEEK
2+ a DAY
1.  Fruit juice, like orange, apple,
grape, fresh, frozen or canned
(not sodas or other drinks)
2.  How often do you eat any
fruit, fresh or canned
(not counting juice)?
3.  Vegetable juice like tomato
juice, V-8, or carrot
4.  Green salad
5.  Potatoes, any kind, including
baked, mashed or french fried
6.  Vegetable soup, or stew with
vegetables
7.  Any other vegetables, including
string beans, peas, corn,
broccoli or any other kind
8.  Fiber cereals like Raisin Bran,
Shredded Wheat or
Fruit-n-Fiber
9.  Beans such as baked beans,
pinto, kidney, or lentils
(not green beans)
10.  Dark bread such as whole
 wheat or rye
2480385897
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Developed by the Data Capture Services Unit in the UNC-CH Center for Health Promotion & Disease Prevention
www.hpdp.unc.edu/services/datacapture
Now I’d like to ask you about two types of walking: walking for transportation (e.g., to the store or
work), then walking for recreation, health and fitness. If the walking that you do for transportation is
also for recreation, health or fitness, please tell me about it only once.
1.  In a usual week, do you walk to get to or from somewhere (such as walking to a
store or bus stop) or for recreation, health or fitness (including walking your dog)?
yes no
Walking for Transportation
2.  In a usual week, how many times do you walk as a
means of transportation, such as going to and from
work, walking to the store, or walking to a bus stop?
Î if 0, skip to Q. 5
3.  Please estimate the total time you spend walking as a
means of transportation in a usual week.  (e.g., 5
times by 10 minutes = 50 minutes) minutes
times
hours
4.  Let me know which of the following places you walk to as a means
of transportation in a usual week. [Mark all that apply.]
to or from work (or study)
to or from bus stop
to or from store
to or from restaurant
to or from friend's house
other place #1
other place #2
Î
Î
For example:
Linda lives 20 minutes away from work. She chooses to walk there rather than drive mainly because
she wants to improve her fitness. If Linda says that she walks for transportation (3 times per week for
a total of 120 minutes), she would not repeat that information under walking for recreation, health or
fitness.
Section F:   Neighborhood Physical Activity Questionnaire
Walking
8567385899
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Developed by the Data Capture Services Unit in the UNC-CH Center for Health Promotion & Disease Prevention
www.hpdp.unc.edu/services/datacapture
7.  Could you tell me where you walk for recreation, health or fitness in a usual week?
 [Mark all that apply.]
park
neighborhood
school
to or from restaurant
to or from a store
fitness center
other place #1
other place #2
Î
Î
Other Leisure Time Physical Activities
The next set of questions is about other leisure time physical activities that you do in a
usual week, besides what you have already mentioned.  Do not include walking.
8.  In a usual week, do you do any other vigorous or moderate intensity leisure time
physical activities?  Do not include any walking.
yes no Î Skip Section G
Walking for Recreation, Health or Fitness:
5.  In a usual week, how many times do you walk for
recreation, health or fitness (including walking
your dog)?
Î
if 0, skip to  Other
Leisure Time
Physical Activities
6.  Please estimate the total time you spend walking for
recreation, health or fitness in a usual week.
(e.g., 5 times by 10 minutes = 50 minutes) hours minutes
If you have already reported recreational walking, please do not report it again for the
following questions.
times
0849385894
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www.hpdp.unc.edu/services/datacapture
11.  In a usual week, how many times do you do vigorous
  intensity leisure time physical activities which cause a
  large increase in breathing and heart rate?
Î if 0, skip to Q. 13
12.  What do you estimate is the total time you spend
  doing vigorous intensity leisure time physical
  activities in a usual week.
  (e.g., 3 times by 20 minutes = 60 minutes)
minuteshours
times
13.  Apart from what you have already mentioned, in a usual week do you do any other
  moderate intensity leisure time physical activities like dancing, cycling, social tennis, golf,
  or gardening?  Moderate intensity physical activities cause a moderate increase in
  breathing and heart rate.
yes no Î
14.  In a usual week, how many times do you do moderate
  intensity leisure time physical activities which cause a 
  moderate increase in breathing and heart rate?
if no, skip to Section G
times
15.  What do you estimate is the total time you spend
  doing moderate intensity leisure time physical 
  activities in a usual week?
  (e.g., 1 time for 1 hour = 1 hour)
hours minutes
9.  Could you tell me where you do these leisure time physical activities in a usual week?
 [Mark all that apply.]
park
neighborhood
school
fitness center
other place #1
other place #2
Î
Î
10.  In a usual week, do you do any vigorous intensity leisure time physical activities 
  like jogging, aerobics, swimming laps, or competitive tennis?  Do not include
  walking or moderate intensity physical activities.  Vigorous intensity physical
  activities cause a large increase in breathing and heart rate.
yes no Î if no, skip Q. 13
4854385894
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Developed by the Data Capture Services Unit in the UNC-CH Center for Health Promotion & Disease Prevention
www.hpdp.unc.edu/services/datacapture
Section G:  Dealing with Numbers
Now I’d like to know how comfortable you are dealing with numbers. Some people are more
comfortable than others. For each of the following questions, please choose the answer that best
reflects how good you are at doing the following things:
1.  How good are you at working with fractions?
not at all
good
extremely
good
2.  How good are you at working with percentages?
not at all
good
extremely
good
3.  How good are you at calculating a 15% tip?
not at all
good
extremely
good
5. How often do you find numerical information to be useful?
not at all
good
extremely
good
4.  How good are you at figuring out how much a shirt will cost if it is 25% off?
never very often
7704385891
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/ / 2 0 1
month day year
Date:
Developed by the Data Capture Services Unit in the UNC-CH Center for Health Promotion & Disease Prevention
www.hpdp.unc.edu/services/datacapture
Section A
Now I’ll read a list of things some people do after learning new information. Thinking about how
you feel right now, how motivated are you to…
a lot less
motivated
a little less
motivated
no change in
motivation
a little more
motivated
a lot more
motivated
1. Eat more fruits and vegetables
2. Eat more fish and lean meat rather
     than meats that are high in fat
3. Eat more fiber in your diet
4. Eat fast food less often
5. Reduce sugar in your diet
6. Eat a special diet that might help
     manage your health
7. Get more exercise or be more
     physically active
8. Spend less time sitting or being
     sedentary (like when you’re watching
     TV or using a computer)
9. Move closer to family who can help
     take care of you as you get older
10.Reduce stress in your everyday life
11.Try new methods for relaxing, such as
     meditation, progressive relaxation, or
12.  Get more sleep
13.  Drink less alcohol or stop drinking it
14.  If you smoke, quit smoking
15.  Is there anything else you feel
      motivated to do or to stop doing?
yes
no
Î
4019143967
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Section B
Now I’d like to talk to you about heart disease. People think different things about heart disease. We
would like to know what you think.
not at all
serious
slightly
serious
somewhat
serious
moderately
serious
very
serious
1. How serious a threat to health is
     heart disease?
not at all
strong
slightly
strong
somewhat
strong
moderately
strong
very
strong
2. My chances of developing heart
     disease in the future are:
3.  What is the percent chance that you will develop heart disease in the next 10 years?
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
strongly
disagree
disagree neither agree
or disagree
agree
4. My financial security would be
     endangered if I got heart disease.
strongly
agree
5.  I believe that heart disease would
     be a very serious illness for me to
     develop.
6. If I had heart disease, my whole life
     would change.
7. If I got heart disease, it would be
     more serious than other diseases.
8. Heart disease would endanger my
     marriage (or a significant relationship).
9. If I had heart disease my career would
     be endangered.
10.  Heart disease is a hopeless disease.
11.  My feelings about myself would
      change if I got heart disease.
12.  Problems I would experience from
      heart disease would last a long time.
13  I am unlikely to develop heart disease
     in the future.
2838143964
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Section C
In Heart Healthy Lenoir, we talked about a healthy eating plan. Healthy eating means eating more:
- Healthy fats. Healthy fats are fats such as those found in vegetable oils, nuts, and fish.
- Fruits and vegetables.
- Whole grains such as whole wheat bread and brown rice.
strongly
disagree
disagree neither agree
or disagree
agree
1. Healthy eating is effective in
    preventing heart disease.
strongly
agree
2. The benefits of following the healthy
     eating plan outweigh the costs.
3. I have the time to follow the healthy
    eating plan to prevent heart disease.
4. I would be discouraged from
     following at least one of the steps of
     the healthy eating plan during the
     next week because I would feel silly
     doing so.
5.  If I follow the healthy eating plan, I
     am less likely to get heart disease.
6.  Following at least one of the steps of
     the healthy eating plan during the
     next week would cause me too many
     problems.
7. I am able to follow the healthy eating
     plan to prevent getting heart disease.
8. Healthy eating works in preventing
     heart disease.
9. I would be discouraged from
     following at least one of the steps of
     the healthy eating plan during the
     next week as it would take too much
     time.
And eating less:
- Unhealthy fats. Unhealthy fats are trans fats that are found in some baked goods, packaged snack
foods, band fried foods at restaurants.
- Processed meats like bacon, hot dogs, and cold cuts.
- Foods with added sugar and salt-like, sugar-sweetened beverages and some prepared foods.
Thinking about that healthy eating plan, please answer the following questions.
10. I can easily follow the healthy eating
     plan to prevent heart disease.
7190143960
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strongly
disagree
disagree neither agree
or disagree
agree strongly
agree
Section D
In Heart Healthy Lenoir, we talked about walking as aerobic physical activity. The program
recommended walking briskly for 150 minutes a week. This would be about 30 minutes of walking
on five days of the week. This can be divided into ten-minute segments of walking.
Thinking about that recommendation, please answer the following questions.
1. I would be discouraged from taking at
    least one 30-minute walk during the
    next week as it would take too much
    time.
2.  I would be discouraged from taking
    at least one 30-minute walk a week
    because I would feel silly doing so.
3.  Walking for 30 minutes a day is
     effective in preventing heart disease.
4.  Walking for 30 minutes a day works
     in preventing heart disease.
5. If I walk for 30 minutes a day, I am
     less likely to get heart disease.
6.  I am able to walk 30 minutes a day
    to prevent getting heart disease.
7.  I have the time to walk for 30
    minutes a day to prevent heart disease.
8.  I can easily walk for 30 minutes a day
      to prevent heart disease.
9. The benefits of taking at least one
     30-minute walk a week outweigh the
     costs.
10.  Taking at least one 30-minute walk
      during the next week would cause me
      too many problems.
2313143962
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Section E
These questions are again about your thoughts about heart disease.
The thought of developing heart disease makes me feel:
not at all slightly somewhat mosderately very
1. Frightened
2.  Anxious
3.  Worried
4.  Scared
Section F strongly
disagree
disagree neither agree
or disagree
agree strongly
agree
1. If someone is meant to get a serious
    disease, it doesn’t matter what kinds
    of food they eat, they will get that
    disease anyway.
2. I will get diseases if I am unlucky.
3.  If someone is meant to get a serious
    disease, they will get it no matter
    what they do.
4. Everything that can go wrong for me
   does.
5. If someone gets a serious disease,
     that’s the way they were meant to
     die.
6. My health is a matter of luck.
7. If someone is meant to have a
     serious disease, they will get that
     disease.
8. I will have a lot of pain from illness.
9. If someone has a serious disease and
     gets treatment for it, they will
     probably still die from it.
10. How long I live is a matter of luck.
4024143963
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strongly
disagree
disagree neither agree
or disagree
agree strongly
agree
11.  If someone was meant to have a
      serious disease, it doesn’t matter
      what doctors and nurses tell them
      to do, they will get the disease
      anyway.
12.  I will suffer a lot from bad health.
13.  How long I live is predetermined.
14.  I will stay healthy if I am lucky.
15.  I will die when I am fated to die.
16.  I often feel helpless in dealing with
      the problems of life.
17.  My health is determined by fate.
18.  Sometimes I feel that I’m being
       pushed around in life.
19.  My health is determined by
       something greater than myself.
20.  There is really no way I can solve
       some of the problems I have.
5171143967
 171 
Return of Results
STOFHLA
1 / 4
STOF1 v. 1.0
: a.m. p.m.Start time:
/ / 2 0 1
month day year
Date:
Interviewer:
: a.m. p.m.Stop time:
Instructions
Here are some other medical instructions that you or anybody might see around the hospital.
These instructions are in sentences that have some of the words missing.  Where a word is
missing, a blank line is drawn, and 4 possible words that could go in the blank appear just
below it.  I want you to figure out which of those 4 words should go in the blank, which word
makes the sentence make sense.  When you think you know which one it is, fill in the bubble
next to that word and then go on to the next one.  When you finish the page, turn the page
and keep going until you finish all the pages.
Stop at the end of 7 minutes
Developed by the Data Capture Services Unit in the UNC-CH Center for Health Promotion & Disease Prevention
www.hpdp.unc.edu/services/datacapture
yes noUNC to review?QC done by:
6264475756
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Passage A:  X-ray Preparation
Your doctor has sent you to have a __________ X-ray.  You must have an __________ stomach
stomach
diabetes
stitches
germs
 when you come for __________ .  The X-ray will __________ from 1 to 3  __________ to do.
asthma
empty
incest
anemia
is
am
if
it
take
view
talk
look
beds
brains
hours
diets
The Day Before the X-ray
For supper have only a  __________ snack of fruit, __________ and jelly, with coffee or tea.
little
broth
attack
nausea
toes
throat
toast
thigh
After __________ , you must not __________ or drink anything at __________ until after
minute
midnight
during
before
easy
ate
drank
eat
you have __________ the X-ray.
ill
all
each
any
are
has
had
was
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The Day of the X-ray
Do not eat __________ .  Do not __________ , even __________ .
appointment
walk-in
breakfast
clinic
drive
drink
dress
dose
heart
breath
water
cancer
If you have any  __________ ,call the X-ray __________ at 616-4500.
answers
exercises
tracts
questions
Department
Sprain
Pharmacy
Toothache
Passage B: Medicaid Rights & Responsibilities
I agree to give correct information to  __________ if I can receive Medicaid.  I __________ to provide
hair
salt
see
ache
the county information to  __________ any statements given in this __________ and hereby
hide
risk
discharge
prove
emphysema
application
gallbladder
relationship
agree
probe
send
gain
give permission to the  __________ to get such proof.  I  __________ that for Medicaid I must report
inflammation
religion
iron
county
investigate
entertain
understand
establish
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any ________ in my circumstances within ________ (10) days of becoming ________ of the change.
changes
hormones
antacids
charges
three
one
five
ten
award
aware
away
await
I understand  __________ if I do not like the  __________ made on my case,
thus
this
that
than
marital
occupation
adult
decision
I have the  __________ to a fair hearing.  I can   __________ a hearing by writing or __________
bright
left
wrong
right
request
refuse
fail
mend
counting
reading
calling
smelling
the county where I applied.  If you  __________ TANF for any family  __________ ,  you will have to
wash
want
cover
tape
member
history
weight
seatbelt
  __________ a different application form.   __________ ,we will use the __________
relax
break
inhale
sign
Since
Whether
However
Because
lung
date
meal
pelvic
on this form to determine your   __________ .
hypoglycemia
eligibility
osteoporosis
schizophrenia
6382475757
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Section A
Now I’ll read a list of things some people do after learning new information. Thinking about how
you feel right now, how motivated are you to…
a lot less
motivated
a little less
motivated
no change in
motivation
a little more
motivated
a lot more
motivated
1. Eat more fruits and vegetables
2. Eat more fish and lean meat rather
     than meats that are high in fat
3. Eat more fiber in your diet
4. Eat fast food less often
5. Reduce sugar in your diet
6. Eat a special diet that might help
     manage your health
7. Get more exercise or be more
     physically active
8. Spend less time sitting or being
     sedentary (like when you’re watching
     TV or using a computer)
9. Move closer to family who can help
     take care of you as you get older
10.Reduce stress in your everyday life
11.Try new methods for relaxing, such as
     meditation, progressive relaxation, or
12.  Get more sleep
13.  Drink less alcohol or stop drinking it
14.  If you smoke, quit smoking
15.  Is there anything else you feel
      motivated to do or to stop doing?
yes
no
Î
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Section B
Now I’d like to talk to you about heart disease. People think different things about heart disease. We
would like to know what you think.
not at all
serious
slightly
serious
somewhat
serious
moderately
serious
very
serious
1. How serious a threat to health is
     heart disease?
not at all
strong
slightly
strong
somewhat
strong
moderately
strong
very
strong
2. My chances of developing heart
     disease in the future are:
3.  What is the percent chance that you will develop heart disease in the next 10 years?
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
strongly
disagree
disagree neither agree
or disagree
agree
4. My financial security would be
     endangered if I got heart disease.
strongly
agree
5.  I believe that heart disease would
     be a very serious illness for me to
     develop.
6. If I had heart disease, my whole life
     would change.
7. If I got heart disease, it would be
     more serious than other diseases.
8. Heart disease would endanger my
     marriage (or a significant relationship).
9. If I had heart disease my career would
     be endangered.
10.  Heart disease is a hopeless disease.
11.  My feelings about myself would
      change if I got heart disease.
12.  Problems I would experience from
      heart disease would last a long time.
13  I am unlikely to develop heart disease
     in the future.
9731258870
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Section C
In Heart Healthy Lenoir, we talked about a healthy eating plan. Healthy eating means eating more:
- Healthy fats. Healthy fats are fats such as those found in vegetable oils, nuts, and fish.
- Fruits and vegetables.
- Whole grains such as whole wheat bread and brown rice.
strongly
disagree
disagree neither agree
or disagree
agree
1. Healthy eating is effective in
    preventing heart disease.
strongly
agree
2. The benefits of following the healthy
     eating plan outweigh the costs.
3. I have the time to follow the healthy
    eating plan to prevent heart disease.
4. I would be discouraged from
     following at least one of the steps of
     the healthy eating plan during the
     next week because I would feel silly
     doing so.
5.  If I follow the healthy eating plan, I
     am less likely to get heart disease.
6.  Following at least one of the steps of
     the healthy eating plan during the
     next week would cause me too many
     problems.
7. I am able to follow the healthy eating
     plan to prevent getting heart disease.
8. Healthy eating works in preventing
     heart disease.
9. I would be discouraged from
     following at least one of the steps of
     the healthy eating plan during the
     next week as it would take too much
     time.
And eating less:
- Unhealthy fats. Unhealthy fats are trans fats that are found in some baked goods, packaged snack
foods, band fried foods at restaurants.
- Processed meats like bacon, hot dogs, and cold cuts.
- Foods with added sugar and salt-like, sugar-sweetened beverages and some prepared foods.
Thinking about that healthy eating plan, please answer the following questions.
10. I can easily follow the healthy eating
     plan to prevent heart disease.
6374258870
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strongly
disagree
disagree neither agree
or disagree
agree strongly
agree
Section D
In Heart Healthy Lenoir, we talked about walking as aerobic physical activity. The program
recommended walking briskly for 150 minutes a week. This would be about 30 minutes of walking
on five days of the week. This can be divided into ten-minute segments of walking.
Thinking about that recommendation, please answer the following questions.
1. I would be discouraged from taking at
    least one 30-minute walk during the
    next week as it would take too much
    time.
2.  I would be discouraged from taking
    at least one 30-minute walk a week
    because I would feel silly doing so.
3.  Walking for 30 minutes a day is
     effective in preventing heart disease.
4.  Walking for 30 minutes a day works
     in preventing heart disease.
5. If I walk for 30 minutes a day, I am
     less likely to get heart disease.
6.  I am able to walk 30 minutes a day
    to prevent getting heart disease.
7.  I have the time to walk for 30
    minutes a day to prevent heart disease.
8.  I can easily walk for 30 minutes a day
      to prevent heart disease.
9. The benefits of taking at least one
     30-minute walk a week outweigh the
     costs.
10.  Taking at least one 30-minute walk
      during the next week would cause me
      too many problems.
7434258878
 179 
Return of Results
PMT2 Survey
5 / 7
PMT2  v. 1.0
Section E
These questions are again about your thoughts about heart disease.
The thought of developing heart disease makes me feel:
not at all slightly somewhat mosderately very
1. Frightened
2.  Anxious
3.  Worried
4.  Scared
Section F strongly
disagree
disagree neither agree
or disagree
agree strongly
agree
1. If someone is meant to get a serious
    disease, it doesn’t matter what kinds
    of food they eat, they will get that
    disease anyway.
2. I will get diseases if I am unlucky.
3.  If someone is meant to get a serious
    disease, they will get it no matter
    what they do.
4. Everything that can go wrong for me
   does.
5. If someone gets a serious disease,
     that’s the way they were meant to
     die.
6. My health is a matter of luck.
7. If someone is meant to have a
     serious disease, they will get that
     disease.
8. I will have a lot of pain from illness.
9. If someone has a serious disease and
     gets treatment for it, they will
     probably still die from it.
10. How long I live is a matter of luck.
2577258871
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strongly
disagree
disagree neither agree
or disagree
agree strongly
agree
11.  If someone was meant to have a
      serious disease, it doesn’t matter
      what doctors and nurses tell them
      to do, they will get the disease
      anyway.
12.  I will suffer a lot from bad health.
13.  How long I live is predetermined.
14.  I will stay healthy if I am lucky.
15.  I will die when I am fated to die.
16.  I often feel helpless in dealing with
      the problems of life.
17.  My health is determined by fate.
18.  Sometimes I feel that I’m being
       pushed around in life.
19.  My health is determined by
       something greater than myself.
20.  There is really no way I can solve
       some of the problems I have.
1790258877
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Section G
strongly
disagree
disagree neither agree
or disagree
agree strongly
agree
1. This information helped you accept
    the way things work out in life.
People are affected in different ways by health information. We would like to know how the
information you have learned has affected you.
2. This information helped you learn to
    deal better with uncertainty.
3. This information taught you how to
    adjust to things you cannot change.
4. This information helped you take
    things as they come.
5. This information helped you look at
    things in a more positive way.
0841258873
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month day year
Date enrolled:
Form completed by: participant only
interviewer only
both
Interviewer ID:
Section 1:
Î
Developed by the Data Capture Services Unit in the UNC-CH Center for Health Promotion & Disease Prevention
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Section 2:   Health
I’m going to start by asking you some questions about your health right now and your current daily
activities. Please try to answer every question as accurately as you can.
1.  In general, would you say your health is:
excellent very good good fair poor
The following two questions are about activities you might do during a typical day.  Does
your health now limit you in these activities?  If so, how much?
2.  moderate activities, such as moving a table, pushing a vacuum cleaner, bowling or
  playing golf:
yes, limited a lot yes, limited a little no, not limited at all
3.  climbing several flights of stairs:
yes, limited a lot yes, limited a little no, not limited at all
During the past 4 weeks, have you had any of the following problems with your work or
other regular activities as a result of your physical health?
4.  accomplished less than you would like:
yes no
5.  were limited in the kind of work or other activities:
yes no
8970061573
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During the past 4 weeks, were you limited in the kind of work you do or other regular
activities as a result of any emotional problems (such as feeling depressed or anxious)?
6.  accomplished less than you would like:
yes no
7.  didn't do work or other activities as carefully as usual:
yes no
8.  During the past 4 weeks, how much did pain interfere with your normal work (including
  both work outside the home and housework)?
not at all a little bit moderately quite a bit extremely
The next few questions are about how you feel and how things have been during the past
4 weeks. For each question please give the one answer that comes closest to the way you
have been feeling.
all of
the time
most of
the time
a good
bit of
the time
some of
the time
a little of
the time
none of
the time
9.   have you felt calm
  and peaceful?
10.  did you have a lot of energy?
11.  have you felt downhearted
  and blue?
12.  During the past 4 weeks, how
  much of the time has your
  physical health or
  emotional problems
  interfered with your social
  activities (like visiting with
  friends, relatives, etc.)
 How much of the time during the
past 4 weeks . . .
7606061578
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13.  been a very nervous person?
How much of the time during
the last month have you . . .
14.  felt so down in the dumps that
 nothing could cheer you up?
15.  been a happy person?
all of
the time
most of
the time
a good
bit of
the time
some of
the time
a little of
the time
none of
the time
Section 3:   Health Behaviors In this part, I’m going to ask you about a few health-related behaviors like diet.
Thinking about your eating habits over the past month, about how often do
you eat each of the following foods? Remember breakfast, lunch, dinner, snacks
and eating out
2-3 times
a WEEK
4-6 times
a WEEK
once a
DAY
less than
1/WEEK
once a
WEEK
2+ a DAY
1.  Fruit juice, like orange, apple,
grape, fresh, frozen or canned
(not sodas or other drinks)
2.  How often do you eat any
fruit, fresh or canned
(not counting juice)?
3.  Vegetable juice like tomato
juice, V-8, or carrot
4.  Green salad
5.  Potatoes, any kind, including
baked, mashed or french fried
6.  Vegetable soup, or stew with
vegetables
7.  Any other vegetables, including
string beans, peas, corn,
broccoli or any other kind
8.  Fiber cereals like Raisin Bran,
Shredded Wheat or
Fruit-n-Fiber
9.  Beans such as baked beans,
pinto, kidney, or lentils
(not green beans)
10.  Dark bread such as whole
 wheat or rye
4700061570
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Now I’d like to ask you about two types of walking: walking for transportation (e.g., to the store or
work), then walking for recreation, health and fitness. If the walking that you do for transportation is
also for recreation, health or fitness, please tell me about it only once.
1.  In a usual week, do you walk to get to or from somewhere (such as walking to a
store or bus stop) or for recreation, health or fitness (including walking your dog)?
yes no
Walking for Transportation
2.  In a usual week, how many times do you walk as a
means of transportation, such as going to and from
work, walking to the store, or walking to a bus stop?
Î if 0, skip to Q. 5
3.  Please estimate the total time you spend walking as a
means of transportation in a usual week.  (e.g., 5
times by 10 minutes = 50 minutes) minutes
times
hours
4.  Let me know which of the following places you walk to as a means
of transportation in a usual week. [Mark all that apply.]
to or from work (or study)
to or from bus stop
to or from store
to or from restaurant
to or from friend's house
other place #1
other place #2
Î
Î
For example:
Linda lives 20 minutes away from work. She chooses to walk there rather than drive mainly because
she wants to improve her fitness. If Linda says that she walks for transportation (3 times per week for
a total of 120 minutes), she would not repeat that information under walking for recreation, health or
fitness.
Section 4:   Neighborhood Physical Activity Questionnaire
Walking
2379061570
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7.  Could you tell me where you walk for recreation, health or fitness in a usual week?
 [Mark all that apply.]
park
neighborhood
school
to or from restaurant
to or from a store
fitness center
other place #1
other place #2
Î
Î
Other Leisure Time Physical Activities
The next set of questions is about other leisure time physical activities that you do in a
usual week, besides what you have already mentioned.  Do not include walking.
8.  In a usual week, do you do any other vigorous or moderate intensity leisure time
physical activities?  Do not include any walking.
yes no Î Skip to Section 5
Walking for Recreation, Health or Fitness:
5.  In a usual week, how many times do you walk for
recreation, health or fitness (including walking
your dog)?
Î
if 0, skip to  Other
Leisure Time
Physical Activities
6.  Please estimate the total time you spend walking for
recreation, health or fitness in a usual week.
(e.g., 5 times by 10 minutes = 50 minutes) hours minutes
If you have already reported recreational walking, please do not report it again for the
following questions.
times
9848061578
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11.  In a usual week, how many times do you do vigorous
  intensity leisure time physical activities which cause a
  large increase in breathing and heart rate?
Î if 0, skip to Q. 13
12.  What do you estimate is the total time you spend
  doing vigorous intensity leisure time physical
  activities in a usual week.
  (e.g., 3 times by 20 minutes = 60 minutes)
minuteshours
times
13.  Apart from what you have already mentioned, in a usual week do you do any other
  moderate intensity leisure time physical activities like dancing, cycling, social tennis, golf,
  or gardening?  Moderate intensity physical activities cause a moderate increase in
  breathing and heart rate.
yes no Î
14.  In a usual week, how many times do you do moderate
  intensity leisure time physical activities which cause a 
  moderate increase in breathing and heart rate?
if no, skip to Section 5
times
15.  What do you estimate is the total time you spend
  doing moderate intensity leisure time physical 
  activities in a usual week?
  (e.g., 1 time for 1 hour = 1 hour)
hours minutes
9.  Could you tell me where you do these leisure time physical activities in a usual week?
 [Mark all that apply.]
park
neighborhood
school
fitness center
other place #1
other place #2
Î
Î
10.  In a usual week, do you do any vigorous intensity leisure time physical activities 
  like jogging, aerobics, swimming laps, or competitive tennis?  Do not include
  walking or moderate intensity physical activities.  Vigorous intensity physical
  activities cause a large increase in breathing and heart rate.
yes no Î if no, skip Q. 13
1380061571
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Section 5
Now I’ll read a list of things some people do after learning new information. Thinking about how
you feel right now, how motivated are you to…
a lot less
motivated
a little less
motivated
no change in
motivation
a little more
motivated
a lot more
motivated
1. Eat more fruits and vegetables
2. Eat more fish and lean meat rather
     than meats that are high in fat
3. Eat more fiber in your diet
4. Eat fast food less often
5. Reduce sugar in your diet
6. Eat a special diet that might help
     manage your health
7. Get more exercise or be more
     physically active
8. Spend less time sitting or being
     sedentary (like when you’re watching
     TV or using a computer)
9. Move closer to family who can help
     take care of you as you get older
10.Reduce stress in your everyday life
11.Try new methods for relaxing, such as
     meditation, progressive relaxation, or
12.  Get more sleep
13.  Drink less alcohol or stop drinking it
14.  If you smoke, quit smoking
15.  Is there anything else you feel
      motivated to do or to stop doing?
yes
no
Î
3464061576
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Section 6
Now I’d like to talk to you about heart disease. People think different things about heart disease. We
would like to know what you think.
not at all
serious
slightly
serious
somewhat
serious
moderately
serious
very
serious
1. How serious a threat to health is
     heart disease?
not at all
strong
slightly
strong
somewhat
strong
moderately
strong
very
strong
2. My chances of developing heart
     disease in the future are:
3.  What is the percent chance that you will develop heart disease in the next 10 years?
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
strongly
disagree
disagree neither agree
or disagree
agree
4. My financial security would be
     endangered if I got heart disease.
strongly
agree
5.  I believe that heart disease would
     be a very serious illness for me to
     develop.
6. If I had heart disease, my whole life
     would change.
7. If I got heart disease, it would be
     more serious than other diseases.
8. Heart disease would endanger my
     marriage (or a significant relationship).
9. If I had heart disease my career would
     be endangered.
10.  Heart disease is a hopeless disease.
11.  My feelings about myself would
      change if I got heart disease.
12.  Problems I would experience from
      heart disease would last a long time.
13  I am unlikely to develop heart disease
     in the future.
3154061572
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Section 7
In Heart Healthy Lenoir, we talked about a healthy eating plan. Healthy eating means eating more:
- Healthy fats. Healthy fats are fats such as those found in vegetable oils, nuts, and fish.
- Fruits and vegetables.
- Whole grains such as whole wheat bread and brown rice.
strongly
disagree
disagree neither agree
or disagree
agree
1. Healthy eating is effective in
    preventing heart disease.
strongly
agree
2. The benefits of following the healthy
     eating plan outweigh the costs.
3. I have the time to follow the healthy
    eating plan to prevent heart disease.
4. I would be discouraged from
     following at least one of the steps of
     the healthy eating plan during the
     next week because I would feel silly
     doing so.
5.  If I follow the healthy eating plan, I
     am less likely to get heart disease.
6.  Following at least one of the steps of
     the healthy eating plan during the
     next week would cause me too many
     problems.
7. I am able to follow the healthy eating
     plan to prevent getting heart disease.
8. Healthy eating works in preventing
     heart disease.
9. I would be discouraged from
     following at least one of the steps of
     the healthy eating plan during the
     next week as it would take too much
     time.
And eating less:
- Unhealthy fats. Unhealthy fats are trans fats that are found in some baked goods, packaged snack
foods, band fried foods at restaurants.
- Processed meats like bacon, hot dogs, and cold cuts.
- Foods with added sugar and salt-like, sugar-sweetened beverages and some prepared foods.
Thinking about that healthy eating plan, please answer the following questions.
10. I can easily follow the healthy eating
     plan to prevent heart disease.
0850061572
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strongly
disagree
disagree neither agree
or disagree
agree strongly
agree
Section 8
In Heart Healthy Lenoir, we talked about walking as aerobic physical activity. The program
recommended walking briskly for 150 minutes a week. This would be about 30 minutes of walking
on five days of the week. This can be divided into ten-minute segments of walking.
Thinking about that recommendation, please answer the following questions.
1. I would be discouraged from taking at
    least one 30-minute walk during the
    next week as it would take too much
    time.
2.  I would be discouraged from taking
    at least one 30-minute walk a week
    because I would feel silly doing so.
3.  Walking for 30 minutes a day is
     effective in preventing heart disease.
4.  Walking for 30 minutes a day works
     in preventing heart disease.
5. If I walk for 30 minutes a day, I am
     less likely to get heart disease.
6.  I am able to walk 30 minutes a day
    to prevent getting heart disease.
7.  I have the time to walk for 30
    minutes a day to prevent heart disease.
8.  I can easily walk for 30 minutes a day
      to prevent heart disease.
9. The benefits of taking at least one
     30-minute walk a week outweigh the
     costs.
10.  Taking at least one 30-minute walk
      during the next week would cause me
      too many problems.
2215061579
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Section 9
These questions are again about your thoughts about heart disease.
The thought of developing heart disease makes me feel:
not at all slightly somewhat moderately very
1. Frightened
2.  Anxious
3.  Worried
4.  Scared
Section 10 strongly
disagree
disagree neither agree
or disagree
agree strongly
agree
1. If someone is meant to get a serious
    disease, it doesn’t matter what kinds
    of food they eat, they will get that
    disease anyway.
2. I will get diseases if I am unlucky.
3.  If someone is meant to get a serious
    disease, they will get it no matter
    what they do.
4. Everything that can go wrong for me
   does.
5. If someone gets a serious disease,
     that’s the way they were meant to
     die.
6. My health is a matter of luck.
7. If someone is meant to have a
     serious disease, they will get that
     disease.
8. I will have a lot of pain from illness.
9. If someone has a serious disease and
     gets treatment for it, they will
     probably still die from it.
10. How long I live is a matter of luck.
3949061574
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strongly
disagree
disagree neither agree
or disagree
agree strongly
agree
11.  If someone was meant to have a
      serious disease, it doesn’t matter
      what doctors and nurses tell them
      to do, they will get the disease
      anyway.
12.  I will suffer a lot from bad health.
13.  How long I live is predetermined.
14.  I will stay healthy if I am lucky.
15.  I will die when I am fated to die.
16.  I often feel helpless in dealing with
      the problems of life.
17.  My health is determined by fate.
18.  Sometimes I feel that I’m being
       pushed around in life.
19.  My health is determined by
       something greater than myself.
20.  There is really no way I can solve
       some of the problems I have.
Section 11
strongly
disagree
disagree neither agree
or disagree
agree strongly
agree
1. This information helped you accept
    the way things work out in life.
People are affected in different ways by health information. We would like to know how
the information you have learned has affected you.
2. This information helped you learn to
    deal better with uncertainty.
3. This information taught you how to
    adjust to things you cannot change.
4. This information helped you take
    things as they come.
5. This information helped you look at
    things in a more positive way.
2240061577
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Section 12:  Demographics
1.  What is the highest grade or year of regular school you have completed?  [Mark only one.]
1 2 3 4 5 6 7 8 9 10 11
12 13 14 15 16 17 18 19 20 21+
never attended school
2.  Are you now:  [choose one]
married
widowed
divorced
separated
never married
living with partner
3.  Do you smoke cigarettes now?
every day
some days
not at all
.
packs per day
8a.  If every day or some days, on average, how  many
  packs of cigarettes do you now smoke a day?Î
4.  Do you currently have health insurance?
yes no
2662061575
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5.  During the past 12 months, was there any time when you had no health insurance at all?
yes
no
Î 5a. For how many months of the past 12 months did you have no
 health insurance?
1 2 3 4 5 6
7 8 9 10 11 12
5b.  What is the one main reason why you did not have any
    health insurance?
can't afford/too expensive
not eligible due to working status/changed employer/lost job
not eligible due to citizenship/immigration status
family situation changed
can get health care for free/pay for own care
not eligible due to health or other problems
don't believe in insurance
switched insurance companies, delay between jobs
other Î
6.  Which of the following best describes your current main daily activities and/or responsibilities?
  [Choose one.]
working full time (30 or more hours/week)
working part time (less than 30 hours/week)
unemployed or laid off
looking for work
student
keeping house or raising children full-time
do not work due to health reasons
retired
5012061577
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7.  What type of work do/did you do in your current or most recent job?  [Choose one.]
Î specify
The next questions are important to help us understand your economic situation.  Please
answer as accurately as possible.  The information will not be reported in any way that allow
you to be personally identified.
8.  What was the total combined income of your household in the past year including
  income from all sources such as wages, salaries, Social Security, or retirement
  benefits, help from relatives and so forth?  Please tell us the total income before taxes.
less than $5000
$5,000 to $9,999
$10,000 to $14,999
$15,00 to $19,999
$20,000 to $29,999
$30,000 to $39,999
$40,000 to $49,999
$50,000 to $59,999
$60,000 to $69,999
$70,000 to $79,999
$80,000 to $89,999
$90,000 to $99,999
$100,000 or more
don't know
refused to answer
9.  How many people live in your household, including you?
10.  Of the persons living in your household (including you),
  how many are 18 years and older?
11.  Of the persons living in your household how many are
  under 18 years of age?
number of people
number of people
number of people
management, business, and financial (chief executives, financial managers, etc.)
professional and related  (engineer, architect, dentist, etc.)
service (waitress, cook maintenance, house or hotel cleaner, etc.)
sales (cashier, counter clerk, telemarketing, etc.)
administrative support, clerical (file clerk, answering service, hotel clerk, etc.)
construction (carpentry, electrician, painter, plumber, etc.)
installation, maintenance and repair (auto mechanic, building maintenance,
production (assembly line, meat packing, printing, farming, etc.)
transportation & material moving (bus or truck driver, railroad, service station
other
electronic installation & repair, etc.)
or parking lot attendant, garbage or recycling collector, etc.)
0518061573
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APPENDIX 6.4: BASELINE VARIABLES 
A. THE SHORT TEST OF FUNCTIONAL HEALTH LITERACY IN ADULTS (STOFHLA) 
TABLE 9. STOFHLA FREQUENCY TABLE 
Variable Value Overall Control Intervention Pr > |ChiSq| 
Literacy Low Literacy 16 (25.81%) 8 (25.81%) 8 (25.81%) 1.0000 
 High Literacy 46 (74.19%) 23 (74.19%) 23 (74.19%)  
N (%) 
 
TABLE 10. STOFHLA MEANS 
Variable Overall Control Intervention Pr > |t| 
Overall Literacy Score 27.79±10.09 27.71±10.72 27.87±9.59 0.9504 
Low Literacy Participants’ Score 12.50±7.62 11.50±8.42 13.50±7.15 0.6165 
High Literacy Participants’ Score 33.11±2.55 33.35±2.31 32.87±2.80 0.5307 
Administration Time (Minutes) 6.49±1.17 6.62±1.32 6.37±1.00 0.4072 
Mean ± Standard Deviation 
 
TABLE 11. DEMOGRAPHICS – MEANS 
Variable Overall Control Intervention Pr > |t| 
Age When Enrolled In Current Study 60.86±8.62 61.51±7.80 60.20±9.46 0.5543 
Years Spent In HHL 2.09±0.14 2.07±0.13 2.10±0.15 0.3882 
Years Since HHL 1.79±0.29 1.77±0.30 1.81±0.29 0.5923 
What Is The Highest Grade You Have 
Completed? 
12.31±2.18 12.48±2.28 12.11±2.10 0.5128 
How Many People Live In Your 
Household, Including You? 
2.00±1.27 1.97±1.30 2.04±1.26 0.8398 
Number Of People In Your Household 
>= 18 Years Old 
1.56±0.82 1.61±0.76 1.50±0.88 0.5996 
Number Of People In Your Household 
< 18 Years Old 
0.31±0.75 0.35±0.80 0.25±0.70 0.5956 
Mean ± Standard Deviation 
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TABLE 12. DEMOGRAPHICS – FREQUENCY TABLE 
Variable Value Overall Control Intervention Pr > |ChiSq| 
What Is Your Sex? Male 18 
(29.03%) 
8  
(25.81%) 
10 (32.26%) 0.7802 
 Female 44 
(70.97%) 
23 
(74.19%) 
21 (67.74%)  
      
Enrolled In Hypertension 
Arm Of HHL?  
Yes 56 
(90.32%) 
29 
(93.55%) 
27 (87.10%) 0.6713 
 No 6    
(9.68%) 
2    
(6.45%) 
4 (12.90%)  
      
Enrolled In Lifestyle Arm Of 
HHL?  
Yes 21 
(33.87%) 
9 (29.03%) 12 (38.71%) 0.5921 
 No 41 
(66.13%) 
22 
(70.97%) 
19 (61.29%)  
      
Enrolled In Genomics Arm 
Of HHL? 
Yes 62 
(100.0%) 
31 
(100.0%) 
31 (100.0%)  
 No 0 ( 0.00%) 0 ( 0.00%) 0 ( 0.00%)  
      
What Is The Highest Grade 
You Have Completed?* 
8 3 ( 5.08%) 1 ( 3.23%) 2 ( 7.14%) 0.8019 
 10 5 ( 8.47%) 3 ( 9.68%) 2 ( 7.14%)  
 11 3 ( 5.08%) 1 ( 3.23%) 2 ( 7.14%)  
 12 37 
(62.71%) 
19 
(61.29%) 
18 (64.29%)  
 14 3 ( 5.08%) 3 ( 9.68%) 0 ( 0.00%)  
 15 2 ( 3.39%) 1 ( 3.23%) 1 ( 3.57%)  
 16 4 ( 6.78%) 2 ( 6.45%) 2 ( 7.14%)  
 18 1 ( 1.69%) 0 ( 0.00%) 1 ( 3.57%)  
 21 1 ( 1.69%) 1 ( 3.23%) 0 ( 0.00%)  
      
Marital Status* Married 14 
(23.73%) 
5  
(16.13%) 
9 (32.14%) 0.7208 
 199 
Variable Value Overall Control Intervention Pr > |ChiSq| 
 Widowed 11 
(18.64%) 
6  
(19.35%) 
5 (17.86%)  
 Divorced 15 
(25.42%) 
9  
(29.03%) 
6 (21.43%)  
 Separated 4    
(6.78%) 
3    
(9.68%) 
1 ( 3.57%)  
 Never 
Married 
12 
(20.34%) 
6  
(19.35%) 
6 (21.43%)  
 Living 
with a 
Partner 
3    
(5.08%) 
2    
(6.45%) 
1 ( 3.57%)  
      
Do You Smoke Cigarettes 
Now?* 
Every 
Day 
4 ( 6.78%) 1 ( 3.23%) 3 (10.71%) 0.5983 
 Some 
Days 
6 (10.17%) 3 ( 9.68%) 3 (10.71%)  
 Not at 
All 
49 
(83.05%) 
27 
(87.10%) 
22 (78.57%)  
      
Do You Currently Have 
Health Insurance?* 
Yes 54 
(91.53%) 
28 
(90.32%) 
26 (92.86%) 1.0000 
 No 5 ( 8.47%) 3 ( 9.68%) 2 ( 7.14%)  
      
During The Past 12 Months, 
Was There Any Time When 
You Had No Health 
Insurance At All?* 
Yes 11 
(18.64%) 
4 (12.90%) 7 (25.00%) 0.3204 
 No 48 
(81.36%) 
27 
(87.10%) 
21 (75.00%)  
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Variable Value Overall Control Intervention Pr > |ChiSq| 
Which Of The Following 
Best Describes Your 
Current Main Daily 
Activities And/Or 
Responsibilities?* 
Working Full 
Time (>= 30 
hours) 
15 
(25.42%) 
9 
(29.03%) 
6 (21.43%) 0.9512 
 Working Part 
Time (< 30 
hours) 
7 
(11.86%) 
3  
(9.68%) 
4 (14.29%)  
 Unemployed 
or Laid Off 
2  
(3.39%) 
1  
(3.23%) 
1 ( 3.57%)  
 Looking for 
Work 
1  
(1.69%) 
1  
(3.23%) 
0 ( 0.00%)  
 Student 3  
(5.08%) 
2  
(6.45%) 
1 ( 3.57%)  
 Keeping House 
or Raising 
Children 
1  
(1.69%) 
1  
(3.23%) 
0 ( 0.00%)  
 Do Not Work 
Due to Health 
Reasons 
12 
(20.34%) 
6 
(19.35%) 
6 (21.43%)  
 Retired 18 
(30.51%) 
8 
(25.81%) 
10 (35.71%)  
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Variable Value Overall Control Intervention Pr > |ChiSq| 
What Type Of Work 
Do/Did You Do In Your 
Current Or Most Recent 
Job?* 
Management, 
Business, and 
Financial 
3  
(5.08%) 
1  
(3.23%) 
2 ( 7.14%) 0.4264 
 Professional 
and Related 
6 
(10.17%) 
4 
(12.90%) 
2 ( 7.14%)  
 Service 6 
(10.17%) 
2  
(6.45%) 
4 (14.29%)  
 Administrative 
Support, 
Clerical 
2  
(3.39%) 
2  
(6.45%) 
0 ( 0.00%)  
 Construction 3  
(5.08%) 
1  
(3.23%) 
2 ( 7.14%)  
 Production 9 
(15.25%) 
7 
(22.58%) 
2 ( 7.14%)  
 Transportation 
& Material 
Moving 
3  
(5.08%) 
2  
(6.45%) 
1 ( 3.57%)  
 Other 27 
(45.76%) 
12 
(38.71%) 
15 (53.57%)  
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Variable Value Overall Control Intervention Pr > |ChiSq| 
Income* Less Than $5,000 7 (12.07%) 5 (16.13%) 2 ( 7.41%) 0.9017 
 $5,000-$9,999 6 (10.34%) 2 ( 6.45%) 4 (14.81%)  
 $10,000-$14,999 8 (13.79%) 5 (16.13%) 3 (11.11%)  
 $15,000-$19,999 11 (18.97%) 5 (16.13%) 6 (22.22%)  
 $20,000-$29,999 5 ( 8.62%) 2 ( 6.45%) 3 (11.11%)  
 $30,000-$39,999 4 ( 6.90%) 2 ( 6.45%) 2 ( 7.41%)  
 $40,000-$49,999 2 ( 3.45%) 2 ( 6.45%) 0 ( 0.00%)  
 $50,000-$59,999 6 (10.34%) 4 (12.90%) 2 ( 7.41%)  
 $60,000-$69,999 3 ( 5.17%) 1 ( 3.23%) 2 ( 7.41%)  
 $70,000-$79,999 2 ( 3.45%) 1 ( 3.23%) 1 ( 3.70%)  
 $100,000 or more 1 ( 1.72%) 1 ( 3.23%) 0 ( 0.00%)  
 Don't Know 2 ( 3.45%) 1 ( 3.23%) 1 ( 3.70%)  
 Refused to Answer 1 ( 1.72%) 0 ( 0.00%) 1 ( 3.70%)  
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Variable Value Overall Control Intervention Pr > |ChiSq| 
How Many People Live In  1 25 (42.37%) 15 (48.39%) 10 (35.71%) 0.6592 
Your Household, Including  2 21 (35.59%) 9 (29.03%) 12 (42.86%)  
You?* 3 7 (11.86%) 3 ( 9.68%) 4 (14.29%)  
 4 3 ( 5.08%) 2 ( 6.45%) 1 ( 3.57%)  
 5 1 ( 1.69%) 1 ( 3.23%) 0 ( 0.00%)  
 6 1 ( 1.69%) 1 ( 3.23%) 0 ( 0.00%)  
 7 1 ( 1.69%) 0 ( 0.00%) 1 ( 3.57%)  
      
Number Of People In Your  0 2 ( 3.39%) 0 ( 0.00%) 2 ( 7.14%) 0.3815 
Household >= 18 Years Old* 1 31 (52.54%) 17 (54.84%) 14 (50.00%)  
 2 18 (30.51%) 9 (29.03%) 9 (32.14%)  
 3 7 (11.86%) 5 (16.13%) 2 ( 7.14%)  
 4 1 ( 1.69%) 0 ( 0.00%) 1 ( 3.57%)  
      
Number Of People In Your  0 49 (83.05%) 25 (80.65%) 24 (85.71%) 0.9241 
Household < 18 Years Old* 1 4 ( 6.78%) 2 ( 6.45%) 2 ( 7.14%)  
 2 4 ( 6.78%) 3 ( 9.68%) 1 ( 3.57%)  
 3 2 ( 3.39%) 1 ( 3.23%) 1 ( 3.57%)  
N (%) 
*N=59 Overall; N=31 Control; N=28 Intervention 
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TABLE 13. PHENOTYPIC RISK – FREQUENCY TABLE 
Variable Value Overall Control Intervention Pr > |ChiSq| 
Framingham Risk Score  Low Over 10 
Years 
23 
(37.10%) 
13 
(41.94%) 
10 (32.26%) 0.5014 
 Average Over 
10 Years 
11 
(17.74%) 
7 
(22.58%) 
4 (12.90%)  
 High Over 10 
Years 
22 
(35.48%) 
9 
(29.03%) 
13 (41.94%)  
 Low Over 2 
Years 
6 
(9.68%) 
2 
(6.45%) 
4 (12.90%)  
      
Do You Take Medicine For 
High Blood Pressure Or 
Hypertension? (Baseline) 
Yes 56 
(98.25%) 
28 
(100.0%) 
28 (96.55%) 1.0000 
 No 1 
(1.75%) 
0 
(0.00%) 
1 (3.45%)  
      
Do You Take Medicine For 
High Blood Pressure Or 
Hypertension? (24mo) 
Yes 56 
(98.25%) 
28 
(96.55%) 
28 (100.0%) 1.0000 
 No 1 
(1.75%) 
1 
(3.45%) 
0 (0.00%)  
      
Change In Hypertension 
Medication Status Over The 
Course Of HHL 
Stopped Meds 
Since HHL 
Baseline 
1 
(1.69%) 
1 
(3.45%) 
0 (0.00%) 1.0000 
 No 
Change/Still 
On Meds 
57 
(96.61%) 
28 
(96.55%) 
29 (96.67%)  
 Started Meds 
Since HHL 
Baseline 
1 
(1.69%) 
0 
(0.00%) 
1 (3.33%)  
      
Participant Has Diabeties 
(A1c>6.5) 
Yes 22 
(35.48%) 
7 
(22.58%) 
15 (48.39%) 0.0620 
 No 40 
(64.52%) 
24 
(77.42%) 
16 (51.61%)  
 205 
Variable Value Overall Control Intervention Pr > |ChiSq| 
      
Smoking Status At 24mo Every Day 5 
(8.06%) 
1 
(3.23%) 
4 (12.90%) 0.4791 
 Some Days 6 
(9.68%) 
3 
(9.68%) 
3 (9.68%)  
 Not At All 51 
(82.26%) 
27 
(87.10%) 
24 (77.42%)  
      
Change In Smoking Status 
Over HHL 
No 
Change/Non-
Smoker 
47 
(75.81%) 
26 
(83.87%) 
21 (67.74%) 0.7052 
 Stopped 
Smoking 
4 
(6.45%) 
1 
(3.23%) 
3 (9.68%)  
 Decreased 
Smoking 
2 
(3.23%) 
1 
(3.23%) 
1 (3.23%)  
 No 
Change/Still 
Smoker 
7 
(11.29%) 
3 
(9.68%) 
4 (12.90%)  
 Increased 
Smoking 
1 
(1.61%) 
0 
(0.00%) 
1 (3.23%)  
 Started 
Smoking 
1 
(1.61%) 
0 
(0.00%) 
1 (3.23%)  
      
Has A Doctor Ever Told You 
That You Have Had A Heart 
Attack? (Baseline) 
Yes 6 
(9.68%) 
2 
(6.45%) 
4 (12.90%) 0.6713 
 No 56 
(90.32%) 
29 
(93.55%) 
27 (87.10%)  
N (%) 
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TABLE 14. PHENOTYPIC RISK – MEANS 
Variable Overall Control Intervention Pr > |t| 
Change In Total Cholesterol Over HHL 
(Baseline Carried Forward If Missing) 
-8.79±35.98 -13.89±42.25 -3.28±27.52 0.2926 
Total Cholesterol Lab Value At 24mo 177.37±29.03 179.89±27.69 174.64±30.74 0.5201 
Change In HDL Over HHL (Baseline 
Carried Forward If Missing) 
-1.21±8.81 -4.15±8.12 1.96±8.57 0.0111 
HDL Lab Value At 24mo 51.27±18.33 49.78±12.17 52.88±23.41 0.5472 
Change In SBP Over HHL (Baseline 
Carried Forward If Missing) 
-8.55±21.66 -10.29±20.84 -6.76±22.69 0.5286 
SBP Lab Value At 24mo 127.75±18.09 127.51±16.89 128.00±19.54 0.9160 
Change In A1c Over HHL (Baseline 
Carried Forward If Missing) 
-0.16±0.97 -0.11±0.47 -0.21±1.32 0.7117 
A1c Lab Value At 24mo 6.76±1.48 6.44±1.08 7.10±1.78 0.1096 
Mean ± Standard Deviation 
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TABLE 15. GENOMIC RISK – FREQUENCY TABLE 
Variable Value Overall Control Intervention Pr > |ChiSq| 
Genomic Risk Score 
(Additive) 
Low 40 
(64.52%) 
21 
(67.74%) 
19 (61.29%) 0.7911 
 Average 22 
(35.48%) 
10 
(32.26%) 
12 (38.71%)  
 High 0 ( 0.00%) 0 ( 0.00%) 0 ( 0.00%)  
      
rs543874 – BMI SNP No Deleterious 
Alleles 
30 
(48.39%) 
14 
(45.16%) 
16 (51.61%) 0.6995 
 One Allele 29 
(46.77%) 
16 
(51.61%) 
13 (41.94%)  
 Two Alleles 3 ( 4.84%) 1 ( 3.23%) 2 ( 6.45%)  
      
rs6567160 – BMI SNP No Deleterious 
Alleles 
41 
(66.13%) 
20 
(64.52%) 
21 (67.74%) 1.0000 
 One Allele 20 
(32.26%) 
10 
(32.26%) 
10 (32.26%)  
 Two Alleles 1 ( 1.61%) 1 ( 3.23%) 0 ( 0.00%)  
      
rs2258119 – SBP SNP No Deleterious 
Alleles 
29 
(46.77%) 
15 
(48.39%) 
14 (45.16%) 0.7649 
 One Allele 27 
(43.55%) 
14 
(45.16%) 
13 (41.94%)  
 Two Alleles 6 ( 9.68%) 2 ( 6.45%) 4 (12.90%)  
      
rs7903146 – T2DM SNP No Deleterious 
Alleles 
29 
(46.77%) 
13 
(41.94%) 
16 (51.61%) 0.7816 
 One Allele 25 
(40.32%) 
14 
(45.16%) 
11 (35.48%)  
 Two Alleles 8 
(12.90%) 
4 
(12.90%) 
4 (12.90%)  
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Variable Value Overall Control Intervention Pr > |ChiSq| 
rs6511720 – LDL SNP No Deleterious 
Alleles 
45 
(72.58%) 
19 
(61.29%) 
26 (83.87%) 0.1046 
 One Allele 15 
(24.19%) 
10 
(32.26%) 
5 (16.13%)  
 Two Alleles 2 ( 3.23%) 2 ( 6.45%) 0 ( 0.00%)  
      
rs646776 – LDL SNP No Deleterious 
Alleles 
29 
(46.77%) 
15 
(48.39%) 
14 (45.16%) 1.0000 
 One Allele 24 
(38.71%) 
12 
(38.71%) 
12 (38.71%)  
 Two Alleles 9 
(14.52%) 
4 
(12.90%) 
5 (16.13%)  
      
rs3764261 – HDL SNP No Deleterious 
Alleles 
26 
(41.94%) 
12 
(38.71%) 
14 (45.16%) 0.6774 
 One Allele 32 
(51.61%) 
16 
(51.61%) 
16 (51.61%)  
 Two Alleles 4 ( 6.45%) 3 ( 9.68%) 1 ( 3.23%)  
      
rs16942887 – HDL SNP No Deleterious 
Alleles 
46 
(74.19%) 
22 
(70.97%) 
24 (77.42%) 0.8786 
 One Allele 14 
(22.58%) 
8 
(25.81%) 
6 (19.35%)  
 Two Alleles 2 ( 3.23%) 1 ( 3.23%) 1 ( 3.23%)  
      
rs2036527 – Smoking SNP No Deleterious 
Alleles 
32 
(51.61%) 
18 
(58.06%) 
14 (45.16%) 0.6654 
 One Allele 23 
(37.10%) 
10 
(32.26%) 
13 (41.94%)  
 Two Alleles 7 
(11.29%) 
3 ( 9.68%) 4 (12.90%)  
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APPENDIX 6.5: REGRESSION ANALYSES FOR SECONDARY AND TERTIARY 
OUTCOMES 
  
A. MOTIVATION TOWARDS STRESS REDUCTION  
TABLE 16. REGRESSION ANALYSIS FOR MOTIVATION TOWARDS STRESS REDUCTION 
Label Estimate 
Standard 
Error DF t Value Pr > |t| 
Control Time 1 4.0090 0.2395    
Control Time 3 4.1865 0.2361    
Intervention Time 1 4.1000 0.2424    
Intervention Time 3 3.8685 0.2424    
Control: Time 3 vs. Time 1 0.1775 0.1787 111 0.99 0.3229 
Intervention: Time 3 vs. Time 1 -0.2315 0.1788 111 -1.29 0.1981 
Control vs. Intervention: Time 3 vs. Time 1 0.4090 0.2528 111 1.62 0.1086 
Intervention Low GRS Time 1 4.0000 0.2897    
Intervention Low GRS Time 3 4.0370 0.2897    
Intervention Average GRS Time 1 4.2000 0.3887    
Intervention Average GRS Time 3 3.7000 0.3887    
Intervention Low GRS: Time 3 vs. Time 1 0.03704 0.2137 111 0.17 0.8627 
Intervention Average GRS: Time 3 vs. Time 1 -0.5000 0.2867 111 -1.74 0.0839 
Intervention: Low GRS vs. Average GRS: Time 3 vs. Time 1 0.5370 0.3575 111 1.50 0.1359 
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B. THREAT APPRAISAL 
TABLE 17. REGRESSION ANALYSIS FOR PERCEIVED THREAT 
Label Estimate 
Standard 
Error DF t Value Pr > |t| 
Control Time 1 4.9048 0.2473    
Control Time 3 4.7571 0.2473    
Intervention Time 1 4.7167 0.2539    
Intervention Time 3 4.7611 0.2539    
Control: Time 3 vs. Time 1 -0.1476 0.1655 113 -0.89 0.3743 
Intervention: Time 3 vs. Time 1 0.04444 0.1699 113 0.26 0.7941 
Control vs. Intervention: Time 3 vs. Time 1 -0.1921 0.2372 113 -0.81 0.4198 
Intervention Low GRS Time 1 4.8333 0.3035    
Intervention Low GRS Time 3 4.7222 0.3035    
Intervention Average GRS Time 1 4.6000 0.4071    
Intervention Average GRS Time 3 4.8000 0.4071    
Intervention Low GRS: Time 3 vs. Time 1 -0.1111 0.2031 113 -0.55 0.5854 
Intervention Average GRS: Time 3 vs. Time 1 0.2000 0.2725 113 0.73 0.4644 
Intervention: Low GRS vs. Average GRS: Time 3 vs. Time 1 -0.3111 0.3398 113 -0.92 0.3618 
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TABLE 18. REGRESSION ANALYSIS FOR PERCEIVED VULNERABILITY 
Label Estimate 
Standard 
Error DF t Value Pr > |t| 
Control Time 1 47.9048 5.4015    
Control Time 3 40.0952 5.4015    
Intervention Time 1 32.7222 5.5448    
Intervention Time 3 40.2778 5.5448    
Control: Time 3 vs. Time 1 -7.8095 5.7025 113 -1.37 0.1736 
Intervention: Time 3 vs. Time 1 7.5556 5.8538 113 1.29 0.1994 
Control vs. Intervention: Time 3 vs. Time 1 -15.3651 8.1723 113 -1.88 0.0627 
Intervention Low GRS Time 1 49.4444 6.6273    
Intervention Low GRS Time 3 45.5556 6.6273    
Intervention Average GRS Time 1 16.0000 8.8915    
Intervention Average GRS Time 3 35.0000 8.8915    
Intervention Low GRS: Time 3 vs. Time 1 -3.8889 6.9966 113 -0.56 0.5794 
Intervention Average GRS: Time 3 vs. Time 1 19.0000 9.3870 113 2.02 0.0453 
Intervention: Low GRS vs. Average GRS: Time 3 vs. Time 1 -22.8889 11.7076 113 -1.96 0.0530 
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TABLE 19. REGRESSION ANALYSIS FOR PERCEIVED SEVERITY 
Label Estimate 
Standard 
Error DF t Value Pr > |t| 
Control Time 1 3.4759 0.1873    
Control Time 3 3.3224 0.1873    
Intervention Time 1 3.4901 0.1923    
Intervention Time 3 3.4418 0.1923    
Control: Time 3 vs. Time 1 -0.1536 0.1037 113 -1.48 0.1413 
Intervention: Time 3 vs. Time 1 -0.04830 0.1064 113 -0.45 0.6508 
Control vs. Intervention: Time 3 vs. Time 1 -0.1053 0.1486 113 -0.71 0.4801 
Intervention Low GRS Time 1 3.5247 0.2298    
Intervention Low GRS Time 3 3.3642 0.2298    
Intervention Average GRS Time 1 3.4556 0.3083    
Intervention Average GRS Time 3 3.5194 0.3083    
Intervention Low GRS: Time 3 vs. Time 1 -0.1605 0.1272 113 -1.26 0.2096 
Intervention Average GRS: Time 3 vs. Time 1 0.06389 0.1707 113 0.37 0.7088 
Intervention: Low GRS vs. Average GRS: Time 3 vs. Time 1 -0.2244 0.2128 113 -1.05 0.2940 
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TABLE 20. REGRESSION ANALYSIS FOR PERCEIVED FEAR 
Label Estimate 
Standard 
Error DF t Value Pr > |t| 
Control Time 1 2.9738 0.2565    
Control Time 3 2.7239 0.2572    
Intervention Time 1 2.7917 0.2633    
Intervention Time 3 2.9528 0.2633    
Control: Time 3 vs. Time 1 -0.2499 0.1807 111 -1.38 0.1694 
Intervention: Time 3 vs. Time 1 0.1611 0.1844 111 0.87 0.3842 
Control vs. Intervention: Time 3 vs. Time 1 -0.4110 0.2582 111 -1.59 0.1142 
Intervention Low GRS Time 1 3.0833 0.3147    
Intervention Low GRS Time 3 3.0556 0.3147    
Intervention Average GRS Time 1 2.5000 0.4222    
Intervention Average GRS Time 3 2.8500 0.4222    
Intervention Low GRS: Time 3 vs. Time 1 -0.02778 0.2204 111 -0.13 0.8999 
Intervention Average GRS: Time 3 vs. Time 1 0.3500 0.2957 111 1.18 0.2391 
Intervention: Low GRS vs. Average GRS: Time 3 vs. Time 1 -0.3778 0.3688 111 -1.02 0.3079 
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C. COPING APPRAISAL 
TABLE 21. REGRESSION ANALYSIS FOR COPING EFFICACY 
Label Estimate 
Standard 
Error DF t Value Pr > |t| 
Control Time 2 11.0262 0.6402    
Control Time 3 10.5548 0.6402    
Intervention Time 2 11.2500 0.6572    
Intervention Time 3 11.2889 0.6572    
Control: Time 3 vs. Time 2 -0.4714 0.4139 113 -1.14 0.2571 
Intervention: Time 3 vs. Time 2 0.03889 0.4249 113 0.09 0.9272 
Control vs. Intervention: Time 3 vs. Time 2 -0.5103 0.5932 113 -0.86 0.3915 
Intervention Low GRS Time 2 11.0000 0.7855    
Intervention Low GRS Time 3 11.2778 0.7855    
Intervention Average GRS Time 2 11.5000 1.0539    
Intervention Average GRS Time 3 11.3000 1.0539    
Intervention Low GRS: Time 3 vs. Time 2 0.2778 0.5079 113 0.55 0.5855 
Intervention Average GRS: Time 3 vs. Time 2 -0.2000 0.6814 113 -0.29 0.7697 
Intervention: Low GRS vs. Average GRS: Time 3 vs. Time 2 0.4778 0.8498 113 0.56 0.5751 
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TABLE 22. REGRESSION ANALYSIS FOR DIET RESPONSE EFFICACY 
Label Estimate 
Standard 
Error DF t Value Pr > |t| 
Control Time 1 4.0881 0.2023    
Control Time 3 3.9480 0.2023    
Intervention Time 1 4.0537 0.2077    
Intervention Time 3 4.0398 0.2077    
Control: Time 3 vs. Time 1 -0.1401 0.1154 113 -1.21 0.2273 
Intervention: Time 3 vs. Time 1 -0.01389 0.1185 113 -0.12 0.9069 
Control vs. Intervention: Time 3 vs. Time 1 -0.1262 0.1654 113 -0.76 0.4470 
Intervention Low GRS Time 1 4.0741 0.2482    
Intervention Low GRS Time 3 3.8796 0.2482    
Intervention Average GRS Time 1 4.0333 0.3330    
Intervention Average GRS Time 3 4.2000 0.3330    
Intervention Low GRS: Time 3 vs. Time 1 -0.1944 0.1416 113 -1.37 0.1724 
Intervention Average GRS: Time 3 vs. Time 1 0.1667 0.1900 113 0.88 0.3822 
Intervention: Low GRS vs. Average GRS: Time 3 vs. Time 1 -0.3611 0.2369 113 -1.52 0.1303 
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TABLE 23. REGRESSION ANALYSIS FOR DIET RESPONSE COST 
Label Estimate 
Standard 
Error DF t Value Pr > |t| 
Control Time 1 4.1262 0.2067    
Control Time 3 3.9771 0.2071    
Intervention Time 1 3.8736 0.2122    
Intervention Time 3 3.9861 0.2122    
Control: Time 3 vs. Time 1 -0.1491 0.1065 112 -1.40 0.1643 
Intervention: Time 3 vs. Time 1 0.1125 0.1087 112 1.03 0.3029 
Control vs. Intervention: Time 3 vs. Time 1 -0.2616 0.1522 112 -1.72 0.0884 
Intervention Low GRS Time 1 3.9722 0.2537    
Intervention Low GRS Time 3 3.9722 0.2537    
Intervention Average GRS Time 1 3.7750 0.3403    
Intervention Average GRS Time 3 4.0000 0.3403    
Intervention Low GRS: Time 3 vs. Time 1 0 0.1299 112 0.00 1.0000 
Intervention Average GRS: Time 3 vs. Time 1 0.2250 0.1743 112 1.29 0.1995 
Intervention: Low GRS vs. Average GRS: Time 3 vs. Time 1 -0.2250 0.2174 112 -1.03 0.3029 
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TABLE 24. REGRESSION ANALYSIS FOR PHYSICAL ACTIVITY RESPONSE EFFICACY 
Label Estimate 
Standard 
Error DF t Value Pr > |t| 
Control Time 1 3.7294 0.1883    
Control Time 3 3.7048 0.1883    
Intervention Time 1 3.8715 0.1933    
Intervention Time 3 4.0130 0.1933    
Control: Time 3 vs. Time 1 -0.02460 0.1119 113 -0.22 0.8263 
Intervention: Time 3 vs. Time 1 0.1415 0.1148 113 1.23 0.2205 
Control vs. Intervention: Time 3 vs. Time 1 -0.1661 0.1603 113 -1.04 0.3024 
Intervention Low GRS Time 1 3.8796 0.2311    
Intervention Low GRS Time 3 3.8259 0.2311    
Intervention Average GRS Time 1 3.8633 0.3100    
Intervention Average GRS Time 3 4.2000 0.3100    
Intervention Low GRS: Time 3 vs. Time 1 -0.05370 0.1372 113 -0.39 0.6963 
Intervention Average GRS: Time 3 vs. Time 1 0.3367 0.1841 113 1.83 0.0701 
Intervention: Low GRS vs. Average GRS: Time 3 vs. Time 1 -0.3904 0.2297 113 -1.70 0.0919 
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TABLE 25. REGRESSION ANALYSIS FOR PHYSICAL ACTIVITY RESPONSE COST 
Label Estimate 
Standard 
Error DF t Value Pr > |t| 
Control Time 1 3.9839 0.1904    
Control Time 3 3.9458 0.1904    
Intervention Time 1 3.9778 0.1954    
Intervention Time 3 4.1278 0.1954    
Control: Time 3 vs. Time 1 -0.03810 0.1028 113 -0.37 0.7117 
Intervention: Time 3 vs. Time 1 0.1500 0.1055 113 1.42 0.1580 
Control vs. Intervention: Time 3 vs. Time 1 -0.1881 0.1474 113 -1.28 0.2044 
Intervention Low GRS Time 1 4.0556 0.2336    
Intervention Low GRS Time 3 4.1806 0.2336    
Intervention Average GRS Time 1 3.9000 0.3134    
Intervention Average GRS Time 3 4.0750 0.3134    
Intervention Low GRS: Time 3 vs. Time 1 0.1250 0.1262 113 0.99 0.3239 
Intervention Average GRS: Time 3 vs. Time 1 0.1750 0.1693 113 1.03 0.3034 
Intervention: Low GRS vs. Average GRS: Time 3 vs. Time 1 -0.05000 0.2111 113 -0.24 0.8132 
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D. MALADAPTIVE COPING 
TABLE 26. REGRESSION ANALYSIS FOR FATALISM 
Label Estimate 
Standard 
Error DF t Value Pr > |t| 
Control Time 1 2.3488 0.1626    
Control Time 3 2.4581 0.1626    
Intervention Time 1 2.2689 0.1669    
Intervention Time 3 2.3697 0.1669    
Control: Time 3 vs. Time 1 0.1093 0.07162 113 1.53 0.1298 
Intervention: Time 3 vs. Time 1 0.1008 0.07352 113 1.37 0.1730 
Control vs. Intervention: Time 3 vs. Time 1 0.008452 0.1026 113 0.08 0.9345 
Intervention Low GRS Time 1 2.3528 0.1995    
Intervention Low GRS Time 3 2.4944 0.1995    
Intervention Average GRS Time 1 2.1850 0.2677    
Intervention Average GRS Time 3 2.2450 0.2677    
Intervention Low GRS: Time 3 vs. Time 1 0.1417 0.08788 113 1.61 0.1097 
Intervention Average GRS: Time 3 vs. Time 1 0.06000 0.1179 113 0.51 0.6118 
Intervention: Low GRS vs. Average GRS: Time 3 vs. Time 1 0.08167 0.1470 113 0.56 0.5797 
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TABLE 27. REGRESSION ANALYSIS FOR FATALISM SUBSCALE—PREDETERMINATION  
Label Estimate 
Standard 
Error DF t Value Pr > |t| 
Control Time 1 2.5338 0.1807    
Control Time 3 2.5933 0.1807    
Intervention Time 1 2.3522 0.1855    
Intervention Time 3 2.4950 0.1855    
Control: Time 3 vs. Time 1 0.05952 0.09462 113 0.63 0.5306 
Intervention: Time 3 vs. Time 1 0.1428 0.09713 113 1.47 0.1443 
Control vs. Intervention: Time 3 vs. Time 1 -0.08325 0.1356 113 -0.61 0.5405 
Intervention Low GRS Time 1 2.4944 0.2217    
Intervention Low GRS Time 3 2.7000 0.2217    
Intervention Average GRS Time 1 2.2100 0.2975    
Intervention Average GRS Time 3 2.2900 0.2975    
Intervention Low GRS: Time 3 vs. Time 1 0.2056 0.1161 113 1.77 0.0793 
Intervention Average GRS: Time 3 vs. Time 1 0.08000 0.1558 113 0.51 0.6085 
Intervention: Low GRS vs. Average GRS: Time 3 vs. Time 1 0.1256 0.1943 113 0.65 0.5194 
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TABLE 28. REGRESSION ANALYSIS FOR FATALISM SUBSCALE—LUCK  
Label Estimate 
Standard 
Error DF t Value Pr > |t| 
Control Time 1 1.9333 0.1627    
Control Time 3 2.0143 0.1627    
Intervention Time 1 2.0361 0.1670    
Intervention Time 3 2.1653 0.1670    
Control: Time 3 vs. Time 1 0.08095 0.1046 112 0.77 0.4406 
Intervention: Time 3 vs. Time 1 0.1292 0.1074 112 1.20 0.2315 
Control vs. Intervention: Time 3 vs. Time 1 -0.04821 0.1499 112 -0.32 0.7483 
Intervention Low GRS Time 1 2.0972 0.1996    
Intervention Low GRS Time 3 2.1806 0.1996    
Intervention Average GRS Time 1 1.9750 0.2678    
Intervention Average GRS Time 3 2.1500 0.2678    
Intervention Low GRS: Time 3 vs. Time 1 0.08333 0.1283 112 0.65 0.5175 
Intervention Average GRS: Time 3 vs. Time 1 0.1750 0.1722 112 1.02 0.3116 
Intervention: Low GRS vs. Average GRS: Time 3 vs. Time 1 -0.09167 0.2147 112 -0.43 0.6703 
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TABLE 29. REGRESSION ANALYSIS FOR FATALISM SUBSCALE—PESSIMISM  
Label Estimate 
Standard 
Error DF t Value Pr > |t| 
Control Time 1 2.3175 0.1728    
Control Time 3 2.5286 0.1728    
Intervention Time 1 2.2852 0.1774    
Intervention Time 3 2.2972 0.1774    
Control: Time 3 vs. Time 1 0.2111 0.09481 113 2.23 0.0279 
Intervention: Time 3 vs. Time 1 0.01204 0.09732 113 0.12 0.9018 
Control vs. Intervention: Time 3 vs. Time 1 0.1991 0.1359 113 1.47 0.1456 
Intervention Low GRS Time 1 2.2870 0.2120    
Intervention Low GRS Time 3 2.3611 0.2120    
Intervention Average GRS Time 1 2.2833 0.2845    
Intervention Average GRS Time 3 2.2333 0.2845    
Intervention Low GRS: Time 3 vs. Time 1 0.07407 0.1163 113 0.64 0.5255 
Intervention Average GRS: Time 3 vs. Time 1 -0.05000 0.1561 113 -0.32 0.7493 
Intervention: Low GRS vs. Average GRS: Time 3 vs. Time 1 0.1241 0.1946 113 0.64 0.5251 
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E. DIET 
TABLE 30. REGRESSION ANALYSIS FOR FRUIT AND VEGETABLE SERVINGS 
Label Estimate 
Standard 
Error DF t Value Pr > |t| 
Control Time 1 3.6074 0.3960    
Control Time 3 3.8796 0.3960    
Intervention Time 1 3.6813 0.4065    
Intervention Time 3 4.3308 0.4065    
Control: Time 3 vs. Time 1 0.2722 0.2934 55 0.93 0.3575 
Intervention: Time 3 vs. Time 1 0.6496 0.3011 55 2.16 0.0354 
Control vs. Intervention: Time 3 vs. Time 1 -0.3773 0.4204 55 -0.90 0.3733 
Intervention Low GRS Time 1 3.0006 0.4859    
Intervention Low GRS Time 3 4.3367 0.4859    
Intervention Average GRS Time 1 4.3620 0.6519    
Intervention Average GRS Time 3 4.3250 0.6519    
Intervention Low GRS: Time 3 vs. Time 1 1.3361 0.3599 55 3.71 0.0005 
Intervention Average GRS: Time 3 vs. Time 1 -0.03700 0.4829 55 -0.08 0.9392 
Intervention: Low GRS vs. Average GRS: Time 3 vs. Time 1 1.3731 0.6023 55 2.28 0.0265 
  
 224 
F. PHYSICAL ACTIVITY 
TABLE 31. REGRESSION ANALYSIS FOR TOTAL WALKING TIME 
Label Estimate 
Standard 
Error DF t Value Pr > |t| 
Control Time 1 80.5357 64.5957    
Control Time 3 151.45 64.5957    
Intervention Time 1 123.99 66.3095    
Intervention Time 3 85.1389 66.3095    
Control: Time 3 vs. Time 1 70.9167 89.7040 55 0.79 0.4326 
Intervention: Time 3 vs. Time 1 -38.8556 92.0839 55 -0.42 0.6747 
Control vs. Intervention: Time 3 vs. Time 1 109.77 128.55 55 0.85 0.3969 
Intervention Low GRS Time 1 123.89 79.2550    
Intervention Low GRS Time 3 94.7778 79.2550    
Intervention Average GRS Time 1 124.10 106.33    
Intervention Average GRS Time 3 75.5000 106.33    
Intervention Low GRS: Time 3 vs. Time 1 -29.1111 110.06 55 -0.26 0.7924 
Intervention Average GRS: Time 3 vs. Time 1 -48.6000 147.66 55 -0.33 0.7433 
Intervention: Low GRS vs. Average GRS: Time 3 vs. Time 1 19.4889 184.17 55 0.11 0.9161 
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TABLE 32. REGRESSION ANALYSIS FOR TOTAL MINUTES OF PHYSICAL ACTIVITY 
Label Estimate 
Standard 
Error DF t Value Pr > |t| 
Control Time 1 145.49 134.56    
Control Time 3 277.31 134.56    
Intervention Time 1 285.11 138.13    
Intervention Time 3 274.28 138.13    
Control: Time 3 vs. Time 1 131.82 100.96 55 1.31 0.1971 
Intervention: Time 3 vs. Time 1 -10.8278 103.64 55 -0.10 0.9172 
Control vs. Intervention: Time 3 vs. Time 1 142.65 144.69 55 0.99 0.3285 
Intervention Low GRS Time 1 416.11 165.09    
Intervention Low GRS Time 3 395.06 165.09    
Intervention Average GRS Time 1 154.10 221.50    
Intervention Average GRS Time 3 153.50 221.50    
Intervention Low GRS: Time 3 vs. Time 1 -21.0556 123.88 55 -0.17 0.8657 
Intervention Average GRS: Time 3 vs. Time 1 -0.6000 166.20 55 -0.00 0.9971 
Intervention: Low GRS vs. Average GRS: Time 3 vs. Time 1 -20.4556 207.28 55 -0.10 0.9217 
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